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Summary 
The neurotropic rabies virus (RABV) of the Lyssavirus genus in the Rhabdoviridae 
family is the main causative agent of rabies, a long known zoonotic infectious disease, which 
still accounts for more than 55,000 human deaths each year. The virulence of RABV depends 
on various factors, including multiple mechanisms to counteract the antiviral type I 
interferon system (α-/β-interferons) (IFN) of hosts, which are exerted by the viral 
phosphoprotein P.  
In virus-infected cells IFN is induced after recognition of viral RNAs by pattern 
recognition receptors (PRR), like the RIG-I-like helicases (RLR), which induce downstream 
signaling leading to activation of the transcription factor IRF3 by the kinases TBK1 and IKKi. 
Secreted IFNs induce JAK/STAT signaling, which ultimately leads to expression of numerous 
antiviral and immunestimulatory proteins. RABV P can inhibit both IFN-mediated JAK/STAT 
signaling and RLR-mediated IRF3 activation and thus induction of IFN transcription. The aim 
of this work was to elucidate the molecular mechanisms of P to prevent IFN induction.   
As revealed by site-directed mutagenesis experiments, the RABV P amino acids (aa) 
176-186 are essential for its ability to inhibit IFN induction. RABV P constructs lacking aa 176-
181, 182-186, and 176-186, were unable to inhibit IRF3 activation and IFNβ transcription, 
while other multiple functions of P, such as inhibition of JAK/STAT signaling and support of 
virus replication, were not affected. Recombinant RABV carrying the respective mutations 
(SAD ΔInd1, ΔInd2 and ΔInd1/2) were strong inducers of IFN and were attenuated after 
intracerebral injection into mice, illustrating an essential contribution of IFN inhibition to the 
pathogenicity of RABV.  
The mechanisms applied by RABV P were further elucidated through the 
identification of cellular targets. This study provides first evidence for an interaction of RABV 
P with RLRs and with IRF3. Co-IP experiments revealed an interaction with the RLRs MDA5 
and Lgp2 in non-alerted cells. Moreover, an interaction of P and RIG-I was revealed upon 
stimulation with RIG-I ligands, including 5’-ppp RNA. Interestingly, this finding is in 
concordance with the proposed structural models of RIG-I activation, in which ligand binding 
confers structural changes required for downstream signaling, probably unmasking domains 
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for P binding. In contrast, the conformation of latent MDA5 allows for both, basal signaling 
and P binding in the absence of a ligand.  
Furthermore, it was shown for the first time that RABV P binds to a novel activation-
intermediate form of IRF3, explaining the powerful inhibition of TBK1-mediated IRF3 
activation. P was found to bind IRF3 dependent on the degree and time of stimulation of the 
RLR pathway. P-bound IRF3 revealed phosphorylation of C-terminal residues (S396, S398), 
while phosphorylation of S386, which is critical for IRF3 transcriptional activity, was 
prevented. Mutagenesis of IRF3 S396 and S398 resulted in reduced P binding. These data 
provide evidence for an obligatory sequential phosphorylation of IRF3 in which 
phosphorylation of the C-terminal Ser residues is required to release an auto-inhibitory 
domain (including helix 5) to allow S386 phosphorylation. Notably, however, C-terminal 
phosphomimetic IRF3 mutants still required stimulation to confer substantial P binding, 
strongly suggesting the existence of further unknown modifications required for full IRF3 
activation, and P binding. As revealed by the use of IRF deletion mutants lacking all known 
auto-inhibitory structures (helix 1 and helix 5) the P binding interface of IRF3 involves helix 3 
and 4. 
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1 Introduction 
1.1 Rabies virus (RABV) and the Lyssavirus genus 
Rabies is an acute and lethal encephalitis and appeared in the history of human 
threats already before 2000 B.C., as found in annotations by the Egyptians. This 
makes rabies one of the oldest documented diseases of humans. The pathogen 
associated to the disease was discovered by Remlinger and colleagues in 1903 and 
turned out to be a virus, consequently named rabies virus (RABV) (Rupprecht et al., 
2002). RABV, which is actually one of the 30 first discovered viruses, belongs to the 
order Mononegavirales due to its non-segmented negative-strand RNA genome, and 
was annotated to the Lyssavirus genus of the family Rhabdoviridae. Rhabdoviridae 
are composed of a growing number of viruses, which comprise several livestock 
pathogens such as vesicular stomatitis virus (VSV; Vesiculovirus genus) or bovine 
ephemeral fever virus (BEFV; Ephemerovirus genus), many of which are of economic 
importance. Particularly appreciable, however, is RABV, the prototype of the 
Lyssavirus genus, which is a zoonosis and remains a constant and global threat for 
human health although effective vaccines and post-exposure prophylaxis (PEP) are 
available. Typically, lyssaviruses are associated with bats as reservoir species and 
restricted to certain geographical areas. However, RABV is endemic throughout the 
world and mainly infects terrestrial warm-blooded mammals found in wildlife, such 
as dogs, foxes, raccoons, skunks, jackals, mongooses etc. Human lyssavirus infections 
are still mainly associated with RABV, yet sporadic cases of rabies-like encephalitis 
have been reported from rabies-related lyssaviruses (Johnson et al., 2010). The 
factors involved in limiting the host range and being responsible for crossing the 
species barrier still remain unknown, especially as a very close genetic relationship 
between RABV and rabies-related viruses is obvious.  
 
1.1.1 Lyssavirus taxonomy 
Since the first isolation of a rabies-related virus in Africa 1956, ten viruses have been 
assigned to the Lyssavirus genus in addition to RABV and new isolates are analyzed in 
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ongoing attempts. The relatedness of the first African isolates to RABV was suggested 
14 years later in an electron microscopy study from 1969/1970, where the bullet 
shape morphology characterized the viruses as rhabdoviruses (Shope et al., 1970). Up 
to date, serotyping and genotyping are the common methods to assign lyssaviruses, 
yet also their pathogenicity and immunogenicity are considered (Badrane et al., 
2001). Nowadays, a great variety of other rabies-related viruses have been isolated, 
mostly from bats and from all around the world. Distinct viruses show prevalence for 
specific regions and bat species (see table 1). Interestingly, RABV has also been found 
in bats, however, apparently only in the Americas (Hughes et al., 2005). The reasons 
for this geographical separation and the evolution of bat lyssaviruses still remain 
elusive. In view of the close phylogenetic relationship, it is assumed that all 
lyssaviruses emerged from bat. Though only two of the viruses have been isolated 
from terrestrial animals, namely RABV and Mokola virus (MOKV), an evolutionary 
genetic adaptation seems obvious. Evolutionary relationships amongst the 
lyssaviruses are depicted in a phylogenetic tree (Fig. 1-1). 
 
Figure 1-1: Phylogenetic tree of the lyssaviruses genus. Lyssaviruses are grouped into three phylogroups (I, II and 
III), according to their evolutionary relationship. Lyssaviruses are further assigned to specific genotypes based on 
their nucleotide sequence, immunogenicity and pathogenicity (in brackets or in table (1)). Assignment of ARAV, 
KHUV and IRKV (also SHIBV and BBLV; not shown) to specific Genotypes still has to be performed (figure adapted 
from (Badrane et al., 2001)).  
 
Lyssaviruses are grouped into phylogroups I, II and III, and further annotated to 
distinct genotypes (table 1) due to their nucleotide sequence, immunogenicity and 
pathogenicity. Phylogroup I comprises RABV, and the closely related Australian bat 
lyssavirus (ABLV) (Fraser et al., 1996), Aravan virus (ARAV) (Kuz’min et al., 1992), 
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Khujand virus (KHUV) (Kuzmin et al., 2002), and European bat lyssavirus 2 (EBLV-2) 
(Lumio et al., 1986). Additionally, it contains Irkut virus (IRKV) (Botvinkin et al., 2003), 
Duvenhage virus (DUVV) (Meredith et al., 1971) and EBLV-1 (Schneider et al., 1985). 
Phylogroup II includes the more distinctly related Lagos bat virus (LBV) (Boulger and 
Porterfield, 1958) and MOKV (Shope et al., 1970). Two further viruses, namely 
Shimoni bat virus (SHIBV) (Kuzmin et al., 2010) and Bokeloh bat virus (BBV) (Freuling 
et al., 2011), have been recently proposed to belong to the Lyssavirus genus. Shimoni 
bat virus, which is highly related to LBV, has recently been grouped into phylogroup 
II, yet it might even be assigned as genotypic subgroup of LBV. The West Caucasian 
bat virus (WCBV) (Botvinkin et al., 2003), has specific genetic differences to other 
lyssaviruses, thus phylogroup III was established. WCBV also needs to be further 
characterized for final annotation. The genotypes and epidemiology of all annotated 
lyssaviruses are depicted in table 1 (for review see (Banyard et al., 2011)). 
Table 1. Lyssavirus genotypes (GT) and epidemiology 
 
Virus GT 1
st
 Isolate Spread Reservoirs 
RABV 1 
Cow (PV strain), 
France, 1882 
Worldwide 
mammals, 
chiroptera 
LBV 2 
Bat Eidolon helvum, 
Nigeria, 1956 
Sub-Saharan Africa chiroptera 
MOKV 3 
Shrew, 
Nigeria, 1968 
Sub-Saharan Africa ? 
DUVV 4 
Human, 
South Africa, 1970 
Southern Africa chiroptera 
EBLV 1 5 
Bat Eptesicus serotinus, 
Germany, 1986 
Europe chiroptera 
EBLV 2 6 
Human, 
Finland, 1986 
Europe chiroptera 
ABLV 7 
Bat Pteropus alecto, 
Australia, 1996 
Australia chiroptera 
ARAV  
Bat Myotis blythi, 
Kyrghyzstan, 1991 
Kyrghyzstan chiroptera 
KHUV  
Bat Myotis mystacinus, 
Tajikistan, 2001 
Tajikistan chiroptera 
IRKV  
Bat Murina leucogaster, 
Russia, 2002 
Eastern Siberia chiroptera 
WCBV  
Bat Miniopterus schreibersi, 
Russia, 2002 
Western Caucasus 
Mountains 
chiroptera 
SHIBV  
Bat Hipposideros commersoni, 
Kenya, 2009 
Kenya chiroptera 
BBLV  
Bat Myotis nattererii, 
Germany, 2009 
Germany chiroptera 
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1.1.2 Lyssavirus structure and genomes 
Lyssaviruses, and all other Rhabdoviridae, are characterized by a rod- or bullet-
shaped morphology. Their negative sense RNA genome forms a helical nucleocapsid 
(NC) or ribonucleoprotein (RNP) that is covered by a lipid envelope containing 
trimeric glycoprotein spikes. The 12 kb RNA genome encodes only five genes in the 
conserved order 3’-N-P-M-G-L-5’; these are transcribed to subgenomic mRNAs and 
translated to the respective proteins: the nucleoprotein (N), which encloses the viral 
RNA concurrent with its synthesis to form the NC; the phosphoprotein (P), a crucial 
non-catalytic cofactor for the viral RNA (vRNA) polymerase and for chaperoning 
soluble N protein (N0); the matrix protein (M), which is essential for virus assembly, 
budding, and regulation of RNA synthesis; the trimeric transmembrane glycoprotein 
(G) that attaches to target cells and induces membrane; and the “large” protein (L), 
the catalytic subunit of the viral RNA polymerase.  
                   
Figure 1-2: Rabies virus structure, genome and replication. (A) Electron micrograph of negatively stained rabies 
virions, purified from an infected cell culture (adapted from F. A. Murphy, School of Veterinary Medicine, 
University of California). (B) Illustration of a RABV particle showing virion organization. The viral RNP is composed 
of the RNA genome, the nucleoprotein (N), and the phosphoprotein (P) and forms the helical core. The matrix 
protein (M) forms a linkage between the RNP and the envelope, which is composed of a lipid membrane and the 
glycoprotein (G). (C) Organization of RABV RNA genome. The genome has a negative orientation, and comprises 
the genes N, P, M, G, L. Upon infection, sequential transcription of a 58 nt long 5’-ppp leader RNA and five capped 
and polyadenylated mRNAs takes place. mRNAs are translated into respective proteins. Replication of a full-length 
antigenome (cRNA) and subsequently genome (vRNA) takes place.  
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Inside the virion, the genome is encapsidated by the nucleoprotein N to form the NC 
and is present in a condensed, superhelical conformation, most likely held together 
by the M protein, which makes it very tight and stable (Naeve et al., 1980). When the 
NC is released into the cytoplasm for replication and transcription, it takes up a 
relaxed form, which allows for RNA synthesis. In this form, the N protein still binds 
tightly to the viral genome to protect it from cellular compounds, like RNases or small 
interfering RNAs, however, the N-RNA shielding is transiently released such that the 
polymerase complex (L/P) can access the RNA (Albertini et al., 2006, 2008). This 
highly controlled and transient access of the viral polymerase to the RNA apparently 
also avoids production of immune-stimulatory long dsRNAs (Weber et al., 2006). 
Transcription of five subgenomic, monocistronic mRNAs takes place that are 5’-
capped and 3’-polyadenylated, just like cellular mRNAs. Transcription proceeds 
exclusively in the 3’-5’ direction, and due to eventual dissociation of the viral 
polymerase at the intergenic regions a gradient of the mRNAs is generated (for 
review see (Whelan et al., 2004)). Prior to transcription of the N gene, synthesis of a 
58 nt long 5’-pppRNA occurs, which is named leader RNA (Leppert et al., 1979). 
Subsequently, translation into viral proteins takes place. The genome RNP serves as a 
template for the generation of full-length anti-genome RNP, which in turn serves as 
template for the production of novel genomic RNPs that may serve for secondary 
transcription, replication, or assembly of new virions (see Fig. 1-2). 
 
1.1.3 Lyssavirus pathogenicity 
Although lyssaviruses are closely related, RABV is a unique member of the Lyssavirus 
genus. As opposed to other lyssaviruses, which are mainly associated to bats, RABV 
emerged as a threat for humans and terrestrial animals. The development of 
inactivated RABV vaccines for humans and pets, live attenuated viruses for wildlife, 
and post-exposure prophylaxis, has eradicated RABV in developed countries 
(Schneider and Cox, 1994). However, despite the availability of an effective vaccine, 
RABV still accounts for more than 50,000 human deaths per year, mainly occurring in 
poor rural regions of Africa and Asia and is largely transmitted by dogs (canine 
rabies). Due to its well-established host reservoir in Africa, Eurasia and North 
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America, including skunks, foxes, raccoons, dogs, jackals, bats etc., and the lack of 
structured vaccination programs in poor countries, an eradication of RABV appears 
difficult.  
RABV is in most cases transmitted via bites or scratches from infected animals. 
Transport of the virus to the CNS causes acute encephalitis and death in > 99 % of the 
cases. A key strategy of RABV to effectively reach the CNS is to avoid cytotoxicity by 
restraining innate immunity and inflammation, therefore maintaining the integrity of 
the neuronal network (Finke and Conzelmann, 2005). Indeed, compared to other 
virus induced encephalitides, little inflammation is observed in rabies. It is actually 
believed that clinical signs result from neuronal dysfunction rather that from 
cytotoxic damage of neurons (Fu and Jackson, 2005). In mutation studies, distinct 
viral proteins have been identified to affect virulence and neuroinvasiveness. For 
instance, the G proteins from distinct RABV strains differ in sequence and receptor 
use (Dietzschold et al., 2008), stimulation of apoptosis (Lafon, 2008), and 
neuroprotective activities (Prehaud et al., 2010). 
For unknown reasons, the incubation period can vary from approximately 1 week till 
up to 6 years, yet it generally takes 1-3 month until clinical signs appear, depending 
on the location of viral entry. First symptoms include fever, pain, and paraesthesia at 
the place of injury. Later hydrophobia, paralysis, or coma can follow. 
The etiological agent of rabies encephalitis was thought to be exclusively RABV, until 
first rabies-related viruses were isolated from European insectovirous bats (Jelesic 
and Nikolic, 1956) and from West African fruit bats (Boulger and Porterfield, 1958) in 
1956. Clinical signs have not only been detected in terrestrial animals and humans; in 
apparently rare cases, infected bats also showed signs of disease, such as atypical 
aggressiveness and finally death (Baer and Smith, 1991). Actually, many lyssaviruses 
have been detected as result of bats exhibiting such clinical signs (Banyard et al., 
2009). The transmission between bat conspecifics, showing clinical signs or not, is 
suggested to occur in their roosts, however, the actual route of transmission is still 
speculative. Apparently, all lyssaviruses are transmitted by direct contact of their 
hosts, which is in contrast to all other rhabdoviruses that are transmitted by insects. 
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Alarmingly, despite RABV, which is known to cause most cases of human rabies, 
sporadic cases of human rabies-like encephalitis caused by other lyssaviruses, namely 
EBLV-1, EBLV-2, ABLV and IRKV (all phylogroup I), have been reported (for review see 
(Banyard et al., 2011)).  
Despite the obvious relatedness amongst lyssaviruses, the factors limiting their host 
range and enabling host switching, thus a spill-over from bats to terrestrial mammals, 
are unclear. However, the potential of non-rabies lyssaviruses to infect mammals, 
including humans, indicates a limited susceptibility, which is the first prerequisite to 
further adaptation to other host species. Interestingly, vaccinations against RABV are 
also effective against other viruses of phylogroup I but not against phylogroup II or III 
(Badrane et al., 2001).  
 
1.1.4 RABV life cycle 
RABV entry: 
Although in vivo RABV and other lyssaviruses are renowned for their high 
neurotropism, resulting in their neuroinvasive character, in vitro they can infect 
nearly any cell type. The cell tropism is mainly determined by the transmembrane 
glycoprotein (G), which recognizes specific receptors via its ectodomain and induces 
membrane fusion (Gaudin, 1995). Receptors identified so far that facilitate cellular 
entry of RABV in vitro, are the nicotinic acetylcholine receptor (nAchR), the neural cell 
adhesion molecule (NCAM), and the neurotrophin receptor (p75NTR) (for review see 
(Lafon, 2005)). However, the importance of p75NTR in vivo has been questioned in a 
recent study (Tuffereau et al., 2007). Internalization of RABV and other lyssaviruses 
occurs via receptor-mediated endocytosis, generating vesicles/endosomes that 
contain complete virus particles. In neurons, these vesicles are transported along 
axonal microtubules in a retrograde fashion towards the cell body (Klingen et al., 
2007). Generation of an acidic pH in the endosome leads to fusion of viral and 
endosomal membrane, release of the virus genome and replication in the cell body. 
New virus particles are formed, which are exclusively transmitted via synaptic 
connections to pre-synaptic neurons (Astic et al., 1993) until reaching the CNS.  
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RABV replication: 
Once the RNP is released into the cytoplasm, it converts from a supercoiled to a 
relaxed form. As already described in part 1.1.2 of this thesis, this transition and the 
transient opening on the N-RNA clamping allows access of the viral RNA polymerase 
to the RNA genome, which serves as template for transcription and replication. 
Transcription of the N, P, M, G, and L gene starts at characteristic transcription start 
sites and continues until the polymerase encounters a stop/polyadenylation signal, 
characterized by a stretch of U residues. The polymerase stutters back and forth to 
generate an approximately 50–150 nt long poly(A) tail. The transcriptional 
stop/polyadenylation signal and the start signal of the neighboring gene are typically 
separated by so-called “intergenic regions” composed of only few, probably non-
transcribed nucleotides, where the polymerase eventually dissociates (Finke et al., 
2000). This generates a gradient of subgenomic, monocistronic mRNAs with a 5’-cap 
and 3’-poly(A) tail (Li et al., 2006; Ogino and Banerjee, 2007) that are translated into 
viral proteins. Finally, novel virions assemble at the plasma membrane (for review 
see (Whelan et al., 2004)).  
The switch from transcription to replication goes along with two distinct forms of the 
polymerase, referred to as “transcriptase” and “replicase”, in which the L protein 
associates with P alone (L/P), or with P and N (L/P/N), respectively. From a 58 nt long 
region at the genome 3’-end, upstream of the N gene, an abundant amount of 5’-ppp 
leader RNA (see part 1.1.2) is synthesized. Previously, it was believed that synthesis 
of the 5’-ppp leader RNA is required for transcription, however, independent studies 
suggest that a leader-independent transcription initiation is possible. It was proposed 
that the transcriptase can directly enter at the leader/N junction, or scan from the 3’-
end to the leader/N junction to initiate transcription of N mRNA without synthesis of 
leader RNA (Curran and Kolakofsky, 2008; Whelan, 2008). 
Accumulation of the N protein and encapsidation of newly synthesized leader RNA by 
N (N-RNA) serves as a threshold for the initiation of replication of full-length genome. 
In case of vesicular stomatitis virus (VSV), the 5’-ppp leader RNA was found to be 
partially associated to N. Therefore, 5’-pppRNA may represent abortive replication 
products, generated due to insufficient amounts of N protein for encapsidation 
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(Blumberg et al., 1983). Product control may lead to the release of the leader RNA 
product from the polymerase and induces transcription at the leader/N gene junction 
(Vidal and Kolakofsky, 1989). However, in the presence of sufficient levels of N, the 
elaborate encapsidation of the leader RNA leads to formation of the “replicase” 
complex, which ignores the N gene start signal and induces replication to produce a 
full-length positive RNA strand complementary to the complete virus genome (Fig. 1-
2C; for review see (Whelan et al., 2004)). Positive-strand antigenomes are also 
encapsidated by N protein and serve as template for generation of negative-stranded 
genomes. This is driven from a promoter located in the 3’-end of the antigenome, 
complementary to the leader RNA, called trailer RNA. The affinity of the P-L complex 
to the N-trailer RNA is stronger than to the N-leader RNA, producing an up to 50-fold 
excess of genomes over antigenomes (Finke and Conzelmann, 1997). 
 
RABV assembly and budding: 
During assembly of new virus particles, the nascent RNA is encapsidated by the N 
protein. The P protein facilitates polymerization of the N protein on the vRNA by the 
formation of N-P heterodimers in the cytoplasm. P is hereby acting as chaperone for 
N that specifically targets nascent vRNA, thus preventing the N protein from binding 
to cellular RNA and from aggregating (Peluso and Moyer, 1988). The M protein, 
which has been identified to be the major player in virus budding and 
morphogenesis, is able to recognize newly formed RNPs (Mebatsion et al., 1996, 
1999). The G protein, which is transported to the plasma membrane via the ER and 
Golgi, plays rather a supportive role. On the plasma membrane, the M protein 
accumulates on the cytoplasmic side of G-enriched microdomains. During budding, 
RNPs attached to M condense into supercoiled structures, which, together with 
exocytic activity of the G protein, induce membrane curvature to form the bud site 
(Garoff et al., 1998). Viral egress is believed to occur with help of the host Nedd4 E3 
ligase, which recruits the cellular vacuolar protein sorting (VPS) machinery to the bud 
site, inducing separation of the virus particle from the cell (Jayakar et al., 2004; 
Okumura and Harty, 2011).  
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When viral replication in the CNS commences, anterograde axonal transport of virus 
to the skin and salivary glands takes place, and transmission to further hosts is 
possible.  
 
Figure 1-3: Simplified overview of the RABV life cycle. The virus enters the cell via receptor-mediated 
endocytosis (1). Subsequent pH-dependent membrane fusion leads to release of the viral genome into the 
cytoplasm (2). Transcription, translation, and replication produce novel virion components (3). Assembly of viral 
components takes place at the plasma membrane, budding occurs, and new virions are released (4) (adapted 
from (Schnell et al., 2010)).  
 
 
1.1.5 RABV phosphoprotein P 
 
The RABV phosphoprotein P is a multifunctional protein with important roles in 
transcription and replication, but also in counteracting specific steps leading to IFN 
gene expression and IFN-induced STAT signaling. Generally, the P proteins of 
Mononegavirales are critically involved in RNA synthesis, by acting as a non-catalytic 
cofactor of the polymerase complex L-P. In addition, RABV P binds to soluble N 
protein (N0) thereby aiding the specific encapsidation of viral RNA (Chenik et al., 
1994). Moreover, P is a binding partner of various cellular proteins, including dynein 
light chain, indicating a role in intracellular transport of viral components. The 
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diversity of functions and binding partners define P as a “hub” protein, crucial to the 
virus life cycle.  
 
 
Figure 1-4: Overview of RABV phosphoprotein P domains and functions. On top, the RABV P protein is illustrated 
with its three structured domains, the N-terminal domain (PNTD), the central domain (PCED), and the C-terminal 
domain (PCTD), separated by two intrinsically disordered domains. Truncated P forms and their respective 
transcription start sites are indicated by arrows. Phosphorylation sites are indicated and positions described. In 
the beige box the interacting domains, NLS and NES, and the aa that antagonize IRF3 activation are shown 
(adapted from (Rieder and Conzelmann, 2011)). 
 
In addition to the full-length P protein, which is the major product from the P mRNA, 
leaky scanning by the ribosome generates further truncated P proteins from 
downstream in-frame translation initiation codons (AUG). These P forms are named 
P2, P3, P4, and P5 and their initiation codons are located at aa 20, 53, 69, and 83, 
respectively (Chenik et al., 1995). RABV P is a 297 aa phosphoprotein that contains 
three structured domains located at the N-terminus (PNTD), the center of the protein 
(PCED), and the C-terminus (PCTD), separated by two intrinsically disordered domains, 
which provide flexibility. 
The phosphoprotein P deduces its name from its phosphorylated moieties, containing 
phosphorylation sites at S63/S64, S162, S219, and S271. In contrast to VSV P, 
phosphorylation of RABV P is not required for transcription. The N-terminal residue 
S63, which is phosphorylated by a so far unidentified cellular rabies virus-specific 
kinase (Gupta et al., 2000), did not reveal a functional relevance yet (Gerard et al., 
2009). Phosphorylation of C-terminal residues (S162, S210 and S271) by protein 
kinase C (PKC) was found to influence the nucleocytoplasmic distribution of P 
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(Moseley et al., 2007a). While P is entirely located in the cytoplasm, the lack of an N-
terminal NES in P3 - P5 can result in nuclear localization (Pasdeloup et al., 2005; Vidy 
et al., 2007).  
PNTD comprises the binding sites for L and N
0, and is therefore important for the 
polymerase co-function and RNA encapsidation. The central PCED contains a P binding 
domain for the formation of elongated P homodimers both in vitro and in vivo 
(Gerard et al., 2009; Jacob et al., 2001; Ivanov et al., 2010). Self-association of full-
length P dimers was shown to be dispensable for transcription (Jacob et al., 2001). 
However, dimerization has been shown to be essential for the cellular localization of 
P3 and its association with cytoplasmic microtubules (Moseley et al., 2009). Further 
interaction domains include a strong dynein light chain 8 (DLC; LC8) binding site, 
located in the second disordered P domain (Jacob et al., 2000; Raux et al., 2000). 
RABV mutants lacking the DLC binding site appear to have defects in efficient virus 
transcription in neurons (Tan et al., 2007) and subcellular location of P forms seems 
to be distorted (Moseley et al., 2007b). The large PCTD mediates binding to the N-RNA 
complex, and is therefore probably important for linking the polymerase P-L complex 
to the template (Schoehn et al., 2001; Mavrakis et al., 2004; Gerard et al., 2009; 
Ribeiro Jr. et al., 2008; Mavrakis et al., 2006).  
As already mentioned, RABV P is counteracting IFN gene transcription and IFN-
induced STAT signaling and is therefore a major factor in viral escape of the innate 
immune system and inflammation. RABV P interacts with STAT1/2 via its C-terminal 
aa 288-297 (Brzózka et al., 2006). Furthermore, binding of the PCTD to the 
promyelocytic leukemia (PML) protein (also named TRIM19), was found to play a role 
in antiviral activity (Blondel et al., 2002). In this study, the molecular basis of P-
mediated inhibition of IFN induction was addressed (Rieder et al., 2011).  
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1.2 Immune response to RABV 
1.2.1 The interferon (IFN) system 
The host defense against viruses depends on the recognition of ‘‘nonself’’ structures 
of pathogens, so-called pathogen-associated molecular patterns (PAMPs), by pattern 
recognition receptors (PRR) (Janeway Jr. and Medzhitov, 2002). These receptors 
induce signal transduction pathways leading to the secretion of the potent antiviral 
type I IFNs (IFNα/β) but also type III IFNs (IFNλ) and proinflammatory cytokines, like 
TNF and IL12 (Kawai and Akira, 2010; Pichlmair and Sousa, 2007). Type I IFNs are 
antiviral cytokines (Isaacs and Lindemann, 1957) that comprise the single IFNβ and 
the IFNα family (14 subtypes) of partially homologous proteins (Calam, 1980). 
However, besides their essential role in innate immunity, type I IFNs are also able to 
stimulate adaptive immunity by inducing immune-modulatory genes, supporting 
activation of dendritic cells (DC), stimulating macrophages, increasing major 
histocompatibility complex class-I expression, and stimulating antibody secretion. 
These alterations support a Th1-biased immune response, thus integrating innate 
and adaptive immunity (for review see (Goodbourn et al., 2000)). 
 
RLR and TLR signaling: 
Although it is long known that dsRNA, or the synthetic dsRNA analogue poly(I:C), are 
potent inducers of type I IFN (Field et al., 1967), the receptors responsible for 
recognition of nonself RNA, the signaling cascades induced and the transcription 
factors involved have only been discovered in the past 10 years. PRRs of two families 
could be assigned to recognize viral RNA, namely the endosomal transmembrane 
Toll-like receptors (TLRs) 3, 7 and 8, and the cytoplasmic retinoic acid inducible gene-I 
(RIG-I)-like receptors (RLRs) RIG-I and MDA5 (melanoma differentiation-associated 
gene 5) (for reviews see (Kawai and Akira, 2010; Yoneyama and Fujita, 2010)). The 
virus-induced TLRs and RLRs trigger distinct signaling pathways that, however, 
eventually merge in the activation of the IFN regulatory transcription factor (IRF)3 (or 
IRF7), which activates transcription of type I and III IFNs (Honda and Taniguchi, 2006). 
Furthermore, these pathways lead to canonical activation of the nuclear factor-κB 
(NF-κB), which is not only the major transcription factor of a variety of 
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proinflammatory cytokines, such as TNF-α and interleukins, but also supports 
transcription of the early IFNs, such as IFNβ and IFNα4 (Perkins, 2007).   
               
 
Figure 1-5: Induction of IFN and proinflammatory cytokines. The RLRs RIG-I and MDA5 (A) and the TLRs TLR3/7/8 
(B) detect specific viral RNAs (red letters). This induces the formation of downstream signaling complexes (grey), 
which recruit and activate associated kinases (orange). The kinases TBK1 and IKKi phosphorylate and thus activate 
IRF3/7, whereas IKKα only activates IRF7. The IRFs form homo- or hetero-dimers and bind to the IFNα/β promoter 
in the nucleus. Simultaneously, the IKKα/β/γ (IKKγ=NEMO) complex is activated, which induces the ubiquitination 
of IkB so that NF-κB is released and translocates to the nucleus. NF-κB and AP-1 also associate to the IFNα/β 
promoter, allowing the full capacity of IFNα/β transcription. 
 
The RLRs RIG-I and MDA5 are cytoplasmic receptors, and therefore recognize 
cytoplasmic viral RNA. Upon activation, the N-terminal caspase activation and 
recruitment domains (CARDs) of RIG-I or MDA5 interact with the CARD of the 
mitochondrial adaptor IPS-1 (also called MAVS, VISA, or Cardif (Kawai et al., 2005)). 
Subsequently, TRAF3 associates to the C-terminal region of IPS-1, resulting in the 
formation of a large signaling complex with TRADD (Michallet et al., 2008), TANK 
(Pomerantz and Baltimore, 1999), NAP1 (Fujita et al., 2003), and SINTBAD (Ryzhakov 
and Randow, 2007). Complex formation is a pre-requisite for the poorly understood 
activation of the ubiquitous kinase TBK1, and the related IKKi (also named IKKε; 
largely expressed in immune cells), which then phosphorylates and thus activates 
IRF3 or IRF7 at multiple residues of the C-terminus, inducing transcription of IFNα/β. 
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As opposed to IRF3, IRF7 is not present ubiquitously but expression is upregulated by 
IFN signaling. Furthermore, a protein named MITA (also called STING or MPYS), which 
interacts with RIG-I, IPS-1, and possibly IRF3, has been found crucial for RLR signal 
transduction, and was suggested to act as scaffold protein (Bowzard et al., 2009).  
An additional complex is formed on IPS-1 upon RLR activation, where TRADD 
associates with FADD1 and Rip1 (Balachandran et al., 2004). This leads to the 
activation of the latent IKKα/β/γ complex, which phosphorylates the inhibitor of NF-
κB (IκBα) at serines 32 and 36, leading to the proteasomal degradation of the 
inhibitor and activation of NF-κB (Traenckner et al., 1995).  
TLR3/7/8 recognize RNA in endosomal compartments and subsequently associate to 
adaptor proteins containing a TIR domain. TLR3 detects dsRNA and consequently 
interacts with the adapter protein TRIF. This is followed by the recruitment of TRAF3, 
TANK, and the kinase TBK1, which in turn phosphorylates IRF3/7 for activation. The 
ssRNA recognizing TLR7/8 use a common signaling complex, formed on the adapter 
protein MyD88 (Honda et al., 2004), which recruits TRAF6 (Kawai et al., 2004) and 
TRAF3 (Oganesyan et al., 2006), IRAK1 (Uematsu et al., 2005), IRAK4 (Kim et al., 
2007), as well as IKKα (Hoshino et al., 2006). IKKα recruits IRF7 to the signaling 
complex and leads to its activation. TLR3, 7, and 8 also induce activation of NF-κB. 
Activation of IRF3: 
IRF3 belongs to the IRF family (IRF1-9) and is composed of a DNA-binding domain 
(DBD) containing a nuclear localization signal (NLS), a proline-rich domain containing 
a nuclear export signal (NES), a C-terminal IRF association domain (IAD) and several 
regulatory phosphorylation sites (Lin et al., 1999). IRF3 is ubiquitously expressed and 
exists latently in a monomeric form. Although a constant shuttling of IRF3 between 
the cytoplasm and the nucleus (through interaction with exportin CRM1 and 
importin-α members, respectively) takes place, in resting cells the export is 
prevailing. This generates an equilibrium on the part of the cytoplasm (Kumar et al., 
2000). Upon virus infection, phosphorylation of IRF3 by TBK1 or IKKi occurs, inducing 
IRF3 activation.  
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It was shown that the chaperone heat shock protein (Hsp)90 interacts with IRF3 and 
TBK1, hereby probably bringing TBK1 and IRF3 into proximity which facilitates IRF3 
phosphorylation by TBK1 (Yang et al., 2006). Interestingly, the protein translocase of 
outer membrane 70 (Tom70), a mitochondrial import receptor, was found to interact 
with Hsp90 but also IPS-1 upon RNA virus infection. This interaction is crucial for 
activation of TBK1 and IRF3 and it is therefore assumed that Tom70 acts as a critical 
adaptor linking IPS-1 to TBK1/IRF3/Hsp90 (Liu et al., 2010). Furthermore, in vitro 
analyses revealed that cyclophilin (Cyp)B, a protein that facilitates protein folding by 
its cis-trans peptidyl-prolyl isomerase activity, interacts with the auto-inhibitory 
domain of IRF3. This interaction was shown to be essential for virus-induced IRF3 
activation (Obata et al., 2005).  
Diverse reports indicate that specific phosphorylation events induce conformational 
changes that lead to homo/hetero-dimerization of IRF3/7 and association with the 
co-activators of transcription CBP (CREB-binding protein) or p300. This interaction is 
assumed to mask the IRF NES, leading to accumulation in the nucleus (Kumar et al., 
2000). IRF3 binding to PRDIII-I of the IFNβ enhancer is sufficient to induce IFNβ 
transcription (Schafer, 1998), however, simultaneous binding of NF-κB and AP1 
transcription factors to PRDII and PRDIV, respectively, forms the IFNβ enhanceosome 
that fully activates transcription from the IFNβ promoter (Kim et al., 2000).  
Phosphorylation of IRF3 is believed to be the major modification in vivo required for 
transcriptional activation. Activation involves conformational changes that unshields 
the IAD from constrains by auto-inhibitory structures (helices H1 and H5 of the IAD) 
(Qin et al., 2003). Distinct hypothesis are discussed that describe the specific 
phosphorylation events essential for activation. In previous studies involving IRF3 
mutants, mass-spectrometry, or phospho-specific antibodies it was suggested that 
phosphorylation of Ser and Thr residues clustered in two regions of the IRF3 C-
terminus, named site 1 (S385/S386) and site 2 (S396, S398, S402, T404, and S405), 
are decisive. Particularly the S385/S386 phosphorylation is characteristic for the 
active form of IRF3, as it is found in IRF3 dimers and in IRF3 bound to CBP. 
Furthermore, mutation of S385/S386 to non-phosphorylatable alanine abolishes 
activity, stressing their importance in transcriptional activity (Yoneyama et al., 1998).                  
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Figure 1-6: Structure of IRF3. (A) IRF3 comprises an N-terminal DNA binding domain (DBD) that contains an NLS, a 
central proline rich region (PRR) that contains an NES, and a C-terminal IRF association domain (IAD) and 
regulatory domain (RD) containing helices H1-H5. Phosphorylation of serine and threonine residues in the RD, 
such as S385/386 (site 1) and S396, S398, S402, T404, and S405 (site 2) by the virus induced kinases TBK1/IKKi, are 
involved in the activation of IRF3 (adapted from (Hiscott, 2007)). (B) Left: Ribbon diagram of IRF3 IAD in its 
inactive state where the IAD auto-inhibitory helices H1 and H5 (red) confer hydrophobic interactions with the H3 
and H4 helices. C-terminal phosphorylation sites are shown in yellow (shown on the left). Right: Conformational 
changes lead to the interaction of the IAD helices H3 and H4 with the IRF-binding domain (IBiD) of CBP (blue) 
((Hiscott, 2007) figure provided by Dr. Kai Lin). 
 
Given that IRF3 mediates expression of various cytokines upon viral infection and 
ultimately modulates the immune response, the activation of IRF3 is subject to 
multiple regulations. For example, dsRNA induced IRF3 transcriptional activity was 
shown to be terminated by ubiquitinylation. It is suggested that phosphorylation of 
IRF3 at Ser339/Pro340 promotes interaction with the peptidyl-prolyl isomerase Pin1 
(peptidyl-prolyl cis/trans isomerase, NIMA-interacting 1) that might catalyze 
conformational changes of IRF3 finally inducing polyubiquitinylation and proteasome-
dependent degradation. Since phosphorylation of Ser 396 precedes the 
phosphorylation of Ser 339, it is assumed that phosphorylation of cluster II probably 
exposes Ser 339 favoring its subsequent phosphorylation. Ser 339 phosphorylation 
initially results in the fully active IRF3 that homodimerizes and associates with 
CBP/p300. In this state IRF3 is furthermore recognized by Pin1 leading to degradation 
(Bibeau-Poirier et al., 2006; Clément et al., 2008; Saitoh et al., 2006).  
Further proteins have been demonstrated to regulate IRF3 activation. A negative 
regulator of IRF3 is for example the suppressor of IKKi (SIKE) that interacts with IKKi 
and TBK1, thus disrupting their interactions with TRIF, RIG-I and IRF3. Virus induced 
disruption of the binding of SIKE to TBK1/IKKi allows for IRF3 activation (Huang et al., 
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2005). On the other hand, also positive regulators were identified, such as TRIM21 
which interferes with the Pin1/IRF3 interaction, thus preventing IRF3 ubiquitination 
and degradation to sustain IRF3 activation during antiviral response (Yang et al., 
2009). Furthermore, HERC5, an ISG15 E3 ligase, binds IRF3 upon viral infection and 
induces ISGylation of IRF3. This modification also inhibits ubiquitinylation and 
degradation of IRF3 (Shi et al., 2010).  
In a recent study, a further role of IRF3 has been elucidated besides its role as a 
transcription factor, which however is also induced via the RLR-signaling cascade. In 
virus-infected cells and in the additional presence of TRAF2 and TRAF6 which interact 
with the IPS-1/TRAF3/TBK-1 complex, IRF3 induces apoptosis by direct interaction 
with Bax at the mitochondria (via a BH3 domain in the IRF3-IAD H4 helix). This pro-
apoptotic role of IRF3 is independent of the events leading to its transcriptional 
activity but is assumed to depend on distinct, yet unknown phosphorylation events 
by TBK1 (Chattopadhyay et al., 2010).  
 IFN signaling: 
Secreted type I and II IFN acts in an autocrine and paracrine fashion by binding to the 
IFNα/β or IFNγ receptor (IFNAR, IFNGR), respectively, and activating the canonical 
JAK/STAT pathway, which induces the transcription of hundreds of interferon-
stimulated genes (ISG), several of which have antiviral and immune stimulatory 
activity. IFNα/β bind to IFNAR which results in binding of TYK2- and JAK1 and 
subsequent tyrosine phosphorylation of the latent transcription factors STAT1 and 
STAT2. This causes formation of a heteromeric complex (IFN-stimulated gene factor 3 
*ISGF3+) containing STAT1, STAT2, and IRF9. In the case of IFNγ binding to IFNGR, a 
JAK1 and JAK2 dependent tyrosine phosphorylation of STAT1 causes the association 
to STAT1 homodimers called the gamma-activated factor. ISGF3 and gamma-
activated factor bind to DNA sequences called interferon stimulated response 
element (ISRE) and gamma-activated sequences (GAS), respectively, which are 
present in the promoters of many genes, hence promoting their transcription. IFN-
induced JAK/STAT signaling stimulates the expression of many components of the 
PAMP-sensing machinery, hence providing a feedback loop increasing the magnitude 
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of sensing and IFN response (for review see (Kawai and Akira, 2008)). 
 
 
Figure 1-7: IFNα/β- and IFNγ-induced JAK/STAT signaling. IFNα/β and IFNλ act in an auto- and paracrine fashion 
by binding to cell surface IFNAR1/2 and IFNGR1/2, respectively. This results in activation of receptor-associated 
kinases JAK1/TYK2 and JAK1/JAK2, respectively, inducing phosphorylation of STAT1 and STAT2 transcription 
factors. In case of IFNAR signaling, STAT1 and STAT2 dimerize and recruit IRF9 (to form ISGF3), which leads to 
nuclear translocation and transcriptional activation of ISRE genes. IFNGR signaling leads to STAT1 
homodimerization, translocation to the nucleus and transcription of GAS genes. ISGs are expressed, including 
many antiviral proteins. 
 
Proteins encoded by ISGs include, for instance, IRF7 and RLRs, and direct antiviral 
proteins, such as PKR, 2’-5’ OAS and RNaseL, or Mx proteins (Haller et al., 2007b; 
Sandrock et al., 2001; Silverman, 2007; Williams, 1999). The 2’-5’ OAS/RNase L 
system degrades viral and cellular RNAs. PKR is activated by dsRNA (Kerr et al., 1974; 
Lebleu et al., 1976) or by proteins like PACT (Sen and Peters, 2007) and limits viral 
translation by phosphorylating the initiation factor eIF-2. Mx proteins are dynamin-
like GTPases effective against a broad variety of positive- and negative-strand RNA 
viruses (Haller et al., 2007a).  
Furthermore, the PML protein, which is a component of nuclear multiprotein 
complexes named PML nuclear bodies (NBs), has been found to be induced by type I 
and type II IFNs. In PML knockout MEFs, the infectious titers of the RABV strain CVS 
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were significantly increased (Blondel et al., 2002). Additionally, overexpression of the 
PML isoforms IV and IVa, but not other isoforms, resulted in reduction of RABV 
replication, indicating specific antiviral activities (Blondel et al., 2010). 
 
1.2.2 Activation of RLR signaling by RABV 
While expression of TLRs is mostly limited to specialized immune cells, such as 
dendritic cells and macrophages, the RLRs appear to be ubiquitous. RLR signaling 
emerges to be the major path for inducing an IFN response upon RNA virus infection, 
while involvement of TLRs is rather specialized.  
TLR3/7/8 were shown to be involved in recognition of various viruses, including 
respiratory syncytial virus (TLR3) (Rudd et al., 2006) and VSV (TLR7) (Lund et al., 
2004), which may gain access to the endosomal receptor by autophagy (for review 
see (Kawai and Akira, 2010)). However, their role in recognition of RABV is 
controversial (Edelmann et al., 2004). A certain role of TLR3 in response to RABV 
infection was shown when TLR3 was upregulated after RABV infection of mice and in 
the human cerebellar cortex tissues (Jackson et al., 2006). However, a recent study 
with TLR3 knockout mice showed that TLR3 does not contribute to IFN production in 
DC during RABV infections (Faul et al., 2010). It is even possible, that TLR3 might have 
a proviral role as it is involved in the generation of RABV Negri bodies (Menager et 
al., 2009). TLR7/8 was also excluded to be involved in RABV recognition. It was shown 
that the lack of TLR7/8 did not alter IFN expression in RABV-infected mouse DC (Faul 
et al., 2010). Furthermore, TLR7- dependent activation of IFN expression by RABV in 
isolated human pDC was not observed (Hornung et al., 2004).  
The importance of RLRs in the antiviral response was illustrated by generation of RLR 
knockout mice where an adequate antiviral immunity to RNA viruses, including 
rhabdoviruses, could not be mounted (Kato et al., 2006; Kumar et al., 2006). RIG-I, 
MDA5 and laboratory of genetics and physiology 2 (Lgp2) are DExD/H box RNA 
helicases/translocases belonging to the superfamily 2 (SF2) helicases or ATPases 
(Kang et al., 2002; Yoneyama et al., 2004; Rothenfusser et al., 2005). All RLRs contain 
a C-terminal regulatory/repressor domain (RD or CTD) and an ATP-dependent 
1  Introduction 
 
 
21 
helicase domain (HD) that harbors the seven core motifs I (Walker A motif), Ia, II 
(Walker B motif), III, IV, V, and VI. RIG-I and MDA5 additionally contain two N-
terminal tandem CARDs, which interact with CARDs from other proteins, hence being 
mediators in nucleating signaling events. Lgp2, however, lacks a CARD domain and is 
not able to directly convey downstream signaling but rather confers a regulatory role 
(Yoneyama et al., 2005). Interestingly, the closely related RIG-I and MDA5 seem to 
recognize distinct PAMPs of RNA viruses, although both can bind to dsRNA or the 
dsRNA analogue poly(I:C).  
                                  
Figure 1-8: Domain structure of RLRs. (A) Schematic illustration of the RLRs MDA5, RIG-I and Lgp2. All RLRs are 
composed of a C-terminal regulatory domain (RD) and a helicase domain (HD) that contains the seven core motifs 
I, Ia, II and III (domain 1), and IV, V and VI (domain 2). MDA5 and RIG-I additionally contain two N-terminal 
caspase activation and recruitment domains (CARDs) that confer downstream signaling. (B) Sequence comparison 
of the motifs I, II, III, IV, V and VI (Ia not shown) (adapted from (Bamming and Horvath, 2009)). 
 
Whereas RIG-I responds to a variety of positive and negative strand RNA viruses, 
including rhabdoviruses, MDA5 seems to rather recognize positive stranded 
picornaviruses, like encephalomyocarditis virus (EMCV) and may contribute to 
recognition of reovirus and dengue virus (Kato et al., 2006). A recent publication, 
however, revealed an contribution of MDA5 to the induction of type I IFN after 
measles virus (MeV) (Ikegame et al., 2010) and Sendai virus (SeV) (Gitlin et al., 2010) 
infection, both negative stranded RNA viruses like RABV. Furthermore, RABV was 
seen to induce IFN in DC of RIG-I knockout mice (Faul et al., 2010). The identity of 
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specific viral ligands of MDA5 and also RIG-I, and a tentative interplay between the 
two receptors, are still highly discussed. RNA transfection experiments suggested 
differential activation of RLRs. RIG-I was activated by in vitro-transcribed RNAs which, 
like rhabdoviral leader and genome RNAs, contain a 5’-ppp (Hornung et al., 2006) but 
also requires a base-paired region of at least 18-20 nucleotides (5’-ppp-dsRNA) 
(Schmidt et al., 2009). Lgp-2 also recognizes dsRNA, independent of 5’-ppp (Pippig et 
al., 2009). MDA5 was shown to recognize dsRNA lacking 5’-terminal phosphates as 
seen in picornaviruses, which produce RNAs that lack a 5’-ppp and instead have a 
protein (Vpg) linked covalently to the 5’-terminus (Gitlin et al., 2006). Further studies 
suggested that MDA5 prefers longer dsRNA, whilst RIG-I prefers shorter dsRNA (Kato 
et al., 2008). However, recent findings indicate that RIG-I also recognizes much longer 
(>200 bp) dsRNAs not necessarily bearing a 5’-ppp (Binder et al., 2011). The existence 
of such RNAs in infected cells is however controversial, and binding  apparently 
occurs with much lower affinity.  
In order to elaborate the molecular understanding of the RLR activation, diverse 
structural studies have been undertaken. Crystal structures of individual RLR 
domains, in part complexed with specific RNAs, ATP analogues, zinc etc. (Civril et al., 
2011; Cui et al., 2008; Jiang et al., 2011; Pippig et al., 2009; Takahasi et al., 2009; Li et 
al., 2009), but also of full-length RIG-I (Kowalinski et al., 2011; Luo et al., 2011) could 
be successfully resolved. Taken these data together a gross model of general RLR 
activation and a more elaborate model of RIG-I activation is suggested. In the 
absence of a ligand, RIG-I exists in an auto-inhibited state where the CARDs fold back 
to the C-terminal part of RIG-I, probably being shielded from downstream signaling 
by interactions with the HD (or the RD, or both). This conformation sterically hinders 
dsRNA binding to the helicase and K63-polyubiquitinylation of the CARDs, which is 
required for interaction with IPS-1 (Gack et al., 2007). The first step of activation is 
the recognition of 5’-ppp-dsRNA by the flexible RD (much higher affinity compared to 
5’-OH-dsRNA), which leads to co-operative binding of dsRNA and ATP to the HD. A 
conformational switch occurs, driven by ATP hydrolysis that releases the CARDs, 
allowing for their polyubiquitinylation and downstream signaling (Hopfner and 
Michaelis, 2007). It is also suggested that RIG-I forms dimers or oligomers along the 
dsRNA. The ligand specificity could be explained by the distinct residues in the 
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generally conserved RD RNA binding loop. For example, RIG-I, but not MDA5 or Lgp2, 
contains a lysine residue that is critically required for triphosphate binding. 
 
1.3 RABV countermeasures to inhibit IFN 
In order to restrain damage of neuronal circuits for efficient virus spread to the CNS, 
RABV pursues various strategies. In the past years the importance of viral 
counteractions against the host type I interferon system in order to establish an 
infection became evident. RABV phosphoprotein P takes up a key role in the viral 
evasion of the IFN system. In distinct experiments it was shown that RABV P directly 
interferes with IFN induction and also IFN signaling.  
RABV P inhibits IFN induction: 
The shifting of individual rhabdoviral genes to distinct positions in the genome can be 
used as a tool to control expression levels of RABV proteins due to a possible 
dissociation of the viral polymerase at the intergenic regions and the resulting 
attenuated transcription of genes. The expression of RABV P was manipulated by 
generating a recombinant RABV expressing P from the most downstream position 
(SAD ∆PLP: 3’-N-M-G-L-P-5’; wt: 3’-N-P-M-G-L -5’) so that very little amounts of P are 
expressed, just sufficient to support RNA replication. SAD ∆PLP was only slightly 
attenuated in an IFN incompetent cell line but completely failed to replicate in IFN-
competent cells. This effect was correlated with efficient transcription of IFNβ mRNA 
in SAD ∆PLP infected cells, whereas in wt RABV-infected cells IFNβ transcription was 
hardly detectable. In addition, SAD ∆PLP infection resulted in phosphorylation of 
S386 and dimerization of the critical transcription factor IRF3 as opposed to wt virus. 
Ectopic expression of P from plasmids inhibited IRF3 activation, and IRF7 activation to 
a lesser extent, after TBK1 overexpression (Brzózka et al., 2005).  
RABV P inhibits IFN signaling: 
In cells infected with RABV the induction of ISGs and of ISRE- or GAS-controlled 
luciferase by IFNα/β or IFN  treatment was found to be almost completely abolished 
as opposed to cells infected with SAD ∆PLP. This demonstrates that RABV P is a 
potent IFN signaling antagonist. Overexpression of P from plasmid could also inhibit 
1  Introduction 
 
 
24 
ISG promoter activation after stimulation of the cells with IFNα or IFNγ, reinforcing 
the inhibitory role of P. Interestingly, despite the lack of ISRE and GAS-controlled 
gene expression in wt RABV-infected cells, effective phosphorylation of both STAT1 
and STAT2 was observed after IFN treatment. Moreover, the phosphorylated 
isoforms of STATs accumulated in RABV infected cells, whereas in mock-infected cells 
phospho-STATs were rapidly de-phosphorylated. This could be explained in 
immunofluorescence studies after RABV infection or P cDNA transfection, which 
demonstrated STAT and RABV P co-localization in the cytoplasm. Individual studies 
suggested that RABV P associates with activated STATs, thereby sequestering the 
transcription factor in the cytoplasm, unable to bind its promoter (Brzozka et al., 
2006; Vidy et al., 2005). 
Not only full-length P but also the N-terminally truncated P3 can bind to STAT1 and 
retain it in the cytoplasm. Here, P3 associates with microtubules and thereby 
prevents STAT nuclear import. Furthermore, though representing a minor fraction of 
total P products, nuclear P3 can bind STAT1 thereby inhibiting its binding to the 
promoter of the ISGs (Vidy et al., 2007). An intriguing finding was that P3 that is 
localized to the nucleus exists as a monomer, whereas cytoplasmic P3 exists as a 
dimer. Dimerization of P3 in the cytoplasm is essential for the stable association of P3 
with microtubules (Moseley et al., 2009).  
 
Interplay of RABV with antiviral ISGs: 
Inhibition of RABV and other lyssaviruses by otherwise potent antiviral ISGs, such as 
PKR and the 2’-5’ OAS/RNase L system, has not been observed so far. Although 
IFNα/β induced bovine Mx was reported to inhibit specific strains of RABV, human 
Mx protein does not seem to inhibit lyssaviruses (Leroy et al., 2006). The only 
antiviral ISG identified so far to be effective against RABV is PML. However, RABV P of 
the CVS strain has been shown to bind to the PML protein. It is suggested that this 
interaction retains PML in the cytoplasm and hereby inhibits the IFN-induced antiviral 
activities of PML (Blondel et al., 2002; Chelbi-Alix et al., 1998; Everett and Chelbi-Alix, 
2007).  
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1.4 Aim of this thesis 
It was shown that RABV P is a potent inhibitor of the RLR-induced IFN-induction 
pathway and the IFN-induced JAK/STAT pathway. The mechanism of RABV to inhibit 
IFN signaling has been ascribed to the binding of RABV P aa 288-297 to activated 
STAT1/2 and the resulting retention of STATs in the cytoplasm (Brzózka et al., 2006). 
Furthermore, P3 can bind to STAT in the nucleus (Vidy et al., 2007). These interactions 
inhibit binding of STAT transcription factors to promoters of target genes. It has also 
been revealed that RABV P inhibits IRF3 activation (Brzózka et al., 2005) and that the 
internal aa 176-186 are essential for this inhibition (Rieder et al., 2011).  
The aim of this thesis is to elaborate the mechanisms of RABV P to inhibit the IFN 
induction pathway. RABV P deletion mutants and recombinant RABV lacking aa 176-
186, which lost the ability to inhibit IFN induction, were characterized in vitro and the 
pathogenicity of recombinant viruses was analyzed in vivo. Cellular interaction 
partners of RABV P were identified and the mode of inhibitory action elucidated. 
From the data two models are proposed for the course of events leading to inhibition 
of IRF3 activation by RABV P: First, RABV P associates to RLRs depending on their 
conformational state, induced by the presence of an adequate ligand in case of RIG-I 
and independent of a ligand in case of MDA5 and Lgp2. Second, RABV P interacts 
with an activation intermediate of IRF3. Activation of IRF3 is conferred by 
conformational rearrangements that liberate domains essential for transcriptional 
activation of IRF3. The collected data indicates that the domains liberated are 
targeted by RABV P to circumvent transcription of IFN. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Chemicals 
All general solutions and buffers are listed in the appendix. 
Acetone p.a.        Roth 
Acrylamide/Bisacrylamide 29:1 Rotiphorese Gel 40  Roth 
Acetic acid glacial, Rotipuran  100 % p.a.    Roth 
Acetone, Rotipuran  99.8 % p.a.     Roth 
Acridine orange       Roth 
Agarose, UltraPure       Invitrogen 
Ammonium chloride (NH4Cl)      Merck 
Ammonium persulfate; (APS) ((NH4)2S2O8)    Amresco 
Ampicillin sodium salt (Amp)      Roth 
Bacto tryptone       Becton Dickinson 
Bacto yeast extract       Becton Dickinson 
-Mercaptoethanol       Sigma-Aldrich 
Brilliant blue        Biorad 
Bromphenol blue       Sigma-Aldrich 
BSA         Sigma-Aldrich 
Calcium chloride dihydrate (CaCl2 2H2O)    Sigma-Aldrich 
Chloramphenicol succinate sodium salt (CAM)   Sigma-Aldrich 
Deoxychol acid (DOC)      Sigma-Aldrich 
Disodium hydrogen phosphate dihydrate (Na2HP04 2H2O)  Merck 
Dimethyl sulfoxide (DMSO), p.a.     Roth 
DL-Dithiothreitol, BioUltra,  99.5 % (DTT)    Roth 
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Ethylenediamine tetraacetic acid (EDTA)    Sigma 
Ethanol, p.a.        Merck 
Ethidium bromide solution 1 %     Roth 
Ficoll 400        Pharm. Fine Chem. 
Formic acid, p.a.        Merck 
Geneticin (G418)       Invitrogen Gibco 
Glycerol , Rotipuran   99.5 %      Roth 
L-Glutamine        Invitrogen Gibco 
Glyoxal        Sigma-Aldrich 
Hydrochloric acid, Rotipuran  37 % p.a.    Merck 
Hygromycin B        Calbiochem 
Imidazole        Merck 
Isopropyl -D-1-thiogalactopyranoside (IPTG)   Roth 
Isopropanol, p.a.       Merck 
Kanamycin monosulfate salt (Kan)     Sigma-Aldrich 
Lithium chloride, p.a.       Merck 
Leupeptin        Sigma-Aldrich 
Magnesium chloride hexahydrate (MgCl2 6H2O)   Fluka 
Magnesium sulfate heptahydrate (MgSO4 7H2O)   Merck 
Methanol abs., p.a.       Roth 
Milk powder, blotting grade      Roth 
NP-40 substitute       Fluka  
Orange G        Sigma / Fluka 
Paraformaldehyde       Merck 
Phenol red        Merck 
Phenylmethylsulfonylfluorid (PMSF)     Serva 
Polyethyleneimine (PEI), high MW, water-free   Sigma-Aldrich 
Potassium acetate, extra pure (CH3CO2K)    Merck 
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Potassium chloride, p.a. (KCl)     Merck 
Potassium dihydrogen phosphate, p.a. (KH2PO4)   Merck 
Potassium hydrogen carbonate (KHCO3)    Merck 
Sodium citrate x 2H2O      Merck 
Sodium dodecyl sulfate (SDS)     Serva 
Sodium acetate trihydrate, p.a. (NaOAc 3H2O)   Merck 
Sodium chloride, p.a. (NaCl)      Merck 
Sodium hydrogen carbonate (NaHCO3)    Merck 
Sodium hydroxid (NaOH)      Merck 
Sodium orthovanadate (Na3VO4)     Sigma-Aldrich 
Sodium phosphate       Merck 
Tetramethylethylenediamine (TEMED)    Roth 
Tricine, Pufferan  > 99 %      Roth 
Tris, Pufferan   99.9 %       Roth 
Trisodiumcitrate-dihydrate > 99 % p.a.    Roth 
Triton X-100        Merck 
Tween-20        Roth 
Urea, Pufferan   99.5 % p.a.     Roth 
Xylene cyanol        Sigma-Aldrich 
 
2.1.2 Kits 
Plasmid purification: 
Nucleobond  Xtra Midi      Macherey&Nagel 
DirectPrep  96 Miniprep      Qiagen 
Cloning: 
QIAquick  Gel Extraction Kit     Qiagen 
QIAquick  Nucleotide Removal Kit     Qiagen 
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QIAquick  PCR Purification Kit      Qiagen 
Luciferase reporter gene assay: 
Dual Luciferase  Reporter Assay System    Promega 
In vitro transcription: 
MEGAshortscript Kit        Ambion 
Northern blot: 
Ready prime II kit       GE healthcare 
RNA isolation: 
RNeasy  Mini Kit       Qiagen 
Real time PCR: 
Quantitect SYBR  Green PCR Kit     Qiagen 
Transfection: 
Mammalian Transfection Kit      Stratagene 
 
2.1.3 Enzymes and buffers 
DNA polymerases: 
Pfu DNA Polymerase       Fermentas 
10x Pfu Buffer        Fermentas 
Phusion  High Fidelity DNA Polymerase    NEB 
5x Phusion HF Buffer       NEB 
Taq DNA Polymerase       biomaster 
10x amplif. buffer incl. MgCl2 25mM for Taq Pol.   biomaster 
DNase/RNase: 
TURBO DNase  Deoxyribonuclease I, RNase free    Fermentas  
RNase A        Macherey&Nagel 
RNA polymerases: 
Transcriptor Reverse Transcriptase     Roche 
DNase/RNase inhibitors: 
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SUPERase-In        Ambion 
Restriction enzymes: 
Restriction Enzymes       NEB  
NEBuffer 1, 2, 3, 4       NEB 
Ligase: 
T4 DNA Ligase        NEB 
T4 DNA Ligase Buffer       NEB 
Phosphatase : 
Calf Intestine Alkaline Phosphatase (CIAP)    NEB 
Protease Inhibitor: 
cOmplete ULTRA Protease Inhibitor Cocktail Tablets  Roche 
 
2.1.4 Oligonucleotides 
Primers for PCR and sequencing were ordered from metabion. Primer sequences can 
be found in the appendix. 
Miscellaneous: 
Deoxyribonucleotide triphosphate (dNTPs) mix       Bioline 
Polyinosinic:polycytidylic acid (poly I:C)    Sigma 
 Oligo(dT)12-18 Primer      Invitrogen  
dNTPs Set        Bioline   
-32P-ATP        Hartmann Analytic 
Oligonucleotides for in vitro transcription: 
MeV-leader +: 
5’-AATTCGCGTAATACGACTCACTATAACCAAACAAAGTTGGGTAAGGATAGTT 
CAATCAATGATCATCTTCTAGTGCACTT-3’ 
MeV-leader + template: 
5’-AAGTGCACTAGAAGATGATCATTGATTGAACTATCCTTACCCAACTTTGTTTG 
GTTATAGTGAGTCGTATTACGCG-3’ 
MeV-leader –: 
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5’-AATTCGCGTAATACGACTCACTATAAAGTGCACTAGAAGATGATCATTGATTG 
AACTATCCTTACCCAACTTTGTTTGGT-3’ 
MeV-leader – template: 
5’-ACCAAACAAAGTTGGGTAAGGATAGTTCAATCAATGATCATCTTCTAGTGCAC 
TTTATAGTGAGTCGTATTACGCG-3’ 
 
2.1.5 Antibodies 
Primary antibodies (dilution WB, IF): 
Flag M2 polyclonal rabbit (1:20,000, 1:200)    Sigma-Aldrich 
Flag M2 monoclonal mouse (1:20,000, 1:200)    Sigma-Aldrich 
RABV P rabbit custom-made (P160-5) (1:50,000, 1:2000)  Finke Stefan 
RABV RNP (against N, P) rabbit custom-made (S50) (1:20,000, - )  BFAV 
RABV G rabbit custom made (HCA05/1) (1:10,000, -)   Metabion 
RABV N rabbit custom made (S86) (1:10,000, - )   BFAV 
RABV M rabbit custom made (M1B3) (1:10,000, - )   BFAV 
RABV N (FITC-labeled) rabbit (Centocor ) (1:50,000, - )   FDI Fujirebio 
IRF3 (FL-425) rabbit (1:1000, 1:50)      Santa Cruz  
IRF3 phospho386 rabbit (1:1000, - )     IBL 
IRF3 phospho396 rabbit (1:1000, - )     Cell signaling 
IRF3 phospho396 rabbit (1:1000, - )     Upstate 
IRF3 phospho398 rabbit (1:1000, - )     Upstate 
TBK1 (N-term) rabbit (1:1000, - )     Epitomics 
IKKε/IKKi (K-14) goat (1:100, - )     Santa Cruz 
TANK (H-300) rabbit (1:200, - )     Santa Cruz 
Nap1 rabbit (1:500, - )      ABR 
MDA5 rabbit (1:1000, - )        BioCat 
RIG-I rabbit (1:1000, - )      Cell signaling 
Lgp2 rabbit (1:1000, - )      Proteintech Europe 
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NEMO/IKKγ (DA10-12) mouse (1:1000, - )      Cell signaling 
Actin (20-33) rabbit (1:5000, - )     Sigma-Aldrich 
GST (B14) mouse (1:1000, - )      Santa Cruz 
HA rat (1:1000, - )       Roche 
GFP rabbit (1:10,000, - )      Invitrogen 
Secondary antibodies (dilution WB, IF): 
Anti-mouse HRP  (1:20,000, 1:1000)  Jackson ImmunoResearch Laboratories 
Anti-rabbit HRP (1:20,000, 1:1000)  Jackson ImmunoResearch Laboratories 
Anti-human HRP (1:20,000, 1:1000)  Jackson ImmunoResearch Laboratories 
Anti-mouse Alexa 488 ( -, 1:200)     Invitrogen 
Anti-rabbit Alexa 488 ( -, 1:200)     Invitrogen 
Anti-rabbit Alexa 555 ( -, 1:200)     Invitrogen 
Anti-rabbit Alexa 633 ( -, 1:200)     Invitrogen 
Anti-mouse Alexa 633 ( -, 1:200)     Invitrogen 
Diverse immunoreagents (dilution IF): 
TO-PRO-3 iodide (1:1000)       Invitrogen 
 
2.1.6 Cell lines and media 
Cell lines: 
HEK 293T:  Human embryonic kidney cells expressing SV40 T-antigen (ordered from 
ATCC). 
Huh7.5: Human hepatoma cells containing a point mutation leading to non-
functional RIG-I (received from C. Rice). 
HEp-2: Human epidermoid (laryngeal squamous) carcinoma cells (ordered from 
ATCC). 
Vero: African green monkey kidney cells (ordered from ATCC). 
MVi/It: Interscapular tumor cells from Myotis velifer incautus bat (ordered from 
ATCC). 
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TB1/Lu: Lung epithelial cells from Tadarida brasiliensis bat (ordered from ATCC). 
BSR-T7/5: BHK21-derived (baby hamster kidney) cells expressing T7 polymerase 
(received from BFAV). 
 
Media and additives: 
D-MEM         Invitrogen  
G-MEM        Invitrogen  
Fetal Bovine Serum        Invitrogen  
Newborn Calf Serum       Invitrogen 
L-Glutamine 100x (200 mM)      Invitrogen  
Tryptose phosphate       Invitrogen 
MEM amino acids       Invitrogen 
Penicillin/Streptomycin       Invitrogen  
G418 sulfate        Calbiochem/Merck 
0.25 % Trypsin-EDTA       Invitrogen  
 
Medium for HEK 293T, Huh7.5, HEp-2:  D-MEM+3: 
D-MEM  
      + 10 % (v/v) FCS 
      + 2 mM L-Glutamine 
      + 0.2 % (v/v) Penicillin/Streptomycin 
Medium for BSR-T7/5:    G-MEM+4: 
G-MEM  
      + 10 % (v/v) NCS 
      + 4 % (v/v) Tryptose phosphate 
      + 2 % (v/v) MEM amino acids 
      + 0.2% (v/v) Penicillin/Streptomycin 
      + 1 M G418 every second passage 
Medium for MVi/It and TB1/Lu:   D-MEM+2: 
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      D-MEM  
      + 10 % (v/v) FCS 
      + 0.2 % (v/v) Penicillin/Streptomycin 
 
2.1.7 Bacteria and media 
Bacteria: 
Plasmid amplification: E. coli XL-1 Blue     Stratagene 
Recombinant protein expression: E. coli Rosetta (DE3)   Novagen 
Media for propagation of bacteria: 
LB medium:     85 mM NaCl 
0.5 % Yeast extract 
1 % (w/v) Bactotryptone 
1 mM MgSO4 
LB++:      85 mM NaCl 
0.5 % Yeast extract 
1 % (w/v) Bactotryptone 
1 mM MgSO4 
1 mM MgSO4 
10 mM KCl 
LB plates:     1000 ml LB medium  
      + 15 g Agar 
LB medium and LB plates were supplemented with the appropriate antibiotics: 
ampicillin (100 μg/ml), chloramphenicol (25 μg/ml), or kanamycin (25 μg/ml). 
 
2.1.8 Plasmids  
Commercially acquired plasmids: 
pCR3: eukaryotic expression vector, CMV-promoter controlled Invitrogen 
pEGFP-N3: eGFP vector, CMV-promoter controlled  Clontech  
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p125-Luc: Firefly luciferase, IFNβ promoter controlled  Promega 
pISRE-Luc: Firefly luciferase, ISRE controlled    Clontech 
pCMV-RL: Renilla luciferase, CMV-promoter controlled   Promega 
pCMV-myc vector        Invitrogen 
Plasmids kindly provided: 
pCAGGs:  
Cloning vector containing a ß chicken actin promoter; A. Garcia-Sastre.  
pCR3-RABV P:  
Expression plasmid for RABV P cloned into pCR3 vector; K. Brzózka. 
pCR3-RABV P ∆Ind1:  
Expression plasmid for RABV P lacking aa 176-181 cloned into pCR3 vector 
(restriction sites Acc65I/NotI); K. Brzózka (Rieder et al., 2011). 
pCR3-RABV P ∆Ind2:  
Expression plasmid for RABV P lacking aa 181-186 cloned into pCR3 vector 
(restriction sites Acc65I/NotI); K. Brzózka (Rieder et al., 2011). 
pCR3-RABV P-Ig:  
Expression plasmid for RABV P-Ig cloned into pCR3-Ig vector (restriction site 
HindIII); K. Brzózka. 
pCR3-Ig-RABV P:  
Expression plasmid for RABV P cloned into pCR3-Ig vector (restriction sites 
EcoRI/NotI); K. Brzózka. 
pCR3-Ig-RABV P2:  
Expression plasmid for RABV P2 (aa 19-297) cloned into pCR3-Ig vector 
(restriction sites EcoRI/NotI); K. Brzózka. 
pCR3-Ig-RABV P3:  
Expression plasmid for RABV P3 (aa 52-297) cloned into pCR3-Ig vector 
(restriction sites EcoRI/NotI); K. Brzózka. 
pCR3-Ig-RABV P4:  
Expression plasmid for RABV P4 (aa 69-297) cloned into pCR3-Ig vector 
(restriction sites EcoRI/NotI); K. Brzózka. 
pCR3-RABV P∆191-297:  
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Expression plasmid for RABV P 1-190 cloned into pCR3-Ig vector (restriction 
sites Acc65I/NotI); K. Brzózka. 
pCR3-RABV P∆199-297:  
Expression plasmid for RABV P 1-198 cloned into pCR3-Ig vector (restriction 
sites Acc65I/NotI); K. Brzózka. 
pCR3-RABV P∆217-297:  
Expression plasmid for RABV P 1-216 cloned into pCR3-Ig vector (restriction 
sites Acc65I/NotI); K. Brzózka. 
pCR3-RABV P∆245-297:  
Expression plasmid for RABV P 1-244 cloned into pCR3-Ig vector (restriction 
sites Acc65I/NotI); K. Brzózka. 
pcDNA3.1-Flag-RIG-I:  
Expression plasmid for human RIG-I cloned into pcDNA3.1-Flag vector 
(restriction sites EcoRV/XhoI, inserts SnabI/XhoI); K. Brzózka. 
pcDNA3.1-Flag-MDA5:  
Expression plasmid for human MDA5 cloned into pcDNA3.1-Flag vector 
(restriction sites EcoRV/XhoI, inserts SnabI/XhoI); K. Brzózka. 
pcDNA3.1-Flag-Lgp2:  
Expression plasmid for human Lgp2 cloned into pcDNA3.1-Flag vector 
(restriction sites EcoRV/XhoI, inserts SnabI/XhoI) ; K. Brzózka. 
pcDNA3.1-Flag-MDA5 ΔCARD:  
Expression plasmid for human MDA5 with a deletion of the CARD domain 
cloned into pcDNA3.1-Flag vector (restriction sites EcoRV/XhoI, inserts 
SnabI/XhoI); K. Brzózka. 
pcDNA3.1-Flag-MDA5 HD:  
Expression plasmid for human MDA5 helicase domain cloned into pcDNA3.1-
Flag vector (restriction sites EcoRV/XhoI, inserts SnabI/XhoI); K. Brzózka. 
pcDNA3.1-Flag-Lgp2 HD:  
Expression plasmid for human Lgp2 helicase domain cloned into pcDNA3.1-
Flag vector (restriction sites EcoRV/XhoI, inserts SnabI/XhoI); K. Brzózka. 
pcDNA3.1-Flag-Lgp2 RD:  
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Expression plasmid for human Lgp2 regulatory domain cloned into pcDNA3.1-
Flag vector (restriction sites EcoRV/XhoI, inserts SnabI/XhoI); K. Brzózka. 
pEBOS-RIG-I CARD (ΔRIG-I): 
Expression plasmid of human RIG-I CARD domain (aa 1-284) cloned into 
pEBOS vector; A. Krug. 
pCR3-Flag-MeV-VΔC:  
MeV-V containing a point mutation, which prevents coexpression of C cloned 
into pCR3 vector (restriction sites EcoRI/NotI); C. Pfaller.  
pET-28M-SUMO3-GFP: 
Bacterial expression vector for SUMO3-tagged constructs (EMBL); K.-P. 
Hopfner, S. Akira. 
pM6P-HisD/Flag-Sintbad: 
Expression plasmid for mouse Flag-Sintbad (Ryzhakov and Randow, 2007); G. 
Ryzhakov.  
pM6P-HisD/Flag-Nap1: 
Expression plasmid for mouse Flag-Nap1 (Ryzhakov and Randow, 2007); G. 
Ryzhakov.  
pM6P-HisD/Flag-NEMO: 
Expression plasmid for human Flag-NEMO (Ryzhakov and Randow, 2007); G. 
Ryzhakov.  
pFlag-IRF3-5D : 
Expression plasmid for constitutively active IRF3 with aa substitutions S396D, 
S398D, S402D, T404D and S405D (Lin et al., 1998); J. Hiscott. 
pEF-p50-IRF3-J2A: 
Expression plasmid for p50-IRF3 with aa substitutions S385A, S386A cloned 
into pEF vector (Takahasi et al., 2010); T. Fujita. 
pEF-p50-IRF3-396A : 
Expression plasmid for p50-IRF3 with aa substitution S396A cloned into pEF 
vector (Takahasi et al., 2010); T. Fujita. 
pEF-p50-IRF3-2A : 
Expression plasmid for p50-IRF3 with aa substitutions S396A and S398A 
cloned into pEF vector (Takahasi et al., 2010); T. Fujita. 
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pEF-p50-IRF3-3A : 
Expression plasmid for p50-IRF3 with aa substitutions S402A, T404A and 
S405A, cloned into pEF vector (Takahasi et al., 2010); T. Fujita. 
pEF-p50-IRF3-5A : 
Expression plasmid for p50-IRF3 with aa substitutions S396A, S398A, S402A, 
T404A and S405A, cloned into pEF vector (Takahasi et al., 2010); T. Fujita. 
pEF-p50-IRF3-J2A5D : 
Expression plasmid for p50-IRF3 with aa substitutions S385A, S386A, S396D, 
S398D, S402D, T404D and S405D, cloned into pEF vector (Takahasi et al., 
2010); T. Fujita. 
pFlag-IRF3 S339A: 
Expression plasmid for Flag-IRF3 with aa substitution S339A (Clément et al., 
2008); M. J. Servant. 
pFlag-IRF3 2A/S339A: 
Expression plasmid for Flag-IRF3 with aa substitutions S396A, S398A and 
S339A (Clément et al., 2008); M. J. Servant. 
pFlag-IRF3 3A/S339A: 
Expression plasmid for Flag-IRF3 with aa substitutions S402A, T404A, S405A 
and S339A (Clément et al., 2008); M. J. Servant. 
pFlag-IRF3 5A/S339A: 
Expression plasmid for Flag-IRF3 with aa substitutions S396A, S398A, S402A, 
T404A, S405A and S339A (Clément et al., 2008); M. J. Servant. 
pFlag-IRF3 396A/S339A: 
Expression plasmid for Flag-IRF3 with aa substitutions S396A and S339A 
(Clément et al., 2008); M. J. Servant. 
pFlag-IRF3 2D/S339A: 
Expression plasmid for Flag-IRF3 with aa substitutions S396D, S398D and 
S339A (Clément et al., 2008); M. J. Servant. 
pFlag-IRF3 5D/S339A: 
Expression plasmid for Flag-IRF3 with aa substitutions S396D, S398D, S402D, 
T404D, S405D and S339A (Clément et al., 2008); M. J. Servant. 
pEF-RIG-I: 
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Expression plasmid for RIG-I (wt) (Cui et al., 2008); A. Krug. 
pFlag-IPS-1: 
Expression plasmid for Flag-IPS-1; S. Akira. 
pFlag-TBK1:  
Expression plasmid for Flag-TBK-1; K. Brzózka, S. Marozin. 
pSAD L16: 
Expression plasmid containing the full-length RABV genome cDNA cloned into 
pSAD vector; S. Finke. 
pSAD PΔInd1: 
Expression plasmid containing the full-length RABV genome cDNA with 
deletion of aa 176-181 in the P gene (Rieder et al., 2011); K. Brzózka. 
pSAD PΔInd2: 
Expression plasmid containing the full-length RABV genome cDNA with 
deletion of aa 182-186 in the P gene (Rieder et al., 2011); K. Brzózka. 
pSDI-HH-flash: 
Expression plasmid containing the firefly luciferase gene flanked by leader and 
trailer sequence of RABV (Ghanem et al., 2011); A. Ghanem. 
pTIT-RABV-L: 
Expression plasmid for T7-dependent expression of RABV L (Finke and 
Conzelmann, 1999); S. Finke. 
pTIT-RABV-N:  
Expression plasmid for T7-dependent expression of RABV N (Finke and 
Conzelmann, 1999); S. Finke. 
pTIT-RABV-P: 
Expression plasmid for T7-dependent expression of RABV P (Finke and 
Conzelmann, 1999); S. Finke. 
Plasmids generated during this thesis: 
pCR3-Flag-RABV P:  
Expression plasmid for RABV P cloned into pCR3 vector (restriction sites 
Acc65I/XhoI). 
pCR3-RABV P Ind1/2:  
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Expression plasmid for RABV P cloned into pCR3 vector (restriction sites 
Acc65I/NotI). 
pCR3-Ig-RABV P 82-216:  
Expression plasmid for RABV P aa 69-216 cloned into pCR3 vector (restriction 
sites EcoRI/NotI). 
pCR3-Ig-RABV P 82-244:  
Expression plasmid for RABV P aa 82-216 cloned into pCR3 vector (restriction 
sites EcoRI/NotI). 
pCR3-Ig-RABV P 52-216:  
Expression plasmid for RABV P aa 82-216 cloned into pCR3 vector (restriction 
sites EcoRI/NotI). 
pCMV-myc-MDA5:  
Expression plasmid of human MDA5 cloned into pCMV-myc vector 
(Invitrogen; restriction sites SfiI/XhoI). 
pCAGGs-Flag-MDA5 CARD 1-350:  
Expression plasmid of human MDA5 CARD domain (aa 1-350) cloned into 
pCAGGs vector (restriction sites Acc65I/XhoI). 
pCAGGs-Flag-MDA5 1-449:  
Expression plasmid of human MDA5 aa 1-449 cloned into pCAGGs vector 
(restriction sites Acc65I/XhoI). 
pCAGGs-Flag-MDA5 287-449:  
Expression plasmid of human MDA5 aa 287-449 cloned into pCAGGs vector 
(restriction sites Acc65I/XhoI). 
pCAGGs-Flag-RIG-ICD/HD-MDA5RD:  
Expression plasmid of the chimeric protein RIG-ICD/HD-MDA5RD with N-
terminal Flag-Tag, cloned into pCAGGs vector (restriction sites Acc65I/XhoI). 
pCAGGs-Flag-RIG-ICD/HD-Lgp2RD:  
Expression plasmid of the chimeric protein RIG-ICD/HD-Lgp2RD with N-
terminal Flag-Tag, cloned into pCAGGs vector (restriction sites Acc65I/XhoI). 
pCAGGs-Flag-MDA5CD/HD-RIG-IRD:  
Expression plasmid of the chimeric protein MDA5CD/HD-RIG-IRD with N-
terminal Flag-Tag, cloned into pCAGGs vector (restriction sites Acc65I/XhoI). 
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pCAGGs-Flag-MDA5CD/HD-Lgp2RD:  
Expression plasmid of the chimeric protein MDA5CD/HD-Lgp2RD with N-
terminal Flag-Tag, cloned into pCAGGs vector (restriction sites Acc65I/XhoI). 
pCAGGs-Flag-Lgp2HD-RIG-IRD:  
Expression plasmid of the chimeric protein Lgp2HD-RIG-IRD with N-terminal 
Flag-Tag, cloned into pCAGGs vector (restriction sites Acc65I/XhoI). 
pCAGGs-Flag-Lgp2HD-MDA5RD:  
Expression plasmid of the chimeric protein Lgp2HD-MDA5RD with N-terminal 
Flag-Tag, cloned into pCAGGs vector (restriction sites Acc65I/XhoI). 
pCAGGs-Flag-RIG-ICD-MDA5HD-RIG-IRD:  
Expression plasmid of the chimeric protein RIG-ICD-MDA5HD-RIG-IRD with N-
terminal Flag-Tag, cloned into pCAGGs vector (restriction sites Acc65I/XhoI). 
pCAGGs-Flag-MDA5CD-RIG-IHD-MDA5RD:  
Expression plasmid of the chimeric protein MDA5CD-RIG-IHD-MDA5RD with 
N-terminal Flag-Tag, cloned into pCAGGs vector (restriction sites Acc65I/XhoI). 
pCAGGs-Flag-Sintbad:  
Expression plasmid of mouse Flag-Sintbad cloned into pCAGGs vector 
(restriction sites EcoRI/NheI). 
pCAGGs-Flag-Nap1:  
Expression plasmid of mouse Flag-Nap1 cloned into pCAGGs vector 
(restriction sites EcoRI/NheI). 
pCAGGs-Flag-NEMO:  
Expression plasmid of human Flag-NEMO cloned into pCAGGs vector 
(restriction sites EcoRI/NheI). 
pCAGGs-Flag-Rip1:  
Expression plasmid of human Flag-Rip1 cloned into pCAGGs vector (restriction 
sites Acc65I/XhoI). 
pFlag-IRF3: 
Expression plasmid for pFlag-IRF3 cloned by mutagenesis PCR from pFlag-IRF3 
S339A. 
pFlag-IRF3 2A: 
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Expression plasmid for Flag-IRF3 with aa substitutions S396A and S398A, 
cloned by mutagenesis PCR from pFlag-IRF3 2A/S339A. 
pFlag-IRF3 3A: 
Expression plasmid for Flag-IRF3 with aa substitutions S402A, T404A and 
S405A, cloned by mutagenesis PCR from pFlag-IRF3 3A/S339A. 
pFlag-IRF3 5A: 
Expression plasmid for Flag-IRF3 with aa substitutions S396A, S398A, S402A, 
T404A and S405A, cloned by mutagenesis PCR from pFlag-IRF3 5A/S339A. 
pFlag-IRF3 396A: 
Expression plasmid for Flag-IRF3 with aa substitution S396A, cloned by 
mutagenesis PCR from pFlag-IRF3 396A/S339A. 
pFlag-IRF3 398A: 
Expression plasmid for Flag-IRF3 with aa substitution S398A, cloned by 
mutagenesis PCR from pFlag-IRF3. 
pFlag-IRF3 AADDD: 
Expression plasmid for Flag-IRF3 with aa substitutions S396A, S398A, S402D, 
T404D and S405D, cloned by mutagenesis from Fl-IRF3 5D (Lin et al., 1998). 
pFlag-IRF3 DDAAA: 
Expression plasmid for Flag-IRF3 with aa substitutions S396D, S398D, S402A, 
T404A and S405A, cloned by mutagenesis from Fl-IRF3 5D (Lin et al., 1998). 
pCAGGs-Flag-IRF3 150-427: 
Expression plasmid of human Flag-IRF3 aa 150-427 cloned into pCAGGs vector 
(restriction sites Acc65I/XhoI). 
pCAGGs-Flag-IRF3 185-427: 
Expression plasmid of human Flag-IRF3 aa 185-427 cloned into pCAGGs vector 
(restriction sites Acc65I/XhoII). 
pCAGGs-Flag-IRF3 200-427: 
Expression plasmid of human Flag-IRF3 aa 200-427 cloned into pCAGGs vector 
(restriction sites Acc65I/XhoII). 
pCAGGs-Flag-IRF3 300-427: 
Expression plasmid of human Flag-IRF3 aa 150-427 cloned into pCAGGs vector 
(restriction sites Acc65I/XhoII). 
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pCAGGs-Flag-IRF3 200-384: 
Expression plasmid of human Flag-IRF3 aa 150-427 cloned into pCAGGs vector 
(restriction sites Acc65I/XhoII). 
pFlag-IRF3 L192R, L195R, L196R: 
Expression plasmid for Flag-IRF3 with aa substitutions L192R, L195R, and 
L196R, cloned by mutagenesis from pFlag-IRF3. 
pFlag-IRF3 L322R, I326R, I330R: 
Expression plasmid for Flag-IRF3 with aa substitutions L322R, I326R, and 
I330R, cloned by mutagenesis from pFlag-IRF3. 
pFlag-IRF3 L375R, M378R, A379R: 
Expression plasmid for Flag-IRF3 with aa substitutions L192R, L195R, and 
L196R, cloned by mutagenesis from pFlag-IRF3. 
pET28M-SUMO3-RABV P: 
Expression plasmid for purification of RABV P, cloned into pET28M-SUMO3-
GFP (restriction sites AgeI, XhoI). 
 
2.1.9 Recombinant proteins 
Proteins purified during this thesis: 
RABV P; purified from the expression vector pET28M-SUMO3-RABV P in Rosetta DE3 
bacteria. 
Proteins kindly provided: 
His-RIG-I, purified from the Baculovirus expression vector (pFBDM) in High Five™ cells 
(Cui et al., 2008); A. Kirchhofer. 
His-MDA5, purified from the Baculovirus expression vector (pFBDM) in High Five™ 
cells (Cui et al., 2008); A. Kirchhofer. 
Commercially acquired proteins: 
GST-TBK1; Abnova. 
GST-Nap1; Abnova. 
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2.1.10 Viruses 
Viruses kindly provided: 
SAD L16:  
Recombinant rabies virus with the nucleotide sequence of the attenuated 
vaccine strain SAD B19 (gene bank accession M31046.1), generated by rescue 
from a full-length cDNA plasmid (Schnell et al., 1994); K.K. Conzelmann. 
SAD PLP:   
Recombinant rabies virus derived from SAD L16 generated by deletion of the 
P gene, and insertion of the P gene after a sequence resembling the N/P gene 
border downstream of the L ORF. The full-length cDNA plasmid was used for 
rescue (Brzòzka et al., 2005); K. Brzózka.  
SAD Ind1:  
Recombinant rabies virus derived from SAD L16, harboring the aa deletion 
176-181 in the phosphoprotein, generated by rescue from a full-length cDNA 
plasmid (Rieder et al., 2011); K. Brzózka. 
SAD Ind2: 
Recombinant rabies virus derived from SAD L16, harboring the aa deletion 
182-186 in the phosphoprotein, generated by rescue from a full-length cDNA 
plasmid (Rieder et al., 2011); K. Brzózka. 
Sendai virus (DI)-H4: 
Defective interfering particles of Sendai virus (SeV DI-H4) used for induction of 
IFN  (Strahle et al., 2006); D. Garcin. 
Viruses generated during this thesis: 
SAD Ind1/2: 
Recombinant rabies virus derived from SAD L16, harboring the aa deletion 
176-186 in the phosphoprotein, generated by rescue from a full-length cDNA 
plasmid.  
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2.1.11 Equipment 
Apparatuses: 
Bacteria shaker ISF-1-W       Kuhner 
Centrifuge 5417C (rotor F45-30-11)      Eppendorf  
Centrifuge Evolution RC (SLC6000 and SS34 rotors)   Sorvall 
Centro LB 960 plate luminometer      Berthold 
CO2 Incubator        SANYO 
Digital Sonifier W-250 D       Branson 
Fireboy plus        Integra Biosciences 
Forma Scientific Water-Jacketed Incubator 3250    Labotect 
Forma ULT deep freezer       Thermo Scientific 
Freezer GU1202        Liebherr 
Fridge KU1710        Liebherr 
Fusion FX7         Vilber Lourmat 
Gel Doc System        Biorad 
GJ Balance        Kern 
Horizontal gel electrophoresis system S/M/L/XL    Peqlab/OWL 
ilShin Deep freezer        Nunc 
IX71 UV-light microscope       Olympus 
Jobin Yvon FluoroMax-P fluorimeter    Horiba 
LightCycler 2.0        Roche 
LSM 510 Meta Laser Scanning Microscope     Carl Zeiss 
Mini Quick Spin RNA Columns     Roche 
NanoDrop ND-1000 Spectrophotometer     Peqlab 
Neubauer improved counting chamber     Marienfeld 
Optimax Typ TR developing machine    MS Laborgeräte 
PIPETBOY acu        IBS 
Pipettes (2, 10, 20, 100, 200, 1000 μl)     Gilson 
Pipettes (2, 10, 20, 100, 200, 1000 μl)     Eppendorf 
Roller mixer SRT2        Stuart 
Scientifica Magnetic Stirrer/heater Unit     VELP 
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Semidry Blotting System       Peqlab 
Superdex 75 column        GE Healthcare 
Sterilguard Class II Type A/B3 sterile workbench    The Baker Company 
Standard Power Pack P25       Biometra 
Swip SM25 Shaker        Edmund Bühler 
Thermocycler T3        Biometra 
Thermomixer 5436        Eppendorf 
TMS light microscope      Nikon 
Typhoon 9400 Variable Mode Imager     GE Healthcare 
Vacu-Blot system       Biometra 
Varifuge 3.0 R        Heraeus 
Vertical gel electrophoresis system      Biorad 
Disposables: 
12-well plates        BD Falcon 
24-well plates        BD Falcon 
96-well plates        BD Falcon 
6-well plates         BD Falcon 
50 ml Falcons         BD Falcon 
15 ml Falcons         BD Falcon 
Amicon Ultra-15 Centrifugal filter devices (MWCO 10,000)  Millipore 
Capillary pipet tips 200 μl       Biozym 
Cell culture flasks (T25, T75, T175)      BD Falcon 
Combitips plus 10 ml        Eppendorf 
Combitips plus 5 ml        Eppendorf 
Coversplips 18 x 18 mm       Roth 
Cuvette: UVette        Eppendorf 
Microscope slides 76 x 26 mm     Roth 
PCR Softstrips 0,2 ml        Biozym 
Polypropylene reaction tubes (0.25, 0.5, 1.5, 2 ml)   Eppendorf 
Roche LightCycler Capillaries 20 μl      Roche 
Safe-Lock Tubes (0.5, 1.5, 2 ml)      Eppendorf 
SafeSeal -Tips (2,5 μl, 10 μl, 20 μl, 200 μl, 1,000 μl)   Biozym 
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2.1.12 Miscellaneous 
1 kb DNA Ladder        NEB 
0.5 – 10 kb RNA ladder      Invitrogen 
Alexa Fluor 488-5(or 7-) UTP       Invitrogen 
Anti-Flag  M2-Agarose from Mouse     Sigma-Aldrich 
Dialysis membrane Zellutrans (MWCO 8,000-10,000)   Roth 
DPBS          Invitrogen 
Duralon-UV  membranes      Stratagene 
Gel Blotting Paper        Machery-Nagel 
Gravity flow Strep-Tactin Superflow Column    IBA BioTAGnology 
His6-SENP2CD        Boston Biochem 
HiTrap Q HP ion exchange column      GE Healthcare 
Hyperfilm ECL        GE Healthcare 
Immobilon-P blotting membrane (PVDF)     Millipore 
Immobilon-FL blotting membrane (PVDF)     Millipore 
Lipofectamine  2000       Invitrogen 
Ni-NTA Agarose        QIAGEN 
Nitrocellulose membrane Protran BA 83 Whatman   GE healthcare 
Oligo(dT)12-18 Primer       Invitrogen 
PCR Marker         NEB 
Precision Plus Protein Standards     Biorad 
Protein A-Sepharose CL-4B       GE Healthcare 
Serological pipettes (5, 10, 25 ml)     Costar 
Streptavidin-Agarose       Sigma-Aldrich 
Universal type I Interferon (IFN alpha A/D)     PBL  
Vectashield  Mounting Medium for Fluorescence   Vector Laboratories 
Western Lightning Plus-ECL       PerkinElmer 
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2.2 Methods 
2.2.1 Cell culture 
The cell lines used were stored in incubators at 37 °C and with 5 % CO2. The work 
performed on all cell lines was always under sterile conditions. For experiments the 
cells were cultivated in T25 or T75 flasks in their described media. The cell cultures 
were passaged every three days by splitting them in an appropriate ratio generally 
ranging from 1:6 – 1:10.     
2.2.2 Plasmid construction: cloning and mutagenesis 
Polymerase chain reaction (PCR) 
DNA polymerases synthesize the DNA strand by multiple cycles of denaturation of 
the dsDNA (95-98 °C), annealing of specific primers to the free 3’-OH-end of the 
template (depending on primer: usually 45-50 °C) and elongation (68-72 °C), resulting 
in synthesis of the complementary strand. Correct size of PCR products can be 
validated by agarose gel electrophoresis.  
For standard PCR a 100 µl PCR-mix was prepared: 
Components     amount 
DNA-template   1 pg - 10 ng 
5’ primer (10 µM)   5 µl  
3’ primer (10 µM)   5 µl  
5x Buffer HF            20 µl 
DMSO               3 µl 
dNTP-mix    0.8 µl (0.2 mM per nucleotide) 
Phusion polymerase   1 µl (2 U) 
H20dd        ad 100 µl 
The PCR-program was comprised of the following steps: 
Step  Temp.  Time   
1.  98 °C  30 sec   
2.  98 °C  30 sec   
3.   50 °C  30 sec                 30x  
4.  72 °C             15 sec/kbp   
5.  72 °C           10 min   
6.     4 °C  ∞   
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For purification of standard PCR products the QIAquick PCR Purification Kit was 
applied, following the protocol of the producer.  
For mutagenesis PCR a 100 µl PCR-mix was prepared: 
Components     amount 
DNA-template   1 pg - 10 ng 
5’ primer (10 µM)   2.5 µl  
3’ primer (10 µM)   2.5 µl  
10x Buffer with MgCl2       10 µl   
dNTP-mix    1 µl (0.25 mM per nucleotide) 
bioPfu polymerase   1 µl (2 U) 
H20dd        ad 100 µl 
 
The PCR-program was comprised of the following steps: 
Step  Temp.  Time   
1.  95 °C  30 s    
2.  95 °C  10 s   
3.   50 °C  30 s               18x  
4.  68 °C             4 min/kbp    
5.  68 °C           30 min   
6.     4 °C  ∞   
 
Subsequently, DNA was digested with DpnI restriction enzyme for at least 3 hours at 
37 °C to remove all methylated template DNA (5’-GATC-3’ methylation generated 
during bacterial plasmid DNA amplification). 10 µl newly synthesized mutated 
plasmid DNA was directly transformed into bacteria for amplification. 
For contamination control PCR a 25 µl PCR-mix was prepared: 
Components     amount 
DNA-template   100 pg 
5’ primer i.e. hAc for (10 µM) 0.625 µl  
3’ primer i.e. hAc rev (10 µM) 0.625 µl  
10x Buffer with MgCl2       2.5 µl   
DMSO     2.5 µl 
dNTP-mix    0.25 µl (0.25 mM per nucleotide) 
Taq polymerase   0.25 µl (2 U) 
H20dd        ad 25 µl 
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The PCR-program was comprised of the following steps: 
Step  Temp.  Time   
1.  95 °C  1 min   
2.  95 °C  30 sec   
3.   45 °C  30 sec               36x  
4.  72 °C             45 sec/kbp    
5.  72 °C           10 min   
6.     4 °C  ∞ 
 
Restriction endonuclease digestion 
For the site-directed insertion of a DNA fragment into a vector, or fusion of DNA 
fragments, digestion with specific restriction enzymes that create characteristic DNA 
ends (3’ or 5’ prime overhangs, sticky or blunt ends, depending on the enzyme), was 
applied. For this purpose, 5-10 μg PCR-product and the vector were incubated with 
restriction enzymes (time and temperature depending on the enzyme). To prevent 
re-ligation of the vector backbones, 10,000 U CIAP enzyme was subsequently added 
to the vector restriction digestion for further incubation (30 min, 37 °C). The digested 
DNA fragments of particular size were applied to agarose gel electrophoresis.  
Agarose gel electrophoresis of nucleic acids 
For the agarose gel, agarose powder was mixed with 1 x TAE buffer at a specific 
concentration, i.e. 1 % agarose for DNA fragments >500 bp and in case of <500 bp 
2 % agarose. Samples containing DNA were mixed with 20 % Orange G loading buffer 
and loaded into the wells of the agarose gel. Additionally, a 1kb marker (1 % gel) or 
PCR marker (2 % gel) was loaded. In the meshwork of the agarose gel, DNA fragments 
were separated according to their size. Gels were run for 30 min to 1 hour at 120 V.  
For visualization of DNA by UV-light the running buffer contained 0.075 % ethidium 
bromide in 1 x TAE. Images were acquired on a BioRad GelDoc system. DNA 
fragments for ligation are excised from the gel and purified by the QIAquick Gel 
Extraction Kit following the protocol of the producer.    
Ligation  
Ligation of a specific DNA insert into a designated vector, cut with the same 
restriction enzymes, is carried out using the T4 DNA ligase (o/n, 16 °C) by the 
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formation of covalent phosphodiester-bonds between the free 5´-phosphate group 
and the free 3´-OH-group of the desoxyribose of the complementary ends. 
For ligation a 20 µl mix was prepared: 
Components     amount 
PCR-product (insert)   10 µl 
Linear vector        0.5 µl 
T4 DNA ligase        0.5 µl 
10x T4 DNA ligase buffer    2 µl 
H20dd           ad 20 µl 
To selectively amplify ligated plasmids or plasmid DNA in general, plasmids contain 
an antibiotic resistance gene. Plasmid DNA was transformed into bacteria, plated out 
onto LB-plates containing a suitable antibiotic, and bacteria were incubated at 37 °C 
o/n. Single colonies for plasmid preparations or for production of inoculum for 
protein expression were isolated. 
 Transformation of bacteria 
50 µl chemically competent bacteria of the E. coli strain XL-1 Blue or E. coli Rosetta 
DE3 were thawed on ice and 10 µl ligation mix or 1 µl plasmid DNA was added (20 
min, on ice). After a heat shock (2 min, 42 °C) and another 2 min on ice, 200 µl LB++ 
was added to the bacteria and shaken for 30 – 60 min at 37°C.  
DNA-preparation (MINI-, MIDI-prep) 
Colonies grown o/n were picked from the LB-plates and transferred into 1 ml (small 
scale MINI preparation) antibiotic containing LB-medium and shaken o/n at 37°C. To 
harvest the bacterial cells they were centrifuged (10 min, 4 °C, 2500 rpm). The 
bacterial pellet was resuspended in 200 μl Flexi I, lysed with 200 μl Flexi II (5 min, RT), 
and neutralized with 200 μl Flexi III (5 min, on ice). In a centrifugation step (10 min, 4 
°C, 14000 rpm) the cell debris was removed and the supernatant transferred to 400 
μl isopropanol to precipitate the DNA. DNA was pelleted (10 min, 4 °C, 14000 rpm), 
dried and solubilized in 50 μl H20dd. To validate ligation of the correct insert, a 
control digest of 1 μg DNA was carried out using the appropriate restriction enzymes 
and subjected to agarose gel electrophoresis. Size of insert and vector were validated 
using a 1kb marker as reference.  
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For large scale MIDI preparation, colonies or 75 µl of the transformed bacterial 
suspension were transferred to 50 ml LB-medium (or 100 ml in case of recombinant 
protein expression), containing a specific antibiotic, and shaken o/n at 37 °C. 
Bacterial cells were pelleted (20 min, 4 °C, 3500 rpm) and the DNA was purified by 
using the Nucleobond Xtra Midi kit following the protocol of the producer. 
Concentration of the DNA was determined using the NanoDrop ND-1000 
spectrophotometer.  
Plasmid DNA sequencing was carried out by GATC biotech. Requested concentrations 
are 30-100 ng/µl plasmid DNA and 10 pmol/µl sequencing primer, both in 20 μl 
volume. Software of DNAMAN 6.0 and Chromas 1.45 was applied to analyze acquired 
sequences. 
2.2.3 Transfection and infection 
A specific number of cells was initially seeded into an adequate culture dish or well-
plate (6, 12, 24 or 96-well plate or 6 cm dish). For this purpose, cell numbers were 
counted using a Neubauer chamber or estimated due to the size of the culture flask 
and cell density. When cells are confluent, following cell numbers are designated to 
specific culture flasks: T25: 3x106 cells; T75: 9.4x106 cells. Cells were trypsinized, 
taken up in medium and seeded into the desired dish (incubation mostly o/n).   
Culture dish  number of cells volume of medium 
6 cm dish   6x105     2 ml 
6-well plate    3x105     2 ml  
12-well plate    2x105     600 µl  
24-well plate  6x105     300-500 µl 
96-well plate  6x105     100-200 µl 
Transfection 
Cells were transfected with appropriate transfection reagents. For transfection of less 
than two plasmids, polyethyleneimine (PEI) solution (1 mg/ml) was used. PEI was pre-
incubated in D-MEM w/o additives for 5 min, subsequently mixed with the DNA (2 µl 
PEI/µg DNA) for 20 min and added to the cells. For transfection of more than two 
plasmids, Lipofectamine 2000 (2.5 µl Lipofectamine/µg DNA) was used. It was pre-
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incubated with D-MEM w/o additives for 5 min. Plasmids DNA was diluted in D-MEM 
w/o additives and combined with diluted Lipofectamine/D-MEM mix. Following 
incubation of 20 min, the solution was added to the cells. For virus rescue, BSR-T7/5 
cells were transfected with calcium phosphate using the Mammalian Transfection Kit 
following the protocol of the producer. 
Infection 
HEK 293T, BSR-T7/5 or HEp-2 cells were grown to a confluence of 60 to 80 % and 
infected at a specific multiplicity of infection (MOI). For luciferase assays and 
quantitative RT-PCR in HEK 293T cells, an MOI of 3 was applied. For growth curve 
analysis of recombinant RABVs in BSR-T7/5, HEp-2 or 293T cells, an MOI of 0.05, and 
for Western blot analysis of protein levels and immunofluorescence microscopy in 
HEp-2 cells, an MOI of 1 was used. 
 
2.2.4 Purification of recombinant proteins 
Purification of recombinant proteins was carried out by His-tag purification from E. 
coli Rosetta. Bacteria were transformed with pET28M-SUMO3-RABV P and grown in 
appropriate LB medium. 100 ml pre-culture was grown at o/n at 37 °C and 10 ml 
thereof transferred to 1 l LB medium. The culture was shaken at 37 °C until an OD600 
of 0.6-0.8 was reached. Expression of the protein His6-SUMO3-RABV P was initiated 
by the addition of 0.5-1 mM IPTG (isopropyl- -D-thiogalactopyranosid) and the 
bacteria were further incubated o/n at 18 °C. Bacteria were pelleted by 
centrifugation in a Sorvall SLC-6000 rotor (20 min, 4 °C, 4,000 g), resuspended in 13 
ml of Buffer A and disrupted by sonification. The suspension was centrifuged again 
using the Sorvall rotor SS-34 (45 min, 4 °C, 10,000 g) to clear the lysate. 6 ml Ni-NTA 
agarose beads, which bind to the His-tag, were added (incubation at 4 °C on roller 
mixer, 1-2 h), and the mixture was transferred to a column. 30-60 ml buffer A was 
applied to wash the column. Subsequently, the protein was eluted with buffer B in 
five 3 ml fractions. Fractions of purified protein were analyzed by SDS-PAGE and 
Coomassie staining. Positive fractions were pooled and dialyzed in dialysis buffer 
(o/n, 4 °C), which contains the protease His-SENP2 (50 nM) to cleave off the His6-
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SUMO-tag. The cleaved tag and the protease were removed by additional incubation 
with 6 ml Ni-NTA agarose (1-2 h, 4 °C), transferred to a column and washed with 10-
20 ml buffer A. The flow-through was dialyzed again (o/n, 4 °C) and proper cleavage 
was verified by SDS-PAGE and Coomassie staining (see 2.2.14, 2.2.16). Finally, the 
protein suspension was transferred to an Amicon Ultra-15 Centrifugal filter device 
and concentrated by centrifugation (steps of 10 min, 4 °C, 3,500 rpm). To determine 
protein concentration, absorption at 280 nm was measured with the NanoDrop ND-
1000 spectrophotometer, and multiplied with the protein’s extinction coefficient 
(determined by ProtParam). Aliquots of purified proteins were shock frozen in liquid 
nitrogen and stored at -80 °C. 
 
2.2.5 Generation of recombinant viruses 
SAD ∆Ind1/2 was generated by using a reverse genetics approach. For this purpose, 
BSR-T7/5 cells were seeded in a 6-well plate and cultivated o/n. One hour before 
transfection, medium was changed to D-MEM. Cells were transfected with 10 μg 
pSAD PΔInd1/2, 5 μg pTIT-RABV N, 2.5 μg pTIT-RABV P, and 2.5 μg pTIT-RABV L using 
the Mammalian transfection kit. 4 hours post transfection (p.t.) the medium was 
changed again to G-MEM+4. 72 hours p.t. the supernatant was passaged; therefore, 
collected, centrifuged (10 min, 4 °C, 1600 rpm) to remove cell debris, and transferred 
to freshly seeded BSR-T7/5 cells (6-well plate). 2 ml of fresh G-MEM+4 medium was 
added to the transfected cells and incubated for further 72 hours. Supernatant was 
passaged again, and transfected cells were trypsinized for splitting. 75 % were split 
into a T25 cell culture flask and 25 % into a 6-well plate and incubated again for 72 
hours. The transfected cells and supernatant passages in 6-well plates were fixed 
with acetone 80 % and analyzed for RABV N protein by incubation with Centocor™ 
(FITC-labeled anti-RABV N monoclonal antibody). Positive rescues were identified by 
scanning for virus foci, using a fluorescent microscope. Supernatant of cells grown in 
corresponding T25 cell culture flasks was collected, cleared from cell debris by 
centrifugation (10 min, 4 °C, 1600rpm), and stored in aliquots at -80 °C. To generate 
virus stock, BSR-T7/5 cells were seeded in T25 flasks and infected at an MOI of 0.01 
to 1. 48 hours post infection (p.i.) the first harvest was carried out by taking the 
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supernatant and removing the cell debris by centrifugation (10 min, 4 °C, 1,600 rpm). 
Fresh medium was added and 96 hours p.i. the second harvest was collected the 
same way. Harvests were stored in aliquots at -80 °C.   
 
2.2.6 Minigenome assay 
BSR-T7/5 cells were seeded in a 6-well plate and cultivated overnight. One hour 
before transfection, medium was changed to D-MEM. Using the Mammalian 
transfection kit, cells were transfected with the helper plasmids pTIT-RABV N (5 μg), 
pTIT-RABV L (2,5 μg), and either one of pTIT-RABV P or pCR3 P∆Ind1/2, or no P at all. 
In addition, 4 μg of the pSDI-HH-flash minigenome, composed of the firefly luciferase 
(FL) gene flanked by the RABV leader and trailer sequence, and 10 ng of the control 
plasmid pCMV-RL were transfected. 48 hours p.t., the cells were lysed in passive lysis 
buffer and subjected to dual luciferase detection by the luminometer.  
  
2.2.7 Titration of virus stocks  
For titration, virus stock was thawed and a 10-fold dilution series was prepared (7 x 
900 μl G-MEM + 100 μl virus/virus dilution). BSR-T/7 cells were seeded into 96-well 
plates and after 2 hours infected with 100 μl of the virus dilution (in duplicates). 48 
hours p.i., cells were fixed with acetone 80 % and stained for RABV N with Centocor. 
Foci were counted using a fluorescence microscope, and the titer, namely focus 
forming units per ml (ffu/ml), was calculated.  
 
2.2.8 Virus growth curves 
To analyze growth kinetics of distinct viruses, growth curves were undertaken. 
Therefore, BSR-T7/5 cells in G-MEM were seeded into a T25 flask and infected in 
suspension with an MOI 0.05. 6 hours p.i., medium was changed to G-MEM+4 and 
after 1 h 1 ml supernatant was collected as first time point. 24 h, 48 h, 72 h, and 96 h 
p.i., further supernatants were collected and frozen at -80 °C. Subsequently, 
supernatants are thawed again and titrated as described above to determine the 
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infectious titers at the given time points. 
 
2.2.9 RNA isolation and reverse transcription (RT) PCR 
Isolation of RNA from mammalian cells was carried out using the RNeasy  Mini Kit 
(QIAGEN) following the protocol of the producer. To determine RNA concentration, 
absorption at 240 nm was measured using the NanoDrop ND-1000 
spectrophotometer. RNAs were stored at -80 °C. For further analysis, total RNA was 
transcribed to cDNA in a reverse transcription (RT) reaction. Prior to the RT, purified 
RNA was digested with DNase I (45 min, 37 °C; inactivation with EDTA 10 min, 65 °C) 
to avoid contamination with genomic DNA. In a contamination control PCR (see 2.2.2) 
absence of DNA was verified. 
For RT PCR the following PCR-mix was prepared: 
Reaction 1: 
Components     amount 
RNA     1 µg 
Oligo-dT (100 ng/µl)   0.5 µl  
H20dd        ad 7.1 µl 
The first RT PCR-program was comprised of the following steps: 
Step  Temp.  Time   
1.  65 °C  10 min    
2.  on ice  5 min   
Reaction 2: 
Components     amount 
Reaction 1    7.1 µl 
RT buffer 1x    2 µl 
SUPERase-In    0.25 µl 
dNTP-mix     0.4 µl (25 mM per nucleotide) 
The second RT PCR-program was comprised of the following steps: 
Step  Temp.  Time   
1.  55 °C  30 min  
2.  85 °C  5 min   
cDNA was stored at -20 °C or analyzed directly. To confirm/exclude the presence of a 
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specific mRNA/cRNA, standard PCR was applied using the appropriate primers. For 
DNA-visualization, agarose gel electrophoresis (2.2.2) was carried out. For 
quantitative analyses of a certain gene, qRT-PCR was undertaken (2.2.11). 
 
2.2.10 Northern blot 
BSR-T7/5 or HEK 293T cells were infected with SAD L16, SAD ∆Ind1, SAD ∆Ind2 and 
SAD ∆Ind1/2, at an MOI of 3, and RNA was isolated 48 hours p.i. (described in 2.2.9). 
2 µg purified RNA in a total volume of 7.2 µl was incubated with 3 µl 5 x phosphate 
buffer and 1.8 µl glyoxal solution (30-45 min, 56 °C). Finally, Blue juice was added. 
RNA samples were loaded onto an RNA agarose gel. For the gel, 2 g agarose (RNA 
grade) was dissolved in 167.3 ml H2O (ultra pure) and 4 ml 50 x phosphate buffer by 
heating. The gel solution was cooled to approximately 30 °C, 26.7 ml formaldehyde 
37 % were added (H2O ad 200 ml), and filled into a 24 cm x 20 cm cast. 
Electrophoresis was carried out using 1 x phosphate buffer at 25 V o/n and RNA was 
stained using acridine orange solution. To visualize RNAs, the gel was washed with 1 x 
phosphate buffer to remove background staining. Subsequently, RNA was transferred 
and cross-linked to a nylon membrane (2 h, -100 mbar) using the Biometra  Vacu-
Blot System. A RABV N-probe was generated by radioactive labeling of PCR products 
of RABV N (25 ng) with 32P-CTP using the Ready prime kit II (GE healthcare). After pre-
incubation of the membrane with Zeta hybridizing buffer (10 min, 68 °C), probes 
diluted in 8 ml Zeta hybridizing buffer were applied (o/n, 68 °C). The membrane was 
washed once with Zeta wash buffer 5 % and twice with Zeta wash buffer 1 % (68 °C, 
20 min) before letting it dry. To analyze RNA profiles, the membrane was exposed to 
a PhosphoScreen (Molecular Dynamics) (2-72 h) and scanned by a STORM Scanner 
(Molecular Dynamics). Images were evaluated by ImageQuant and Microsoft Excel 
software. 
 
2.2.11 Quantitative real time-PCR (qRT-PCR) 
For quantitative analyses of cellular mRNA levels after transfection or infection, the 
total RNA was isolated 24 h p.t./p.i. and reverse transcribed to single strand cDNA 
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(2.2.8). Samples were diluted 1:5 and as reference a standard curve was generated 
by a 10-fold dilution series of one cDNA sample (5 dilutions 1:1, 1:10, 1:100, 1:1000, 
1:10000). The dilutions were set to relative values for quantification of the samples. A 
master mix was prepared containing specific primers and SYBR Green, a cyanine dye 
which preferentially binds to newly transcribed dsDNA. To normalize the results, the 
same samples were subjected to qRT-PCR with primers for a (steady) housekeeping 
gene. The standards, the cDNA 1:5, and a no template sample (negative control) 
were distributed to LightCycler capillaries and placed into a rotor. 
For qRT-PCR a 20 µl PCR-mix was prepared: 
Components     amount 
cDNA      1 µl 
Primer 1    1 µl     
Primer 2    1 µl 
SYBR Green Master Mix   10 µl  
H20      ad 20 µl 
The qRT-PCR-program was comprised of the following steps: 
Step  Temp.  Time   
1.  95 °C  15 min   
2.  94 °C  15 min   
3.   47-53 °C 20 sec               55x  
4.  72 °C             10 sec    
5.   95 °C   10 sec 
6.   40 °C  20 sec 
7.  to 95 °C  10 sec (0.1 °C/s) 
8.   40 °C  30 sec 
Annealing temperatures for the gene of interest, in this case hIFN , and the 
housekeeping gene GAPDH, were 47 °C and 53 °C, respectively. The LightCycler 
software 4.0 was used to obtain a relative quantification, and values of single 
samples were calculated from the standard curve. Finally, IFN  mRNA values were 
normalized against GAPDH. All qRT-PCR assays were carried out in duplicates 
(standard deviations depicted as error bars). Expression levels of corresponding 
proteins were analyzed by SDS-PAGE and Western blotting (see 2.2.14 and 2.2.17). 
 
Melting curve 
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2.2.12 Luciferase reporter gene assay 
To examine IFN induction and IFN signaling, the Dual Luciferase  Reporter Assay 
System was applied. In this system, the two individual reporter enzymes firefly 
luciferase (FL; correlates with evoked effects) and Renilla luciferase (RL; serves as 
baseline transfection control) are simultaneously expressed within a single cell 
culture system. For this purpose, cells were transfected or infected with compounds 
under investigation. To analyze IFN induction, a p125-luc reporter plasmid, with FL 
under the control of the IFN  promoter, was cotransfected with plasmids of interest, 
or 6 h p.i. (50 ng/µl p125-luc and 1 ng/µl pRenilla). For analysis of IFN - or IFN -
induced JAK/STAT signaling, 400 ng/µl pISRE-luc and 10 ng/µl pRenilla or 400 ng/µl 
pGAS-luc and 10 ng/µl pRenilla was transfected, respectively. In this case, the 
luciferase gene is downstream of the ISRE- or GAS-containing promoters. Cells were 
lysed in passive lysis buffer (Promega) 18-24 h p.t. or p.i. and 20 µl cell lysate was 
subsequently incubated with 40 µl firefly- and Renilla substrate in a Luminometer 
(Berthold) by which the luciferase-activities were measured. Corresponding 
expression levels were examined by SDS-PAGE and Western blotting (2.2.14 and 
2.2.17). 
 
2.2.13 Co-immunoprecipitation (Co-IP) 
In order to identify protein interaction partners, Co-IP was applied. HEK 293T cells 
were seeded in a 6 cm dish and transfected with cDNAs coding for potential 
interaction partners. For analysis of viral interaction partners cells could also be 
infected. One day p.t./p.i. the cells were detached from the dish by 1 ml PBS + 5 mM 
EDTA. The cell suspension was centrifuged (5 min, 4 °C, 2,500 rpm) and the pallet 
lysed (1 h, 4 °C) with 300 µl Co-IP buffer containing a protease inhibitor. Following 
lysis, the suspension was centrifuged again (15 min, 4 °C, 14,000 rpm) and the 
supernatant containing the proteins, free of separated cellular residues, was 
transferred to a new tube. 30 µl of the supernatant was mixed with 30 µl protein lysis 
buffer as a control (WCL=whole cell lysate) for the amount of total protein expression 
(10 %). For precipitation of proteins the remaining supernatant (90 %) was incubated 
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with a specific matrix (Flag or sepharose). 
Incubation with a Flag-matrix and precipitation 
The remaining supernatant (90 %) was incubated with 100 µl anti-Flag  M2-Agarose 
(o/n, 4 °C). This matrix is composed of agarose beads that are covalently linked to 
anti-Flag-antibody, thus capturing Flag-tagged proteins. In case the Flag-tagged 
protein interacts with another protein in the cell lysate, the whole complex stays 
captured to the matrix. Potential interacting partners were labeled with a distinct 
tag, such as a His-tag, or a specific antibody had to be used for subsequent detection. 
Any proteins not co-precipitated to the matrix were washed away with 3 x 500 µl Co-
IP buffer (10 min, 4 °C and subsequent centrifugation 2 min, 4 °C, 14,000 rpm).    
Incubation with a SepharoseA-matrix and precipitation 
Besides using the Flag-matrix it is possible to precipitate proteins, for which a specific 
antibody exists, with Protein A-Sepharose. Protein A, which is covalently conjugated 
to sepharose, specifically binds to the Ig-part of antibodies. To prepare a Protein A-
Sepharose-matrix, Sepharose A was washed with 2 x 50 ml buffer A (1.5 g Sepharose 
A/50 ml buffer) (30 min, 4 °C and centrifugation 2 min, 4 °C, 2,000 rpm) on a roller 
mixer. After a further centrifugation step, buffer A was removed and the beads 
incubated with 50 ml of buffer B (30 min, 4 °C). Afterwards, beads were centrifuged 
(2 min, 4 °C, 3,500 rpm), reconstituted in 7.5 ml buffer B and aliquots of 1 ml stored 
at 4 °C. Prior usage, the beads were washed with 3 x 500 µl Co-IP buffer and 
incubated with the antibody (concentration depending on antibody) specific for the 
protein of interest (o/n, 4°C). For precipitation of proteins, the cleared lysate (90 %) 
was incubated with 100 µl SepharoseA-matrix (o/n, 4 °C) and washed with 3 x 500 µl 
Co-IP buffer (10 min, 4 °C and subsequent centrifugation 2 min, 4 °C, 14,000 rpm). 
Finally, the beads were pelleted (2 min, 4 °C, 14,000 rpm) and protein lysis buffer was 
added. SDS-PAGE and Western blot analysis (2.2.14 and 2.2.17) were applied to 
analyze whether proteins had been pulled down by the matrix (IP), and for 
identification of interaction partners (Co-IP). 
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2.2.14 Denaturing polyacrylamide gel electrophoresis (SDS-PAGE) 
For analysis of endogenous protein expression or protein overexpression after 
transfection or infection, cells were lysed with an appropriate amount of SDS- 
containing protein lysis buffer. 
Culture dish/matrix suspension volume of protein lysis buffer 
6-well plate      600 µl 
12-well plate       300 µl  
24-well plate     150 µl 
100 µl Co-IP matrix    150 µl 
Subsequently, lysates were boiled (5 min, 95 °C) to denature the proteins. SDS 
surrounds the protein with a negative charge and the ß-mercaptoethanol prevents 
the reformation of disulfide bonds. The protein samples were separated according to 
their molecular weight using Jagow-gels (polyacrylamide gels). In order to set up the 
apparatus (Peqlab) for electrophoresis, 4 % stacking gel, a non-restrictive large pore 
gel, was layered on top of a 10 % separating gel. The denatured proteins and 
Precision Plus Protein Standard as marker were loaded onto the gel and run o/n at 
~50 volt. Jagow anode and cathode buffer were used as running buffers (see 
appendix for gels and buffers). 
 
2.2.15 Native PAGE 
In case proteins had to be analyzed in their native globular state, i.e. for analysis of 
dimerization, native PAGE was performed. A 7.5 % native gel was prepared in an 
appropriate gel apparatus (Peqlab) containing specific buffers and pre-run at 30 mA, 
30 min. Cells were lysed in 100 µl native lysis buffer for 1 h, 4 °C. Cell debris was 
removed by centrifugation (10 min, 4 °C, 14,500 rpm) and subsequent transfer of 
supernatant to new Eppendorf tubes. 10 µl of the cell lysate was mixed with 10 µl 
native loading buffer, loaded onto the native gel and run for 2 h at 150 mA (see 
appendix for gels and buffers).  
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2.2.16 Coomassie staining 
To visualize proteins following SDS- or native-PAGE directly, the gel was incubated for 
20 min in Coomassie staining solution and subsequently washed with Coomassie 
wash solution (3 x 20-60 min) until bands appeared.  
 
2.2.17 Western blot analysis (semi-dry) 
In order to make proteins accessible to antibody detection, they were transferred 
from within the gel onto a nitrocellulose membrane. For this step, the stacking gel 
was removed and the separating gel was put into semi dry buffer for 10 min for 
equilibration. The gel was then placed face-to-face with the membrane, sandwiched 
by Whatman paper (all soaked in semi-dry buffer) and electroblotted for 2 h at 
400 mA/gel using a semi-dry blotting device (Peqlab). Blotting results in the 
movement of charged proteins from within the gel onto the membrane while 
maintaining the organization they had within the gel. The proteins were exposed on a 
thin surface layer for detection. To avoid non-specific protein interactions of the 
antibody used for detection, the membrane was placed into a solution of 2.5 % milk 
powder in PBS-T (1 h, RT). 
 
2.2.18 Immunodetection 
For visualization of proteins on the membranes, the primary antibody was diluted in 
PBS-T (for appropriate dilutions see 2.1.5.) and applied to the nitrocellulose 
membrane for incubation (2 h, RT or o/n, 4 °C). Subsequently, the nitrocellulose 
membrane was washed with PBS-T (3 x 10 min) to remove unbound antibody. The 
membrane was then incubated with HRP-conjugated or fluorescently labeled 
secondary antibody, diluted in PBS-T (2 h, RT). The membrane was washed again (3 x 
10 min) and ECL solution was applied according to supplier’s manual. Membranes 
were either exposed to a Hyperfilm-ECL and developed or directly subjected to Vilber 
Lourmat Fusion FX7 to visualize protein bands due to Chemiluminescence. In case 
fluorescently labeled secondary antibody was applied, Typhoon 9400 variable Mode 
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Imager or Fusion FX7 were used to visualize protein bands. Immunodetection was 
also performed on fixed whole cells directly and investigated by fluorescent 
microscopy (see 2.2.19). 
 
2.2.19 Immunofluorescence (IF) 
Microscopic (confocal or non-confocal) analysis of cells was undertaken by applying 
immunodetection to specific endogenous or overexpressed proteins using 
fluorescently labeled secondary antibodies, or by overexpression of GFP-fusion 
proteins. For transfection/infection, HEp-2 or Vero cells were seeded on glass cover 
slips in a 24-well format. 24-30 h p.t./p.i., medium was removed and the cells washed 
with 1 x PBS. Subsequently, PBS was removed and cells fixed with 500 µl 3 % PFA/PBS 
(20 min, RT). Cells were rinsed twice with 1 x PBS and the cell membrane was 
permeabilized with 500 µl PBS/0.5 % Triton X-100 (5 min, RT). Then, 500 µl PBS/2 % 
BSA/0.1 % Triton X-100 was applied for 20 min, RT. In case of immunodetection, 
primary antibody was diluted to appropriate concentrations (see 2.1.5.) in PBS/2 % 
BSA/0.1 % Triton X-100 and added to the cells for 1 h, RT. Cells were washed with 
PBS/0.1 % Triton X-100 (3 x 5 min) and incubated with fluorescently-labeled 
secondary antibody, diluted in PBS/2 % BSA/0.1 % Triton X-100, for 1h (in case of 
fluorescently-labeled primary antibody this step was skipped). Cover slips were then 
washed three times with PBS and once with H2Odd and fixed on microscope slides 
using Vectashield mounting medium (Vector Labs) and nail varnish. Slides were dried 
at 4 °C and stored in the dark. Confocal microscopy was carried out on a Laser 
Scanning Microscope (Zeiss) using the LSM Meta software, and non-confocal UV 
microscopy on a UV microscope (Olympus) applying the analySIS software. 
 
2.2.20 In vitro ATPase assay 
ATPase activity of MDA5 and RIG-I was analyzed after stimulation with poly(I:C) and 
in absence or presence of RABV P. A 0.5-2 μM solution of purified MDA5 or RIG-I in 
H2Odd, and a 1 μM solution of RABV P was prepared. 50 μl ATPase dilution buffer 
containing or lacking poly(I:C) was mixed with 1 μl purified RABV P, or no RABV P as 
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control (for buffer compositions see appendix). 1 μl -32P-ATP was added to 29 μl 
H2Odd and 5 μl of the mix was added to the ATPase reaction mixes. The reaction was 
initiated by the addition of the enzymes MDA5 or RIG-I and incubation at 32 °C. A 
time course of ATP hydrolysis was made by applying 1 μl of the reaction mix to a 
polyethyleneiminecellulose plate (Merck, Darmstadt) at 5 min intervals. Air-drying of 
the mixture on the cellulose plate stopped the reaction instantly. ATP hydrolysis was 
evaluated by thin-layer chromatography (TLC) where the plate was incubated in 0.5 
M LiCl/1.0 M formic acid to separate the hydrolyzed -32P from -32P-ATP. The 
amounts of -32P and -32P-ATP were visualized with a phosphoimager (Amersham, 
Bioscience) and quantified using ImageQuant software. Reaction velocities were 
displayed as hydrolyzed -32P against time.  
 
2.2.21 In vitro transcription 
The MEGAshortscript Kit (Ambion) was applied for in vitro transcription as described 
in the manufacturer’s instructions. Measles virus leader template DNA 
oligonucleotides (see 2.1.4) containing a T7 promoter sequence (100 μM) were 
annealed with T7 promoter antisense oligonucleotide (100 μM) in the ratio 1:1 by 
heating (95 °C, 5 min) and subsequent cooling. 2 μl of this oligonucleotide was 
subjected to in vitro transcription (37 °C, o/n). DNase was supplied to digest template 
DNA and recovered RNA was purified using Mini Quick Spin RNA Columns (Roche). 
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3 Results 
3.1 Mechanisms of RABV P to inhibit IFN induction  
RABV P takes up a dual role in the inhibition of innate immune signaling, inhibiting 
IFNα/β- and IFNγ-induced JAK/STAT signaling (Brzòzka et al., 2006; Vidy et al., 2005), 
and also blocking the transcriptional activation of IFN itself by interfering with 
activation of the transcription factors IRF3 and IRF7 (Brzòzka et al., 2005). While it is 
known that RABV P inhibits JAK/STAT signaling by binding to activated STATs, and 
that this inhibition is lost upon deletion of the 10 C-terminal aa 288-297 (Brzòzka et 
al., 2006), the mechanism(s) and domain(s) responsible for inhibiting IRF3 activation 
so far remained elusive. Activation of IRF3 and IRF7 occurs through phosphorylation 
by the kinases TBK1 and IKKi and is triggered by various PRRs. In most cell types IRF3 
is activated after induction of the RLR signaling cascade, or in case of certain viruses 
via the TLR3 signaling cascade. In pDC, IRF7 is furthermore activated by TLR7 
signaling. Distinct studies provide evidence that RABV RNA does not induce TLR3 or 
TLR7 signaling. Only in the latter case RABV P has no inhibitory effects (Pfaller and 
Conzelmann, 2008). In the first part of my dissertation I analyzed P mutants unable to 
prevent IFN induction and showed the relevance of IFN inhibition for pathogenesis of 
recombinant RABV in vivo (Rieder et al., 2011). In the second part, molecular targets 
of P were identified and details on the inhibition mechanism revealed.  
 
3.1.1 Inhibition of IFN induction by RABV P depends on an internal domain 
P is a multifunctional protein involved in both IFN escape and viral RNA synthesis. In 
order to elucidate specific domain(s) or amino acids of RABV P involved in inhibition 
of IFN induction, previous work in the laboratory (by K. Brzózka) involved the 
generation of P mutants with small deletions. Initial screening for their ability to 
inhibit IFNβ promoter activity in dual luciferase assays indicated that the integrity of 
a region between aa 162 and 186 is required for full activity. For a detailed analysis, 
different constructs (PΔ176-181, PΔ182-186, and PΔ176-186) were constructed and 
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compared in dual luciferase assays and qRT-PCR experiments for their ability to 
inhibit IFNβ induction, as well as in native gel experiments for their ability to inhibit 
phosphorylation and dimerization of IRF3. 
 
3.1.1.1 Deletion of RABV P amino acids 176-186 results in loss of IFNβ inhibition 
In dual luciferase assays the expression of IFNβ promoter-controlled firefly luciferase 
(FL) from p125-luc was analyzed after transfection of distinct stimulators of the IFN 
induction cascade, such as constitutively active RIG-I- or MDA5-CARDs, named ∆RIG-I 
(aa 1-284) and ∆MDA5 (aa 1-350), respectively, and TBK1. Each of the inducers was 
coexpressed with plasmids of RABV P, the P deletion constructs, or empty vector 
(EV), into HEK 293T cells. A strong induction of FL expression upon cotransfection of 
∆RIG-I, ∆MDA5 and TBK1 with EV was detected (namely 19-, 9-, and 75-fold, 
respectively), which was almost completely abolished by cotransfection of P wt. 
However, P∆176-181 (P∆Ind1) and P∆182-186 (P∆Ind2) had lost the ability to inhibit 
IFNβ promoter activation significantly as levels of FL activity reached about 75%  of 
the stimulated EV controls. A third mutant, harboring a combined deletion of ∆Ind1 
and ∆Ind2, named P∆176-186 (P∆Ind1/2), also showed a loss of inhibition. 
Interestingly, the strongest residual inhibition was observed in the ∆Ind1/2 mutant, 
leading to the hypothesis that loss of inhibition is due to conformational alterations 
that somehow destroy the inhibitory mechanism, and is not directly conferred by the 
identified domains (Fig. 3-1A). In our recent publication, dual luciferase assays 
revealed that P∆Ind1, P∆Ind2 and P∆Ind1/2 were also able to inhibit mouse IRF7-
induced FL promoter activation when co-expressed with TBK1 (Rieder et al., 2011). 
To corroborate these findings, qRT-PCR experiments were carried out, using IFNβ-
specific primers to evaluate levels of newly transcribed IFNβ mRNA. Expression of 
∆RIG-I from transfected plasmid led to a 760-fold increase of IFNβ mRNA (100 %), 
compared to non-stimulated cells (control). This induction was strongly inhibited by 
coexpression of full-length RABV P, to about 1 %. However, in the presence of the 
deletion mutants P∆176-181, ∆182-186, and ∆176-186, transcription was not 
effectively inhibited, resulting in accumulation of IFNβ mRNA to 83 %, 75 % and 43 % 
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of the control, respectively (Fig. 3-1). Supporting the results from the dual luciferase 
assay, also here, a higher inhibitory of the double deletion mutant ∆176-186 was 
apparent.  
 
 
Figure 3-1: RABV P deletion mutants ∆176-181, ∆182-186 and ∆176-186 show decreased ability to inhibit IFNβ 
induction compared to full-length P. (A) In a dual luciferase reporter gene assay, 0.2 µg full-length RABV P and P 
deletion plasmids were transfected into HEK 293T cells together with 0.2 µg ∆RIG-I (aa 1-284), ∆MDA5 (aa 1-350) 
or TBK1, 50 ng p125-luc reporter plasmid and 1 ng pCMV-Renilla control plasmid using Lipofectamine 2000. 24 h 
p.t. IFNβ promoter-dependent FL activation was analyzed. (B) IFNβ mRNA levels were analyzed in a qRT-PCR 24 h 
after coexpression of 0.4 µg ∆RIG-I and 0.4 µg of full-length P, P deletion constructs or EV in HEK 293T cells using 
Lipofectamine 2000. Experiments depicted were carried out in duplicates, with error bars showing standard 
deviation of the averaged values detected. To prove appropriate protein levels SDS-PAGE was carried out and the 
Western blots stained against RABV P and actin. 
 
In conclusion, aa 176-186 of RABV P are required for its full capacity to inhibit IFNβ 
induction after stimulation with ∆RIG-I, ∆MDA5, and TBK1 in HEK 293T cells. It is 
suggested that the inhibition is impeded due to conformational restraints in RABV P 
caused by the internal deletions. 
 
3.1.1.2 Amino acids 176-186 are essential to efficiently inhibit TBK1- and IKKi- 
induced IRF3 phosphorylation 
As RABV P interferes with IFN induction by inhibiting the phosphorylation and 
dimerization of IRF3 (Brzózka et al., 2005), the results from the dual luciferase assays 
and the qRT-PCRs led us to the assumption that the ∆Ind mutants might have lost 
3  Results 
 
 
68 
their inhibitory potential due to a decreased ability to block IRF3 activation. This was 
analyzed by native gel electrophoresis and subsequent Western blot analysis after 
induction of IRF3 activation by overexpressing TBK1 or IKKi from plasmids. Using an 
antibody specific against phosphorylated IRF3-S386 we could detect phosphorylation 
after stimulation with TBK1 (Fig. 3-2A) and IKKi (Fig. 3-2B). Dimerization was also seen 
by using an IRF3 antibody. In case of RABV P coexpression, the S386 phosphorylation 
and dimerization were not detectable anymore. However, when coexpressing the 
mutants P∆Ind1, P∆Ind2, or P∆Ind1/2, phosphorylation and dimerization of IRF3 were 
visible, although to a lesser extent than in the control (EV); this was found in case of 
activation by both TBK1 and IKKi. Expression of RABV P, P∆Ind mutants, TBK1 and IKKi 
was validated in SDS-PAGE and Western blot analysis. 
 
                
 
Figure 3-2: Native PAGE showing inhibition of IRF3 dimerization and S386 phosphorylation by RABV P, which is 
lost when aa 176-186 are deleted. HEK 293T cells were cotransfected with 5 µg TBK1 (A) or IKKi (B) and 10 µg full-
length RABV P or the deletion mutants P∆Ind1, P∆Ind2, or P∆Ind1/2 using PEI. 24 h p.t. cells were lysed and 
subjected to native PAGE analysis. Western blotting and subsequent incubation with phospho-IRF3-Ser386 and 
IRF3 antibody revealed phosphorylation at Ser386 and dimerization of IRF3, respectively. SDS PAGE was 
undertaken to analyze expression levels of RABV P, P∆Ind mutants, and TBK1 (A) or IKKi (B). 
 
These findings provide evidence that the individual deletions of aa 176-186 disturb 
the function of RABV P to inhibit induction of IFN because the P∆Ind mutants are not 
able anymore to inhibit IRF3 activation. 
 
3.1.2 Generation of recombinant viruses harboring deletions of amino 
acids 176-186   
Consequential to the findings acquired from plasmid transfection experiments, it was 
of interest how the deletions of aa 176-181, 182-186, and 176-186 affect the 
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inhibitory effect of RABV P in a viral context. Therefore, minigenome assays were 
carried out to initially elaborate whether the P∆Ind mutants fulfill the functions of wt 
P necessary for viral RNA synthesis. Subsequently, recombinant RABV were 
generated carrying the respective deletions. 
 
3.1.2.1 P∆Ind proteins support viral growth 
In a minigenome assay the plasmid constructs P∆Ind1, P∆Ind2, and P∆Ind1/2 were 
tested for their ability to rescue a RABV minigenome into functional RNPs and to 
sustain replication and gene expression. The RABV minigenome plasmid pSDI-HH-
flash (Ghanem unpublished and (Conzelmann and Schnell, 1994)), which is composed 
of a FL gene flanked by RABV leader and trailer sequences, was cotransfected 
together with RABV N, L, P, or P deletion mutants into BSR-T7/5 cells. The DNA 
dependent T7 RNA polymerase transcribes the minigenome RNA from the plasmid. In 
case P fulfills its functions as polymerase co-factor, the viral polymerase (L/P) 
transcribes and replicates the minigenome RNA. The cells were harvested 48 h p.t. 
and FL activity was measured in a dual luciferase assay. As shown in figure 3-3, the 
deletion mutants of RABV P were as effective as full-length P to engage into N-P, L-P, 
and N-L-P complexes, thus, to encapsidate T7 transcripts, transcribe FL mRNAs, and 
replicate RNPs, respectively.  
         
Figure 3-3: RABV P deletion mutants ∆176-181, ∆182-186 and ∆176-186 fulfill essential functions to support 
expression from the RABV pSDI-HH-flash minigenome. BSR-T7/5 cells were cotransfected with 4 µg pSDI-HH-
flash minigenome and the helper plasmids that express RABV L (2.5 µg), N (5 µg), and either full-length P, or the 
depicted P deletion mutants (2.5 µg). Transfection of EV instead of P was used as control. 10 ng Renilla luciferase 
was further coexpressed to normalize the FL expression. 48 h p.t. cell lysates were prepared and luciferase 
activities measured. 
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This finding indicates that the deletions in P do not greatly affect virus replication and 
favor the possibility that full-length RABV genomes lacking aa 176-181, 182-186, or 
176-186 in their P gene can be rescued. 
 
3.1.2.2 SAD ∆Ind viruses can grow in IFN-incompetent and IFN-competent cells 
Using the standard RABV reverse genetics approach (Schnell et al., 1994), viable 
RABV harboring the P∆Ind1, P∆Ind2, and P∆Ind1/2 mutations could be rescued from 
cDNA. The generated recombinant viruses were named SAD ∆Ind1, SAD ∆Ind2, and 
SAD ∆Ind1/2. To initially test the ability of the SAD ∆Ind1 and SAD ∆Ind2 to inhibit IFN 
induction, as examined by the P∆Ind plasmid transfection experiments, native PAGE 
and immune fluorescence experiments were undertaken. These showed that the SAD 
∆Ind viruses, like SAD ∆PLP, were incapable of interfering with IRF3 S386 
phosphorylation, dimerization, and nuclear translocation (K. Brzózka; shown in 
(Rieder et al., 2011)). 
Growth kinetics of the recombinant viruses were analyzed in IFN-incompetent BSR-
T7/5 cells (which do not express IFN in response to RLR induction) (Fig. 3-4A), and in 
IFN-competent HEp-2 cells (K. Brzózka; shown in (Rieder et al., 2011)). After infection 
of BSR-T7/5 cells with an MOI of 0.1, the viruses SAD ∆Ind1, SAD ∆Ind2, and 
SAD ∆Ind1/2 reached titers comparable to parental SAD L16, namely up to 108 ffu/ml 
at day 3 p.i. (Fig. 3-4A). SAD ∆Ind1 and SAD ∆Ind2 (SAD ∆Ind1/2 not analyzed) 
showed comparable growth kinetics in IFN-competent HEp-2 cells meaning that the 
recombinant viruses most likely inhibit IFN-mediated JAK/STAT signaling. In contrast, 
SAD ∆PLP, which expresses only basal levels of full-length P (P gene moved from the 
second to the most promoter-distal position), showed a marked delay in propagation 
in HEp-2 cells, yielding 10- to 15-fold lower infectious titers.  
Indeed, SDS-PAGE analyses revealed that in HEp-2 cells infected with SAD ∆Ind1 and 
SAD ∆Ind2 levels of ISGs (such as Mx) were kept at low levels in contrary to cells 
infected with SAD ∆PLP where ISGs were expressed to higher levels (the control SAD 
L16 infection strongly blocked ISG accumulation). The ability of the ∆Ind mutant 
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viruses to still prevent IFN-mediated ISG induction could be corroborated in dual 
luciferase reporter assays, in which ISRE promoter-controlled FL activities were 
analyzed. For this experiment, BSR-T7/5 cells were transfected with pISRE-luc and a 
Renilla control plasmid and 6 h later infected with SAD L16, SAD ∆Ind1, SAD ∆Ind2, 
and SAD ∆PLP at an MOI of 3. 24 h p.i. the cells were stimulated with 1,000 IU/ml 
IFNαA/D, and FL activities were determined. An IFN-induced FL activity could only be 
detected in mock- and SAD ∆PLP-infected cells. However, strong inhibition of ISRE-
promoter activation was clearly seen after infection with L16, and the ∆Ind mutant 
viruses (shown in (Rieder et al., 2011)).  
To conclude, besides the lack of the ∆Ind mutant viruses to inhibit IFN induction, they 
are able to replicate in HEp-2 cells because of their remaining capability to inhibit 
JAK/STAT signaling, thus keeping expression of antiviral ISGs below a critical level. As 
a consequence we believe that inhibition of IFN induction and IFN signaling are 
genetically distinct functions of RABV P (also see (Brzozka et al., 2005, 2006)).   
 
           
 
Figure 3-4: Growth kinetics and protein expression of recombinant viruses SAD ∆Ind1, SAD ∆Ind2, and SAD 
∆Ind1/2, are comparable to SAD L16. (A) BSR-T7/5 cells were infected with the indicated SAD ∆Ind mutant viruses 
at an MOI of 0.1, and compared to SAD L16 and SAD ∆PLP. Infectious titers were determined 24, 48, 72 and 96 h 
p.i. by counting virus foci. (B) For analysis of viral protein expression, HEp-2 cells were infected with SAD L16 and 
respective mutant viruses at an MOI of 1, and cell lysates prepared 24 and 48 h p.i. Western blots were prepared 
and stained with antibodies against G, P, and M, and actin as loading control. Using the Bio 1D software of the 
Fusion molecular imaging device, the chemiluminescent signals were compared and a ratio of M relative to G was 
calculated (L16 at day 2 set to 1.0).   
 
To further characterize growth of SAD ∆Ind1, ∆Ind2, and ∆Ind1/2, HEp-2 cells were 
infected with an MOI of 1 and SDS-PAGE and Western blot analysis were performed 
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to compare protein levels of M, P, and G. In case of SAD ∆Ind1 and ∆Ind1/2, after two 
days a slight attenuation of M and G protein accumulation was visible compared to 
SAD L16 and SAD ∆Ind2. In case of SAD ∆PLP, a lack of protein expression was 
apparent, which is in accordance with its slow growth kinetics in infected HEp-2 cells. 
In a digital readout of chemiluminescent signals, protein expression was quantified 
by Fusion Bio 1D software. Indeed, 2 days p.i. SAD L16 and SAD ∆Ind2, show 
comparable M/G ratios, namely 1.0 and 0.9, respectively. However, SAD ∆Ind1 and 
SAD ∆Ind1/2 show reduced M levels (M/G ratio of 0.7 and 0.6, respectively), which 
indicates an influence of deleting aa 176-181 on M protein levels (Fig. 3-4B).  
 
3.1.2.3 SAD ∆Ind viruses are inducers of IFNβ, yet with diverging capacities 
In order to quantitatively evaluate the induction of IFNβ promoter activation and 
mRNA transcription by ∆Ind mutant viruses, p125-luc dual luciferase reporter assays 
and qRT-PCRs, respectively, were carried out in HEK 293T cells.  
For the luciferase assay, cells were transfected with p125-luc and pCMV-Renilla and 6 
h p.t. infected with SAD L16, SAD ∆Ind viruses, and ∆PLP at an MOI of 3. 24 h p.i., 
IFNβ promoter-controlled FL activities were inhibited strongest in SAD L16 infected 
cells. However, a 5-, 3-, and 4-fold increase in FL activities was detected by SAD 
∆Ind1, SAD ∆Ind2, and SAD ∆Ind1/2, respectively, and even up to 10-fold by SAD 
∆PLP compared to wt virus (Fig. 3-5A).  
These data were supported by qRT-PCR after isolation of RNA from infected HEK 
293T cells and quantification of IFNβ mRNA levels 24 h p.i. As expected, cells infected 
with ∆Ind viruses showed a markedly increased level of IFNβ mRNA transcription, as 
opposed to SAD L16. However, whilst in case of SAD ∆Ind1 and SAD ∆Ind1/2 the 
determined IFNβ transcription levels were strongly upregulated, namely 8-fold and 4-
fold compared to SAD L16, the cells infected with SAD ∆Ind2 only induced a 2-fold 
increase (Fig. 3-5B).  
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Figure 3-5: Infection of HEK 293T cells with SAD ∆Ind1, SAD ∆Ind2, and SAD ∆Ind1/2 showed an increased 
induction of IFNβ compared to SAD L16. HEK 293T cells were infected with the indicated viruses at an MOI of 3 
and investigated for IFNβ induction 24 h p.i. (A) For dual luciferase analysis of IFNβ promoter activation, 100 ng 
p125-luc and 2 ng pCMV-Renilla were expressed from plasmids and 6 h p.t. cells were infected with ∆Ind mutant 
viruses, SAD L16 and SAD ∆PLP. (B) qRT-PCR of total RNA using primers for IFNβ was applied to analyze IFNβ 
mRNA transcription. Western blot analysis was performed to validate comparable expression of RABV P.  
 
These results reveal that in comparison to SAD L16, which powerfully inhibits IFNβ 
induction, the recombinant viruses SAD ∆Ind1, SAD ∆Ind2, and SAD ∆Ind1/2, which 
lack the aa 176-181, 182-186, and 176-186 in their P gene, respectively, lost the 
ability to effectively interfere with IFNβ induction. SAD ∆Ind1 and SAD ∆Ind1/2 are 
more potent inducers of IFNβ than SAD ∆Ind2.  
 
3.1.2.4 SAD ∆Ind1, a strong inducer of IFNβ, has a characteristic transcription and 
replication profile, and is highly attenuated in vivo 
The distinct properties of the SAD ∆Ind viruses concerning the level of IFN induction 
and their protein expression profile were intriguing and further characterization was 
needed. Therefore, Northern blot experiments from total RNA were undertaken to 
investigate transcription (N mRNA) and replication (vRNA) patterns of the respective 
viruses, after infection of HEK 293T and BSR-T7/5 cells at an MOI of 3, by using a 
probe against the nucleoprotein N. As depicted (Fig. 3-6), it could be confirmed that 
correctly sized N mRNA and vRNA but apparently no defective interfering particles 
(inducers of RIG-I activation) were made. Interestingly, calculating the ratio between 
3  Results 
 
 
74 
N mRNA and vRNA using ImageQuant, SAD ∆Ind1 and SAD ∆Ind1/2 apparently 
accumulate more mRNAs per genome than SAD L16 and SAD ∆Ind2 in both HEK 293T 
and BSR-T7/5 cells. Furthermore, SAD ∆Ind1 shows a 4-fold induction of N 
mRNA/vRNA compared to SAD ∆Ind2 in both HEK 293T and BSR-T7/5 cells. SAD 
∆Ind1/2 also accumulates more N mRNAs per genome than SAD ∆Ind2, namely 2-fold 
in HEK 293T cells and 4-fold in BSR-T7/5 cells.  
 
        
             
Figure 3-6: Northern blot analysis of SAD L16 and recombinant SAD ∆Ind viruses. HEK 293T (A) and BSR-T7/5 (B) 
cells, infected with indicated viruses at an MOI of 3, were analyzed for N mRNA transcription and vRNA 
replication, after isolation of total RNA 24 h p.i. An N probe was applied and the signals were detected using 
ImageQuant. The ratio between N mRNA and genome vRNA was calculated and depicted in histograms as the 
percentage of the SAD L16 ratio (set to 100%).  
 
In conclusion, the above shown cell culture experiments demonstrated a loss of 
function of the P deletion mutants P∆176-181, P∆182-186 and P∆176-186, and the 
corresponding recombinant viruses SAD ∆Ind1, SAD ∆Ind2 and SAD ∆Ind1/2, in 
preventing induction of IFNβ after transfection or infection, respectively. However, 
the ability to prevent JAK/STAT signaling and to support virus growth was not 
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compromised. A particularly strong IFN induction by SAD ∆Ind1 and SAD ∆Ind1/2 may 
be due to transcription of IFN-stimulating RNAs.  
A biological relevance has been disclosed after investigating the effect of enhanced 
IRF3 activation of SAD ∆Ind viruses on their pathogenicity in vivo, after intracerebral 
(i.c.) injection into mice (Rieder et al., 2011). Wt mice with a functional IFNα/β-
receptor (IFNAR+/+) or mice lacking the receptor (IFNAR-/-) were infected with 105 ffu 
of SAD L16, SAD ∆Ind1, SAD ∆Ind2 and SAD ∆PLP and survival of mice was monitored 
over 18 days. As one would expect, all IFNAR-/- mice succumbed to infection by any 
of the viruses, with one day delay in case of SAD ∆Ind1 and SAD ∆PLP. However, the 
wt mice showed a strong difference in their reactions to the distinct viruses. Wt mice 
succumbed to SAD L16 infection already after 9 days, while SAD ∆Ind2 required 13 
days to cause death. On the contrary, SAD ∆Ind1 and SAD ∆PLP infections remained 
completely apathogenic, and all mice survived without showing clinical symptoms.  
These experiments provide evidence that the recombinant virus SAD ∆Ind1, which 
lacks the amino acids 176-181, is as attenuated as SAD ∆PLP, while it grows to much 
higher titers in IFN-competent cells (like SAD L16). As the previous experiments 
showed that SAD ∆Ind1 has a higher intrinsic capacity to induce IFN, it is assumed 
that the level of IRF3 activation and IFN expression is the major attenuating factor of 
the virus. The threshold of IFN production might decide whether a virus is 
apathogenic, like SAD ∆Ind1, or lethal, such as SAD ∆Ind2 and SAD L16.  
 
3.1.3 RABV P interacts with proteins of the RLR signaling cascade: 
Interaction with RLRs 
RABV P has been identified as potent antagonist of the cellular IFN system being able 
to interfere with both induction of IFNβ transcription (Brzózka et al., 2005) and IFN-
mediated JAK/STAT signaling (Brzózka et al., 2006; Vidy et al., 2005). The inhibition of 
IFN signaling occurs via interaction of C-terminal aa of RABV P to activated STAT, 
preventing binding of the transcription factor to its promoters. However, a direct 
interaction of P to a cellular protein that explains the inhibition of IRF3 S386 
phosphorylation, dimerization and nuclear import, was not identified so far. In this 
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study potential candidates of the RLR signaling cascade were investigated for their 
interaction with RABV P. 
The RLRs RIG-I, MDA5, and Lgp2, the downstream adaptor proteins IPS-1, Rip-1, 
Sintbad, NEMO, and Nap1, the kinases TBK1 and IKKi, and the transcription factor 
IRF3 were individually coexpressed with RABV P in HEK 293T cells and were analyzed 
for co-precipitation in Co-IP experiments. Strikingly, although repeated experiments 
in resting cells did not identify a clear interaction of RABV P with the proteins 
downstream of the RLRs, as was predicted from the ability of P to prevent TBK1-
mediated IRF3 phosphorylation, an interaction of P with the RLRs themselves, the 
receptors that recognize RABV RNA, was obtained. Functional assays, such as ATPase 
assays, were undertaken to investigate a biochemical relevance of these interactions.  
 
3.1.3.1 RABV P interacts with MDA5 and to a lesser extent Lgp2  
To analyze the interaction of RABV P with Flag-tagged RLRs in resting cells, 3 µg of 
RABV P and 3 µg of either one of the Flag-tagged RLRs were transfected into HEK 
293T cells and 24 h p.t. subjected to Co-IP analysis. In individual experiments, the 
ability of Flag-tagged RIG-I, MDA5, and Lgp2 to co-precipitate P on the Flag-matrix, or 
the ability of P to pulldown Flag-tagged RIG-I or MDA5 on SepahroseA beads (coated 
with antibody against P) were investigated. Proteins captured on the matrix (IP, Co-
IP) and total protein in the expression control (WCL) were analyzed by SDS-PAGE. 
First interesting results revealed an interaction of RABV P with the RIG-I-like helicase 
MDA5, and to a lesser extent with Lgp2, but not with RIG-I (Fig. 3-7B/C). The 
interaction of MDA5 and RABV P seems to be rather strong, considering a rather poor 
precipitation of MDA5 by the Flag-matrix compared to RIG-I and Lgp2. All RLRs 
contain a C-terminal RD and a HD with its motifs I-VI. RIG-I and MDA5 additionally 
have two C-terminal CARDs for downstream signaling (Fig. 3-7A). The activation of 
RIG-I and MDA5 by specific ligands induces conformational changes that ultimately 
influence their capacity for downstream signaling. This fact may influence access and 
possible interaction of RABV P to distinct RLR domains. 
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Figure 3-7: RABV P interacts with MDA5, and to a lesser extent Lgp2. (A) Schematic illustration of RIG-I, MDA5 
and Lgp2. All RLRs contain a C-terminal RD and a HD with the motifs I-VI (beige). RIG-I and MDA5 additionally have 
two C-terminal CARDs (yellow) for downstream signaling. In Co-IP assays Flag-MDA5, Flag-RIG-I, and Flag-Lgp2 
were examined for interaction with RABV P. 3 µg plasmids containing cDNA of Flag-tagged RLRs were 
cotransfected with 3 µg RABV P expression plasmid (pCR3-RABV P) into HEK 293T cells. Cells were lysed 24 h p.t. 
and 10 % of the lysate served as expression control (WCL; bottom panels). (B) 90 % of the cell lysate was 
incubated with a Flag-matrix. Precipitation of Flag-tagged proteins by the matrix (upper panel) and co-
precipitation of RABV P (second panel) were analyzed by SDS-PAGE and Western blot. (C) 90 % of the lysate was 
incubated with SepharoseA beads coated with an antibody against RABV P. RABV P protein precipitation by the 
SepharoseA beads (upper panel) and co-precipitation of Flag-tagged proteins (second panel) were analyzed by 
SDS-PAGE and Western blot. The blots were stained with α-RABV P or α-Flag antibody.  
 
 
3.1.3.2 RABV P interacts with the CARD/HD junction of MDA5 and the HD of Lgp2 
To characterize the region(s) of MDA5 and Lgp2 responsible for interaction with 
RABV P in more detail, constructs of Flag-tagged MDA5 and Lgp2 were generated 
comprising (or lacking) specific domains, such as MDA5 1-350, which contains the 
CARD domain and the helicase domain (HD) motif I, and MDA5 1-449, which contains 
the CARD domain and the HD motifs I, Ia and II. Furthermore, MDA5 HD, MDA5 
∆CARD, Lgp2 HD, and Lgp2 RD were generated (Fig. 3-8A). The Flag-tagged proteins 
were analyzed for interaction with RABV P in Co-IP experiments. 
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In case of MDA5, all constructs containing aa 1-350 were able to interact with RABV 
P, and in a construct where the CARD domain is missing, the interaction was lost. 
Interestingly, an MDA5 deletion construct comprising only aa 288-449, hence the 
CARD/HD junction and HD motifs I, Ia and II, was found sufficient for interaction with 
RABV P. However, the MDA5 HD (aa 327-894) was not able to associate with P which 
implicates an essential role of aa 288-327 for MDA5/P interaction (Fig. 3-8B). 
Furthermore, the abilities of Lgp2 domains (HD and RD) to interact with RABV P were 
analyzed. Obviously, RABV P rather interacts with the N-terminal part of Lgp2, thus 
the HD (Fig. 3-8C).  
Taken together, it seems that binding of RABV P involves the CARD/HD junction of 
MDA5, and the HD of Lgp2. It has to be mentioned that amino acid sequence 
comparison of the RLRs revealed that Lgp2 HD shares 30 % identity to the RIG-I HD 
and 40 % identity the MDA5 HD. If only HD motif I (Walker A motif), and motif I/II 
(Walker A and B motifs) are considered, sequence identities of 87.5 % and 81.25 %, 
respectively, exist between MDA5 and Lgp2, but only 75 % and 68.75 % between RIG-
I and Lgp2.  
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Figure 3-8: RABV P interacts with the MDA5 CARD/HD junction and with an Lgp2 N-terminal domain. (A) 
Schematic overview of MDA5 and Lgp2 mutants that were tested for interaction with RABV P. CARDs are depicted 
in yellow and HD motifs in beige. (B) Flag-MDA5, Flag-MDA5 1-350, Flag-MDA5 1-449, Flag-MDA5 ΔCARD, Flag-
MDA5 HD, Flag-MDA5 288-449 or (C) Flag-Lgp2 HD and Flag-Lgp2 RD were examined for interaction with RABV P 
in Co-IP assays. 3 µg plasmids containing cDNA of Flag-tagged RLRs and RLR-constructs were cotransfected with 3 
µg RABV P expression plasmid (pCR3-RABV P) into HEK 293T cells and lysed 24 h p.t. The Co-IP was carried out as 
described in Fig. 3-7. 
 
 
3.1.3.3 RABV PCTD and PNTD regions confer interaction with MDA5  
As the interaction with MDA5 seems to be rather strong compared to Lgp2 and as the 
question arose whether lyssavirus P proteins act on MDA5 like paramyxovirus V 
proteins, the interaction of RABV P to MDA5 was further elaborated. To restrict the 
interaction interface of RABV P required for MDA5 binding, full-length P (N- or C-
terminal Ig-tag) and the smaller P-forms, P2 (aa 19-297), P3 (aa 52-297) and P4 (aa 69-
297) (N-terminal Ig-tag) were expressed from respective plasmids in HEK 293T cells 
and analyzed 24 h p.t. for interaction with transfected Flag-MDA5 using the Flag-
matrix. Notably, the presence of an N-terminal Ig-tag on P interfered with co-
precipitation by Flag-MDA5, while a C-terminal Ig-tag allowed strong interaction. The 
strength of interaction decreased further when the N-terminal aa 1-52 were lacking, 
such as in P3 and P4 (Fig. 3-9A). These findings point towards an important role of a 
RABV P N-terminal region in MDA5 interaction.  
Further Co-IP experiments were performed to investigate C-terminally truncated 
RABV P constructs, with deletions of aa 191-297, 199-297, 217-297, and 245-297 for 
their interaction with Flag-MDA5 288-449 after cotransfection into HEK 293T cells. 
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Here, a drastic loss of co-precipitation by Flag-MDA5 288-449 was apparent in RABV 
P constructs that lack the C-terminal 80 aa or more (217-297). However, when only 
aa 245-297 of P were deleted, a strong interaction with MDA5 288-449 could be 
detected. It seems that the loss of RABV P aa 217-245 was decisive in the loss of 
interaction (Fig. 3-9B). 
 
Figure 3-9: RABV P lacking aa 20-52 and 217-245 show a reduced interaction with MDA5. 3 µg Flag-MDA5 or 
Flag-MDA5 288-449 and 3 µg RABV P constructs were coexpressed in HEK 293T cells and subjected to Co-IP 
experiments 24 h p.t. (A) Ig-RABV P (6630 nt), RABV P-Ig (6679 nt), Ig-RABV P2 (aa 19-297), Ig-RABV P3 (aa 52-297) 
and Ig-RABV P4 (aa 69-297) were coexpressed with Flag-MDA5. Ig and RABV P were cotransfected with EV to 
exclude unspecific interactions with the matrix. (B) RABV P, RABV P ∆191-297, RABV P ∆199-297, RABV P ∆217-
297 and RABV P ∆245-297 were cotransfected with MDA5 288-449. The Co-IPs were carried out as described in 
Fig. 3-7. 
 
 
Taken these results together, it seems that not only the PNTD but also aa 217-245 of 
the PCTD are important for MDA5 binding. It is possible that certain regions of RABV P 
are only brought into proximity upon tertiary structure formation, hereby displaying 
an interface that recognizes MDA5. Further constructs are generated to elucidate the 
precise binding interface. 
                                 
3.1.3.4 RABV P∆Ind1 is able to interact with MDA5 
In chapter 3.1.1 of this thesis, a domain in RABV P was described that is required for 
inhibition of IRF3 activation, namely aa 176-186. If this stretch of eleven amino acids 
is directly required for interaction with MDA5, or if this deletion renders the protein 
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shape sterically unfavorable for P interaction, was investigated in a further Co-IP 
assay. Initially, interaction of MDA5 and RABV P∆Ind1 (P∆176-181) was analyzed. As 
seen in figure 3-10, the amounts of P and RABV P∆Ind1 that were pulled down with 
Flag-MDA5 on the Flag-matrix were comparable, thus the deletion of aa 176-181 did 
not disturb P/MDA5 interaction. The addition of poly(I:C), a ligand of MDA5 that 
induces its activation and signaling capacity, also had no effect on interaction. 
Therefore, both wt P and P∆Ind1 are able to interact with MDA5 in its basal and 
activated state. Consequently, as P∆Ind1 lost its ability to block RLR signaling, P 
binding to MDA5 alone seems not to be sufficient to prevent IFN induction. 
      
Figure 3-10: RABV P∆Ind1 still interacts with MDA5 and strength of interaction is independent of poly(I:C) 
stimulation. In Co-IP assays RABV P or P∆Ind1 were analyzed for interaction with Flag-MDA5. 3 µg of respective 
plasmids were transfected into HEK 293T cells using PEI. 6 h p.t. cells were further transfected with poly(I:C) or 
with EV. 24 h after poly(I:C) transfection, cell lysates were prepared and analyzed. The Co-IP was carried out as 
described in Fig. 3-7. 
 
3.1.3.5 Activation of RIG-I allows for RABV P association  
In previous experiments investigating P/RLR interactions the transfected cells 
generally had not been treated with immune stimulating agents. Only in case of 
MDA5, poly(I:C) was applied to activate MDA5, which, as already mentioned, did not 
result in an increased interaction with P. However, the interaction of RABV P with 
RLRs was revisited in a situation where the cells were alerted. Therefore, Flag-RIG-I or 
Flag-Lgp2 were coexpressed with RABV P and the interaction analyzed in a Co-IP in 
absence or presence of Sendai virus DI (SeV DI-H4) infection. As positive control, a 
Co-IP of Flag-MDA5 1-350 and RABV P was carried out without stimulation of the 
cells. Indeed, the situation of P/RLR interaction intriguingly changes if the IFN 
induction pathway was stimulated by incubation of the cells with SeV DI-H4. 
Compared to unstimulated cells, where no or only weak interaction of RIG-I or Lgp2 
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with RABV P was observed, in stimulated cells P effectively interacted with RIG-I and 
Lgp2. The efficiency of activated RIG-I and Lgp2 to pull-down P was just as strong as 
by the positive control MDA5 1-350 which does not need to be activated (Fig. 3-11A). 
 
 
Figure 3-11: RABV P interacts with activated RIG-I and Lgp2 and with RIG-I CARDs. (A) In Co-IP assays Flag-RIG-I 
and Flag-Lgp2 were examined for interaction with RABV P with or without SeV DI stimulation. Fl-MDA5 1-350 was 
transfected as positive control without SeV DI stimulation. 3 µg of the Flag-tagged constructs were cotransfected 
with 3 µg RABV P expression plasmid (pCR3-RABV P) into HEK 293T cells using PEI, and analyzed 24h p.t. (B) RABV 
P was coexpressed with increasing amounts of Flag-RIG-I 1-284 (1, 2 and 4 µg) in HEK 293T cells and interaction 
analyzed by Co-IP 24 h p.t. The Co-IP was carried out as described in Fig. 3-7. 
 
As already mentioned, in resting cells the RIG-I signaling activity is repressed by 
interactions of the HD (or also RD) with the CARDs, masking the CARD domains from 
crucial activation modifications and from subsequent interaction with IPS-1. Upon 
ligand binding, a conformational change occurs that releases the CARDs which then 
convey downstream signaling. Concerning the previous findings, it seems that RABV P 
exclusively targets the activated conformations of RIG-I and preferentially of Lgp2. It 
was therefore of interest if a RIG-I construct lacking the repressive domain(s) can 
interact with RABV P without further stimulation. For this purpose, a RIG-I construct 
only composed of the CARDs and the HD motif I (known to be constitutively active), 
named Flag-RIG-I 1-284, was generated. Increasing amounts of Flag-RIG-I 1-284 (1, 2 
and 4 µg) were coexpressed with RABV P in HEK 293T cells without further 
stimulation and interaction analyzed in Co-IP assays. As anticipated, Flag-RIG-I 1-284 
was able to co-precipitate RABV P in a dose dependent manner and without 
activation by a ligand (Fig. 3-11B).  
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Taken together, RABV P is able to interact with MDA5 independent of its activation 
while interaction with Lgp2 is markedly induced upon its activation. In case of RIG-I 
an interaction with RABV P is only observed when a ligand is present. As an 
interaction of P with the RIG-I CARD/HD motif I could be observed without 
stimulation, it seems that only activation of RIG-I allows access to this region, while in 
MDA5 and Lgp2 this region is accessible without stimulation.  
These results were puzzling, yet they fit to findings observed in dual luciferase assays 
which revealed diverse abilities of RIG-I and MDA5 to induce IFNβ in presence or 
absence of certain stimuli. Therefore, p125-luc and pCMV-Renilla were transfected 
into HEK 293T cells and induction of the IFNβ promoter was analyzed. 
           
 
Figure 3-12: Activation of IFNβ promoter is induced by RIG-I and MDA5 depending on their activation. HEK 293T 
cells were transfected with 50 ng p125-luc reporter plasmid and 1 ng pCMV-Renilla using Lipofectamine 2000. (A) 
10 ng RIG-I, MDA5 or EV were cotransfected and 6 h p.t. either 250 ng MeLe RNA or 2500 ng poly(I:C) transfected 
further. (B) 0.2 µg RIG-I, RIG-I 1-284, RIG-I C-terminus, MDA5, MDA5 1-350, MDA5 1-449 or EV were 
cotransfected. After 24 h FL activities were measured and corrected to the Renilla luciferase activity in order to 
normalize the results.  
 
To identify specific ligands that activate RIG-I or MDA5, HEK 293T cells were 
transfected with RIG-I or MDA5 plasmids and 6 h p.t. they were further transfected 
with measles virus leader (MeLe) RNA or poly(I:C). As depicted in figure 3-12A, HEK 
293T cells showed a very low endogenous response to MeLe RNA or poly(I:C) in the 
dual luciferase assays. Pre-existing findings (Yoneyama et al., 2004, 2005) were 
corroborated that on the one hand MeLe RNA specifically induces RIG-I- (23-fold) but 
not MDA5-dependent IFNβ promoter activation. Poly(I:C) on the other hand is 
recognized by both RIG-I and MDA5 which leads to a 12- and 10-fold induction of the 
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IFNβ promoter, respectively. Interestingly, transfection of MDA5 without activation 
by a ligand (compared to EV w/o stimulation) already led to a 8-fold increase in IFNβ 
promoter induction. This finding indicates a basal activity of MDA5, inducing weak 
downstream signaling independent of ligand binding (Fig. 3-12A).  
This ligand independent IFNβ induction by MDA5 was addressed in further dual 
luciferase assays. Here RIG-I and MDA5 were transfected into HEK 293T cells and 
compared to the constitutively active forms RIG-I 1-284 (∆RIG-I), MDA5 1-350 
(∆MDA5), and MDA5 1-449 (all exhibiting a signaling CARD), regarding their intrinsic 
abilities to induce IFNβ without activation by their ligands. Expression of the RIG-I C-
terminal domain served as negative control. As expected, full-length RIG-I and RIG-I 
C-terminus did not induce luciferase levels, while RIG-I 1-284 induced the IFNβ 
promoter 50-fold. However, MDA5, like MDA5 1-350 or MDA5 1-499, induced the 
IFNβ promoter activity 20-fold (Fig. 3-12B). 
These data imply that RIG-I activity depends on a conformational change, which 
ultimately releases previously masked CARDs for downstream interactions, and 
which can then be targeted by RABV P. Full-length MDA5 on the other hand did not 
seem to fully depend on activation by a ligand and holds a conformation that allows 
for basal signaling, also exposing an interface for RABV P binding. 
 
3.1.3.6 Interaction of RABV P with RIG-I or MDA5 does not inhibit their ATPase 
activity 
Although an interaction of RABV P with RLRs is apparent, the functional relevance 
remains unclear. Previous experiments revealed a strong inhibition of IFNβ induction 
by RABV P after TBK1 was overexpressed (Fig. 3-1), therefore, an inhibition must 
occur downstream of TBK1. However, it is possible that RIG-I and MDA5 are 
additional targets of P to reinforce its blockage of the RLR signaling cascade. RIG-I and 
MDA5 are ATPase helicases and in previous studies it was implied that ATP driven 
helicase activity plays a role in their activation (Cui et al., 2008). To investigate an 
effect of RABV P on the ATPase activity of RIG-I and MDA5, thus inhibiting their full 
activation, ATPase assays were undertaken with respective purified proteins. In 
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ATPase assays, the ability of RIG-I and MDA5 to hydrolyze radioactively labeled γ-
32ATP to ADP and γ-32Pi was measured.  
                
Figure 3-13: RIG-I and MDA5 ATPase activity depends on poly(I:C) stimulation and is not inhibited by RABV P. 
ATPase activity was measured in an ATPase assay by analyzing the conversion of radioactively labeled γ-
32
ATP to 
ADP and γ-
32
Pi. By thin layer chromatography γ-
32
ATP and γ-
32
Pi were separated and visualized with a 
phosphoimager (upper panel). Bands were quantified by Image Quant software and reaction velocities illustrated 
in a histogram (γ-
32
Pi/time; lower panel). (A) 0.5 µM purified MDA5 was stimulated with 0.1 µM poly(I:C) and 
compared to unstimulated MDA5. Influence of 1 µM purified RABV P on the activated MDA5 was studied in a 
third sample. (B) 2 µM purified MDA5 and RIG-I were stimulated with 0.1 µM poly(I:C) in the presence or absence 
of RABV P.  
 
Initially, ATP hydrolysis by 0.5 µM MDA5 was investigated in the absence or presence 
of its ligand poly(I:C) (0.1 µM). As illustrated in Fig. 3-13A, in a time course of 30 min 
MDA5 does not show any ATPase activity without poly(I:C). However, if poly(I:C) was 
added a 45-fold increase in conversion of γ-32ATP to γ-32Pi was obtained. Thus, 
poly(I:C) is necessary for ATPase activity of MDA5. To test whether RABV P inhibits 
this activity, 1 µM purified P protein was added and ATP hydrolysis was measured 
under the same conditions. It was found that in vitro ATPase activity of purified 
MDA5 was not affected in the presence of purified P. To investigate the effect of 
RABV P on RIG-I ATPase activity in comparison to MDA5, a further ATPase assay was 
performed using 2 µM purified RIG-I and MDA5. The RLRs were stimulated with 
poly(I:C), an effective ligand of both RLRs (as seen in Fig. 3-12), and ATPase activity 
was analyzed in the absence or presence of P. RIG-I hydrolyzed ATP to similar level as 
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MDA5 (10 % less), and the presence of RABV P did again not reduce ATPase activity 
(Fig. 3-13B). The steeper increase of ATPase activity and the earlier saturation in 
figure 3-13B compared to figure 3-13A, can be explained by the usage of different 
enzyme concentrations (RIG-I/MDA5), namely 2 µM and 0.5 µM, respectively, while 
substrate (poly(I:C)) concentration was kept constant. 
Taken together, RABV P seems not to interfere with RLR ATPase activity. Our working 
hypothesis is that P binding prevents conformational changes or associates to 
domains of RLRs required for association with downstream molecules like IPS-1 
and/or eventually with other RLRs.  
 
        
3.1.4 RABV P interacts with proteins of the RLR signaling cascade: 
Interaction with (partially) activated IRF3 
As mentioned previously, overexpression of TBK1 and IKKi effectively induces IRF3 
phosphorylation at S386, dimerization and transcriptional activity. Coexpression of 
RABV P abrogates this activation (Fig. 3-2 or (Rieder et al., 2011)). This indicates that 
RABV P not only targets RLRs, but must interfere at the step of IRF3 phosphorylation; 
possibly by association with the kinases or with IRF3 directly. However, neither in Co-
IP experiments nor in conventional mass spectrometry analyses an interaction was 
detected (K. Brzózka dissertation). However, in this study I provide evidence for a 
conditional interaction of RABV P with IRF3 and describe a novel activation 
intermediate form of IRF3.  
 
3.1.4.1 RABV P interacts with IRF3 depending on its activation 
In Co-IP experiments, Flag-tagged IRF3, TBK1 or IKKi were coexpressed with RABV P 
in HEK 293T cells and interaction was investigated using a Flag-matrix 24 h p.t. In 
non-activated cells IRF3, TBK1 or IKKi did not purify P on the Flag-matrix. Remarkably, 
however, in cells expressing ∆RIG-I, a stimulator of the IFN induction pathway, a 
strong interaction of Flag-IRF3 with RABV P, but not with TBK1 or IKKi was apparent, 
indicating a direct interaction with IRF3 after its activation (Fig. 3-14A). Thus, 
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although P is known to effectively prevent activation of IRF3, the decisive step that 
revealed the interaction partner of RABV P was the stimulation of the IFN induction 
cascade.  
                 
 
Figure 3-14: RABV P interacts with IRF3 depending on its activation. HEK 293T cells were transfected with 2 µg of 
displayed plasmids and Co-IP assays were undertaken. A) Flag-IRF3, Flag-TBK1 and Flag-IKKi were examined for 
interaction with RABV P (pCR3-RABV P) 24 h p.t., in absence or presence of ∆RIG-I coexpression. (B) Plasmids 
containing cDNA of Flag-tagged RABV P was coexpressed with HA-IRF3 expression plasmid, in absence or presence 
of ∆RIG-I coexpression. EV was coexpressed with HA-IRF3 to exclude the possibility of unspecific interactions of 
HA-IRF3 with the matrix. The Co-IP was carried out as described in Fig. 3-7. 
 
In further Co-IPs, Flag-RABV P was used as the “bait” and the pull down of HA-IRF3 
was analyzed 24 h p.t. of respective plasmids into HEK 293T cells. Again, only in cells 
were ∆RIG-I was coexpressed, an association of HA-IRF3 with RABV P was detected. 
Interestingly, in the expression control (WCL) an increase of IRF3 molecular weight 
could be seen after stimulation with ∆RIG-I. However, this shift was not detected in 
the presence of RABV P. The shift might be due to phosphorylations in the C-terminal 
domain of IRF3, such as S386, which is inhibited by RABV P (Fig. 3-14B).  
The observed P/IRF3 interaction was further investigated by Co-IP experiments in 
which equal levels of Flag-IRF3 and RABV P were expressed (2 µg of each), however, 
with increasing levels of ∆RIG-I (0.1, 0.25, 0.5, 1, 2, 4 µg) activating cells to different 
degrees. To exclude unspecific binding of RABV P to the Flag-matrix a control was 
included where EV was transfected instead of Flag-IRF3. To furthermore exclude an 
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indirect association of ∆RIG-I (non-tagged) with the Flag-matrix (and a P pull down via 
∆RIG-I) the control was in addition transfected with 4 µg ∆RIG-I.  
                 
                    
Figure 3-15: RABV P/IRF3 interaction correlates with the degree of IRF3 activation. HEK 293T cells were 
transfected with 3 µg of Flag-IRF3 and RABV P expression plasmids. Increasing amounts of ∆RIG-I was coexpressed 
(0.1, 0.25, 0.5, 1, 2, 4 µg). 2 µg EV was coexpressed with 2 µg RABV P and 4 µg ∆RIG-I to exclude the possibility of 
unspecific interactions of ∆RIG-I or P with the matrix. The Co-IP was carried out 24 h p.t. as described in Fig. 3-7. 
 
Using phosphospecific antibodies against phosphorylated serines 396 and 398, it was 
shown that these phosphorylations accumulated with increasing amounts of ∆RIG-I, 
while levels of IRF3 were constant (Fig. 3-15). Therefore, although RABV P inhibits 
phosphorylation at S386, phosphorylations at S396 and S398 are apparently not 
affected. Strikingly, the amount of RABV P that associated to IRF3 increased 
drastically with an increased amount of transfected ∆RIG-I, showing a peak in cells 
stimulated with 4 µg ∆RIG-I. 
These experiments clearly show an interaction of RABV P and IRF3 that depends on 
activation of the RLR signaling cascade in the transfected cells. As no interaction was 
apparent in case of TBK1 or IKKi, an indirect association of RABV P with the signaling 
complex via ∆RIG-I is unlikely. It further seems that P/IRF3 interaction increases 
according to increased IRF3 activation and that P does not interfere with S396 and 
S398 phosphorylation. 
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3.1.4.2 RABV P/IRF3 interaction inhibits phosphorylation of IRF3 at serine 386 
while allowing phosphorylation at serines 396 and 398  
To address the highly discussed question of how phosphorylation and therefore 
activation of IRF3 actually takes place, expression profiles of phosphorylated IRF3 
forms over time were generated using commercially available antibodies against 
phosphorylated S386, S396 and S398. HEK 293T cells were transfected with equal 
amounts of Flag-IRF3 and 6 h p.t infected with SeV DI-H4, a potent activator of RIG-I-
dependent IFNβ induction. Cells were harvested at different time points (0, 4, 6, 8, 
10, 12, 24 h p.i.) and expression levels were analyzed by Western blot and 
subsequent staining with the above mentioned phosphospecific antibodies. 
Phosphorylation of IRF3 S386 (site 1), which serves as an indicator for activation, 
emerged after 8 h, peaked at 10-12 h and vanished 24 h after SeV DI-H4 stimulation. 
However, phosphorylation at serines 396 and 398 (site 2) appeared to occur at earlier 
time points, peaking already 8-10 h p.i.  
 
 
                
Figure 3-16: IRF3 phosphorylation of serine 398 and 396 occurs prior to serine 386 phosphorylation. Only serine 
386 phosphorylation is inhibited by RABV P. HEK 293T cells were transfected with 3 µg Flag-IRF3 in absence or 
presence of RABV P, and stimulated with SeV DI-H4. Lysates were prepared 0, 4, 6, 8, 10, 12, and 24 h after 
infection and subjected to SDS-PAGE and Western blot. Phosphorylation of S386, S396 and S398 was detected 
using phosphospecific antibodies.  
 
The influence of RABV P on IRF3 phosphorylation was investigated by coexpressing 
RABV P under the same experimental set-up. Inhibition of S386 phosphorylation by P 
was evident at all time points whilst phosphorylation at S396 and S398 appeared to 
be unaffected (Fig. 3-16).                
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To identify if the IRF3 phosphorylation profile at distinct time points somehow affects 
the interaction between IRF3 and P, the lysates generated for figure 3-16, were used 
in a Co-IP experiment. Thus, Flag-IRF3, stimulated for different periods of time and 
either coexpressed with RABV P or EV, was precipitated by the Flag-matrix, leading to 
a high protein yield. The precipitate was stained with phosphospecific antibodies, and 
the efficiency to pull-down P was investigated. When no P is present, 
phosphorylation at S386, S396 and S398 was nicely detectable, fortifying results from 
the expression control of figure 3-16. In P-expressing cells phospho-S386 was not 
detectable at any time point, however, phospho-S396 and -S398 bands were visible. 
Association of P and IRF3 clearly accumulated over time although P expression levels 
were constant throughout the time course (WCL). This indicates a correlation 
between the IRF3 activation kinetics and P binding.        
 
 
                 
Figure 3-17: RABV P interaction with IRF3 increases according to time of activation. Serine 386 phosphorylation 
is inhibited by IRF3/P interaction. HEK 293T cells were transfected with 3 µg Flag-IRF3 in absence or presence of 
RABV P, and stimulated with SeV DI-H4 for 24 h. Lysates were prepared at 0, 4, 6, 8, 10, 12, and Co-IP carried out 
as described in Fig. 3-7. Phosphorylation of S386, 396 and 398 were detected using phosphospecific antibodies.  
 
In conclusion, RABV P binds IRF3 in an activation-dependent manner, leading to 
inhibition of S386 whilst leaving S396 and S398 phosphorylations predominantly 
unaffected. These findings corroborate the proposed model of a two-step, 
phosphorylation dependent IRF3 activation. Hereby, initially site 2 residues are 
phosphorylated, leading to conformational changes allowing for site 1 
phosphorylation in the absence of P, but inhibition of site 1 phosphorylation in the 
presence of P. 
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3.1.4.3 Site directed mutagenesis of IRF3 serines 396/398 to alanine reduces 
interaction with RABV P  
Regarding the previous findings, it seems that the interaction of P/IRF3 is 
proportional to site 2 phosphorylations, specifically at S398. The possibility arose that 
RABV P might interact with IRF3 at specific site 2 phosphate moieties or that these 
phosphorylations induce an IRF3 conformation that allows for P binding. Therefore, 
mutants were generated where combinations of individual site 2 serines or 
threonines (S396, S398, S402, T404, S405) were exchanged to non-phosphorylatable 
alanine (S/TA). In a Co-IP assay, Flag-tagged mutants called IRF3 2A (S396, 
S398A), IRF3 3A (S402, T404, S405A), or IRF3 5A (all site 2 residuesA), were 
analyzed for interaction with RABV P in the absence or presence of SeV DI-H4 
infection. The interaction of wt IRF3 and IRF3 3A with RABV P was increased upon 
infection, however, IRF3 2A and IRF3 5A, both harboring mutations of  serines 
396/398 to alanine, showed a decrease in IRF3/P interaction after stimulation with 
SeV DI-H4 (Fig. 3-18).  
 
                  
     
Figure 3-18: Mutation of serines 396/398 to alanine reduces RABV P binding after SeV DI-H4 infection. HEK 293T 
cells were transfected with 3 µg Flag-IRF3, Flag-IRF3 IRF3 2A (S396A, S398A), IRF3 3A (S402A, T404A, S405A), and 
IRF3 5A (S396A, S398A, S402A, T404A, S405A) and 3 µg RABV P. 6 h p.t. cells were infected with SeV DI-H4 for 24 
h and compared to unstimulated cells. Lysates were prepared and Co-IP carried out as described in Fig. 3-7.  
 
This indicates that phosphate moieties known to be a prerequisite for IRF3 activation 
are either targeted by RABV P directly or that phosphorylation of S396/S398 induces 
a specific conformation facilitating P binding.  
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Additionally, mutants of IRF3 were generated in which site 2 residues where replaced 
by a phosphomimetic aspartic acid, such as IRF3 5D (all site 2 phosphositesD). IRF3 
5D was characterized to be constitutively active to induce IFNβ transcription without 
stimulation of the cells (Lin et al., 1999). Actually, already overexpression of IRF3 
S396D was previously identified to be sufficient to induce IFNβ (Servant et al., 2003). 
It is believed that the charges introduced by these mutations relieve auto-inhibitory 
structures and thus allows access for kinases that phosphorylate S385/S386. In Co-IP 
experiments IRF3 5D was analyzed for RABV P binding in non-activated cells and in 
cells stimulated with SeV DI-H4. As in previous experiments, IRF3/P interaction could 
only be observed in stimulated cells. Strikingly, P showed only residual binding to 
“constitutively active” IRF3 5D, which is assumed to hold a confirmation that enables 
S386 phosphorylation without stimulation. Interestingly, in stimulated cells IRF3 5D 
co-precipitated P much stronger, and stimulation even further increased S386 
phosphorylation. Furthermore, RABV P does not seem to effectively inhibit S386 
phosphorylation in case of IRF3 5D as opposed to wt IRF3 (Fig. 3-19A).  
            
 
Figure 3-19: Interaction of RABV P with phosphomimetic, constitutively active IRF3 is potentiated by SeV DI-H4 
and ∆RIG-I stimulation. HEK 293T cells were transfected with 3 µg Flag-IRF3 or Flag-IRF3 constructs and 
coexpressed with 3 µg RABV P. Transfected cells were stimulated with SeV DI-H4 or ∆RIG-I for 24 h subjected to 
Co-IP and compared to unstimulated cells. (A) IRF3 and IRF3 5D (S396D, S398D, S402D, T404D, S405D) were 
analyzed for interaction with RABVP. (B) IRF3 5D, IRF3 5D/S339A, IRF3 J2A5D and IRF3 AADDD (S396A, S398A, 
S402D, T404D, S405D) mutants were analyzed for interaction with RABV P. Lysates were prepared and Co-IP 
carried out as described in Fig. 3-7.  
 
This indicates that IRF3 5D holds a stable conformation that allows for S386 
phosphorylation, which cannot be effectively inhibited by RABV P despite a strong 
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interaction. The fact that S386 phosphorylation but also P interaction is further 
induced by stimulation, implies that P does not directly bind to site 2 phosphate 
moieties and that S386 phosphorylation must be induced by further, so far unknown 
modifications beside site 2 phosphorylation, which also favor P binding.  
As IRF3 S396/S398 seem to have a certain role in IRF3 activation and P binding, a 
mutant called IRF3 AADDD was included harboring S396/S398A and 
S402/T404/S405D mutations. Furthermore, IRF3 5D mutants that additionally lack 
S339 and S385/S386 phosphosites were included in the study. RABV P showed only 
residual binding to all of these mutants, however, efficient binding occurred upon 
activation by ∆RIG-I. Only the mutant IRF3 AADDD displayed a weak reduction in P 
interaction which again implies a role of S396/S398 for P binding. However, 
phosphorylation of S339 and S385/S386 seem to be dispensable for P binding. The 
results also indicate an involvement of other residues, and/or additional activation 
mechanisms of IRF3 that lead to conformational changes that allow for P binding.  
 
3.1.4.4 RABV P/IRF3 interaction involves helices H3/H4 of the IRF association 
domain  
As IRF3/P binding is induced by S396/S398 phosphorylation, which probably supports 
activation of IRF3 by releasing inhibitory structures, the interaction was further 
characterized by generating Flag-tagged deletion constructs lacking specific domains 
(such as H1 and/or H5) to investigate their ability to co-precipitate RABV P on a Flag-
matrix (Fig. 3-20A). Due to our previous findings, we support a sequential 
phosphorylation but also suggest that further phosphorylations or regulatory 
mechanisms are involved.  
To characterize the IRF3/P interface, interaction of the distinct IRF3 constructs with P 
was analyzed with or without SeV DI-H4 infection. As could be expected for full-
length IRF3 and IRF3 180-427, comprising all helices of the IAD and RD, interaction 
was only induced by SeV DI-H4 infection. However, the shorter constructs lacking 
auto-inhibitory structures H1 (IRF3 200-427), H1 and H2 (IRF3 300-427), or H1 and H5 
(IRF3 200-384), already displayed increased interaction with P in uninfected cells. 
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Interestingly, although H1 and H5 were lacking, these interactions increased even 
further in activated cells. The constructs comprising the H1 helix (IRF3 and IRF3 185-
427), showed a reduced interaction compared to mutants lacking H1, supporting an 
inhibitory function of H1. Additional deletion of H2 in IRF3 300-427, even further 
increased the efficiency of IRF3 to pull-down RABV P, although expression of this 
mutant was very low (Fig. 3-20B), suggesting a further inhibitory role of H2.  
Interestingly, deletion of the H5 helix in the mutant IRF3 200-384 did not 
substantially decrease strength of interaction with P, which supports the finding that 
H5 is not directly involved in P binding. Furthermore, besides phosphosite S339 that 
is also involved in IRF3 activation, this mutant lacks the C-terminal site 1 and 2 
residues, as well as the constitutively phosphorylated S173/S175. As IRF3 200-384/P 
interaction is also induced after activation only a partial contribution of these 
residues to the conformational rearrangements favoring P binding is probable. 
Eventually, intramolecular displacements must occur that allow for an interaction 
with P even upon removal of inhibitory regions, potentiated by stimulation of the 
cells due to so far unknown activation mechanisms around H3 and H4. 
Taken together, these data indicate that IRF3 helices H3 and H4, which are also 
involved in IRF3 dimerization and CBP interaction, are required for P binding. Access 
of P to these helices is obtained upon removal of H1/H2 and H5 and increased by 
activation. Therefore, a very specific IRF3 activation intermediate that seems not to 
solely rely on phosphorylation of C-terminal residues but on further modifications 
favors P binding. 
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Figure 3-20: RABV P/IRF3 interaction is induced by the lack of IRF3 IAD H1/H2 and H5 helices. (A) Schematic 
overview of IRF3 constructs. IRF3 wt is composed of a DNA-binding domain (DBD), a proline rich domain (PRR), an 
IRF association domain (IAD) and a regulatory domain (RD). The nuclear localization signal (NLS; yellow stripe), 
nuclear export signal (NES; black stripe), and auto-inhibitory helices H1 and H5 are assigned (red arrows). (B) HEK 
293T cells were transfected with 3 µg of assigned Flag-IRF3 constructs and coexpressed with 3 µg RABV P. 
Transfected cells were infected with SeV DI-H4 and compared to unstimulated cells. Lysates were prepared and 
Co-IP carried out as described in Fig. 3-7. 
 
 
3.1.4.5 RABV P∆Ind mutants unable to inhibit serine 386 phosphorylation can 
still interact with IRF3  
In the first part of this thesis, mutants of RABV P were presented that have lost the 
ability to interfere with activation of IRF3, namely RABV P∆Ind1, P∆Ind2 and 
P∆Ind1/2 (see Fig. 3-1). These mutants lost the ability to inhibit IRF3 S386 
phosphorylation, dimerization and transcriptional activity. To investigate whether 
this loss of inhibition results from a loss of IRF3/P interaction, further Co-IP assays 
were carried out.  
Flag-IRF3 was coexpressed with full-length P and P∆Ind1, and the interaction was 
compared in cells stimulated with SeV DI-H4 and unstimulated cells. To elaborate 
effects on S386, S396, and S398 phosphorylation, phosphospecific antibodies were 
used. As displayed in figure 3-21, in unstimulated cells Flag-IRF3 did not co-
precipitate RABV P. However, upon stimulation a strong pull-down of RABV P was 
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detected. Strikingly, interaction with IRF3 was also observed for P∆Ind1 which was 
pulled down by Flag-IRF3 as efficiently as wt P. However, in spite of IRF3 binding, 
P∆Ind1 has lost its ability to inhibit phosphorylation of S386, as observed in previous 
experiments. As expected, phosphorylation of S396/S398 remained unaffected (Fig. 
3-21). 
                                     
 
Figure 3-21: RABV P lacking aa 176-181 is incapable of inhibiting IRF3 phosphorylation and dimerization but can 
still interact with IRF3. HEK 293T cells were transfected with 3 µg of Flag-IRF3 and 3 µg RABV P or RABV P∆Ind1. 
To exclude unspecific binding of P to the matrix, RABV P was also coexpressed with EV. Transfected cells were 
stimulated with SeV DI-H4 and compared to unstimulated cells. Lysates were prepared and Co-IP carried out as 
described in Fig. 3-7. Phosphorylation of S386, S396 and S398 were detected using phosphospecific antibodies.
  
 
Furthermore, mutants P∆Ind2 and P∆Ind1/2 were analyzed for their ability to interact 
with IRF3 as well as for their properties in inhibiting IRF3 S386 phosphorylation, in 
comparison to P∆Ind1 and full-length P. Interactions of P∆Ind2 and P∆Ind1/2 with 
IRF3 in stimulated cells were as strong as in case of wt P and P∆Ind1. No interaction 
occurred in unstimulated cells. Phosphorylation of S386 upon activation by SeV DI-H4 
infection was inhibited only by wt RABV P. As previously described, P∆Ind2 and 
P∆Ind1/2 largely lost the ability to inhibit S386 phosphorylation, like P∆Ind1, and 
almost to levels observed without P expression (Fig. 3-22).  
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Figure 3-22: RABV P∆Ind1, P∆Ind2, and P∆Ind1/2 mutants can interact with IRF3. HEK 293T cells were 
transfected with 3 µg of Flag-IRF3 and 3 µg RABV P, RABV P∆Ind1, RABV P∆Ind2, or RABV P∆Ind1/2. To exclude 
unspecific binding of P to the matrix, RABV P was also coexpressed with EV. Transfected cells were stimulated 
with SeV DI-H4 and compared to unstimulated cells. Lysates were prepared and Co-IP carried out as described in 
Fig. 3-7. Phosphorylation of IRF3 S386 in absence or presence of P, or P∆Ind mutants, was detected using 
phosphospecific antibodies. 
 
 
Therefore, all of the P∆Ind mutants can still interact with IRF3 yet fail to inhibit S386 
phosphorylation and transcriptional activity. This finding also supports the previous 
notion that deletion of aa 176-186 changes structural conformations in P, leading to a 
loss of function regarding IFNβ induction. 
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4 Discussion 
The details of the interplay of viruses and the host innate immune system are just 
being discovered. In the past years the importance of viral counteractions against the 
host type I IFN system in order to establish an infection became evident. The RABV 
phosphoprotein P has been shown to be a potent antagonist of the innate immune 
system by inhibiting both arms of the IFN response. RABV P inhibits IFN induction and 
IFN signaling, by preventing activation of IRF3/7 transcription factors and import of 
activated STAT1/2 transcription factors, respectively (Brzózka et al., 2006, 2005). This 
dual mode of inhibition effectively limits expression of IFN, immune stimulatory and 
antiviral genes and hereby helps RABV to pursue various strategies, such as 
unhindered growth and maintenance of neuronal circuits for efficient virus spread to 
the CNS.  
As shown previously by Brzózka et al., STAT binding is accomplished by the 10 C-
terminal aa of P. However, the mechanisms involved in the inhibition of IFN induction 
still have to be elaborated. In this study, mutants of RABV P lacking aa 176-186, 
which lost the ability to inhibit type I IFN induction while leaving inhibition of STAT 
signaling or other crucial functions of P intact, were characterized in vitro and in vivo, 
revealing a critical contribution to pathogenicity (Rieder et al., 2011). In a second 
part, cellular interaction partners of RABV P could be identified that play major roles 
in the RLR signaling cascade, namely the receptors RIG-I, MDA5, and Lgp2, and the 
transcription factor IRF3, thus providing the mechanistic background for the 
inhibitory effect of P on IFN induction. As RABV P can interact with MDA5 and Lgp2 in 
their “non-activated” state but RIG-I requires ligand-induced activation to be bound 
by P, the findings suggest distinct latent conformational states and activation 
mechanisms of the individual RLRs. Furthermore, RABV P binds an activation 
intermediate of IRF3, thereby inhibiting IRF3 serine 386 phosphorylation, which is 
required for full transcriptional activity. This interaction can be used as tool to 
identify the sequence of events leading to transcriptional activation of IRF3.  
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4.1 Inhibition of type I IFN induction by RABV P depends on amino 
acids 176-186 
In previous studies, the properties of RABV P were analyzed by generating a mutant 
virus, named SAD ∆PLP, in which the P gene is shifted to the most promoter distal 
position (N-M-G-L-P), exhibiting an attenuated P expression due to a possible 
dissociation of the viral polymerase. It was shown that the marginal P levels are 
sufficient to fulfill essential functions in viral RNA synthesis, as SAD ∆PLP was only 
slightly attenuated in IFN incompetent BSR cell lines, with only a 10-fold reduction of 
maximum virus titer compared to wt RABV (SAD L16). However, in IFN-competent 
HEp-2 cells it completely failed to replicate, indicating a role of P in counteracting the 
IFN system. The specific antagonistic role of P on the IFN induction pathway became 
evident when SAD ∆PLP infected cells induced transcription of IFNβ mRNA, whereas 
in SAD L16 infected cells IFNβ transcription was hardly detectable. Furthermore, 
SAD ∆PLP infection resulted in activation of IRF3, as demonstrated by S386 
phosphorylation and IRF3 dimerization, as opposed to SAD L16 where this activation 
was blocked. Ectopic expression of P from plasmid inhibited transcriptional activation 
of IRF3, induced by different stimuli (Brzózka et al., 2005).  
By direct mutagenesis and transfection experiments, an essential domain of RABV P 
required for this interference could be identified. As shown in dual luciferase assays 
and qRT-PCR experiments, the deletion of aa 176-186 in the RABV P gene diminished 
the inhibitory properties of P regarding IFN induction. Upon transfection of the 
plasmids RABV P∆176-181 (P∆Ind1), P∆182-186 (P∆Ind2), and P∆176-186 (P∆Ind1/2) 
into HEK 293T cells and overexpression of distinct stimuli (∆RIG-I, ∆MDA5, TBK1), the 
IFNβ promoter activation and IFNβ mRNA transcription were not inhibited, as 
opposed to full-length RABV P that strongly inhibited IFNβ induction (Fig. 3-1). 
Furthermore, in native gel analyzes the ability of RABV P and the loss of the P∆Ind 
mutants to inhibit IRF3 phosphorylation at S386 and IRF3 dimerization after 
stimulation by TBK1 or IKKi was revealed (Fig. 3-2). Noteworthy is the observation 
that the deletion of RABV P aa 176-181 or aa 182-186 resulted in similarly strong 
defects with respect to IRF3 inhibition, while the combined deletion of the entire 
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domain aa 176-186 appeared to have a less pronounced defect. It can be therefore 
hypothesized that the deletions rather affect a specific protein folding required for 
interference with IRF3 activation than being directly involved in binding targets of the 
signaling complex. The identified domain is positioned in a part of the protein 
predicted to be structurally disordered (Gerard et al., 2009). Moreover it is directly 
adjacent to a region (aa 61-175) nonessential for basic transcription of RABV 
minigenomes (Jacob et al., 2001). 
As indicated by minigenome experiments, the deletions in RABV P∆176-181, P∆182-
186 and P∆176-186 did not critically affect crucial functions in transcription and 
replication (Fig. 3-3). Corresponding recombinant viruses SAD ∆Ind1, SAD ∆Ind2, SAD 
∆Ind1/2 were generated and analyzed for growth kinetics and the ability to interfere 
with IFNβ promoter activity and IFNβ transcription. As expected from the 
transfection experiments, the SAD ∆Ind viruses also showed a reduced ability to 
prevent IFNβ induction as shown in dual luciferase assays and qRT-PCR (Fig. 3-5). This 
data was corroborated by immunofluorescence and native gel analyses of SAD ∆Ind 
infected IFN-competent cells, where IRF3 nuclear localization, and S386 
phosphorylation and dimerization could be detected. Interestingly, all SAD ∆Ind 
viruses showed a clear growth advantage over the SAD ∆PLP, with infectious titers 
comparable to the parental SAD L16 in IFN-competent (HEp-2) and IFN-incompetent 
(BSR-T7/5) cells (Fig. 3-4A). This unhindered growth in IFN-competent cells can be 
explained by the strong capability of the SAD ∆Ind viruses to interfere with IFN-
mediated ISG induction, as confirmed in reporter gene assays and Western blot 
analysis. Infection of HEp-2 cells with SAD ∆Ind viruses also led to an accumulation of 
activated STAT, reflecting a retention of STATs in the cytoplasm and hindered STAT 
recycling (Rieder et al., 2011). This indicates that SAD ∆PLP suffers from induction of 
greater levels of IFN and ISGs in the initially infected cells, thus a more rapid 
establishment of an antiviral state, while the SAD ∆Ind viruses, though inducing IFN, 
can limit this antiviral environment by keeping ISGs low. 
In conclusion, the SAD ∆Ind viruses lost the full capacity to inhibit IRF3 activation and 
IFN induction but are otherwise equipped with the full capacity of IFN resistance and 
virus propagation. 
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4.2 Inhibition of RF3 activation is important for pathogenicity 
Interestingly, the recombinant SAD ∆Ind1 and SAD ∆Ind1/2 viruses induced IFNβ to 
significantly higher quantities than SAD ∆Ind2 (Fig. 3-5A/B). To further characterize 
the viruses, Northern blot experiments were carried out, which revealed that SAD 
∆Ind1 and SAD ∆Ind1/2 mutants produce more mRNAs per genome (Fig. 3-6). It is 
speculated that this could lead to a stronger stimulation of the RIG-I pathway by 
RABV 5’-pppRNAs and therefore an increased IFN induction. The origin of this distinct 
phenotype is unclear, yet a correlation with the reduced expression levels of the SAD 
∆Ind1 and SAD ∆Ind1/2 M protein seems possible (Fig. 3-4B). The RABV M protein 
has been shown to regulate the balance of transcription and replication (Finke et al., 
2003) and the P protein has been shown to interact with M (A. Kern unpublished). 
The involvement of an increased transcription level in increased IFN induction would 
indicate a dominant role of subgenomic RNAs in RLR activation, arguing against a 
previous finding that genome RNA (here of SeV) is the major RIG-I inducer (Rehwinkel 
et al., 2010). However, whether the M protein is responsible for distinct transcription 
levels has to be elucidated further. 
In vivo mouse experiments (performed by L. Stitz, FLI Tübingen) revealed the 
importance of blocking IRF3 activation and IFN induction for RABV pathogenicity (see 
(Rieder et al., 2011)). SAD ∆PLP injection into wt mice did not cause symptoms, 
disease, or death, while wt SAD L16 led to death of the mice within a few days. 
IFNAR-/- mice all succumbed to infection 5 days p.i., yet in case of SAD ∆PLP with one 
day delay. The SAD ∆Ind2 mutant caused the typical rabies symptoms in wt and 
IFNAR-/- mice, but in both cases the course of disease was delayed by several days 
compared to that of SAD L16, approving a protective role of IRF3 activation and IFN 
induction. Strikingly, a high dose of SAD ∆Ind1 virus did not cause symptoms in wt 
mice revealing a severely attenuated phenotype of this virus. Like in SAD ∆PLP 
infection, however, IFNAR-/- mice infected with SAD ∆Ind1 died with one day delay 
compared to SAD L16 and SAD ∆Ind2.  
Taken these results together, SAD ∆Ind recombinant viruses showed growth kinetics 
comparable to SAD L16, yet SAD ∆Ind1 remained completely apathogenic even after 
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i.c. injection into mouse brains. Here it seems that activation of IRF3 and induction of 
IFN by SAD ∆Ind1 is sufficient to activate the host defense system to a protective 
level. This also indicates that neurovirulence of IFN resistant RABV correlates with the 
ability to prevent induction of IFN. 
 
4.3 RABV P interacts with RIG-I-like helicases depending on their 
conformational state  
To clarify the mechanisms utilized by RABV P to inhibit IRF3 activation, potential 
target proteins of RABV P, which function upstream of IRF3 activation in the IFNα/β 
induction pathway, were screened for interaction with P. Therefore, plasmids of 
RABV P and potential interaction partners were coexpressed in HEK 293T cells and 
Co-IP experiments were undertaken. Reproducible interaction of RABV P with various 
members of the RLR signal cascade such as TANK, SINTBAD, NAP1, and TBK1, in 
resting cells could not be revealed. However, when RABV P was coexpressed with the 
RLRs, a co-precipitation of RABV P with MDA5 and to a lesser extend Lgp2, but not 
RIG-I, was apparent (Fig. 3-7). Interestingly, in the presence of an adequate RIG-I 
ligand, a substantial interaction of P with RIG-I was detected as well (Fig. 3-11A).  
Biochemical and structural analyses have revealed that the C-terminal RD of RIG-I 
specifically binds 5’-pppRNAs (Cui et al., 2008), whereas the RDs of MDA5 or Lgp2 can 
accommodate blunt dsRNA ends (Li et al., 2009; Pippig et al., 2009). These studies 
suggested a model according to which inactive RIG-I is present in a closed 
conformation where CARDs are masked, but upon 5’-pppRNA binding to the RD and 
dsRNA binding to the HD, a conformational change occurs allowing the CARDs to 
interact with the downstream adapter IPS-1. It is probable that in the absence of an 
adequate ligand, not only RIG-I CARDs are masked but also the domains recognized 
by RABV P. For MDA5 a similar activation mechanism is probable, however, a distinct 
conformation is suggested that allows for basal signaling in the inactive state, maybe 
also exposing domains recognized by P (Bamming and Horvath, 2009). We suggest 
that RABV P can only interact with the activated open conformation state of RIG-I but 
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also with the non-stimulated MDA5. 
In correlation with this hypothesis, dual luciferase assays revealed differences of RIG-
I and MDA5 concerning their intrinsic signaling properties in the absence or presence 
of specific ligands. In accordance with previous studies, both MDA5 and RIG-I 
respond to poly(I:C), however, MeLe RNA only activates RIG-I to induce IFNβ (Fig. 3-
12A). Interestingly, in the absence of a ligand, the transfection of full-length MDA5 
and constitutively active MDA5 CARDs induced the IFNβ promoter to a similar 
extend, whereas full-length RIG-I did not induce IFN without a ligand (Fig. 3-12B). The 
non-ligand dependent IFN induction and the non-ligand dependent P binding of 
MDA5 observed in this study and findings by others, which also observed elevated 
IFNβ promoter-coupled luciferase activities after ectopic expression of MDA5 
(Bamming and Horvath, 2009), suggest that the non-activated structure of MDA5 is 
different from that of RIG-I.  
 
Figure 4-1: Models of RIG-I and MDA5 conformation in their activated and non-activated states and RABV P 
binding. (A) Illustration of RIG and MDA5 in their activated state upon binding to their ligands 5’-pppRNA (or 
poly(I:C)) and poly(I:C), respectively. The receptors hold an open conformation with the RD bound to the ligand 
and the CARDs exposed so that RABV P could associate. (B) Conformation of RIG-I and MDA5 in non-activated 
cells. It is suggested that RIG-I holds a closed conformation with the CARDs masked by the RD or HD (Cui et al., 
2008). MDA5 is tentatively present in a leaky, not completely closed conformation that allows for basal signaling 
and P binding (Bamming and Horvath, 2009). 
 
The finding that P interacts with MDA5 was surprising as rhabdoviruses are thought 
to predominantly activate RIG-I and not MDA5. As already described, RABV produces 
a 5’-pppRNA during its life cycle which is known to be the main ligand for RIG-I. 
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MDA5, however, was shown to predominantly recognize a picornavirus (EMCV) and 
the dsRNA analogue poly(I:C), which is also recognized by RIG-I. However, the RABV 
P/MDA5 interaction might resemble the situation found in paramyxoviruses, which 
are also recognized mainly by RIG-I but whose V proteins bind MDA5, thus inhibiting 
RLR signaling (Andrejeva et al., 2004; Ikegame et al., 2010). As the exact mechanism 
of RLR activation, such as the physiological ligand for MDA5, and an eventual co-
operation or interaction of RIG-I and MDA5 is still highly discussed, the RLR/P 
interaction can be  benefitial in elucidating these questions.  
To further characterize this interaction, MDA5 constructs composed of distinct 
(functional) domains were generated and analyzed for interaction with RABV P (Fig. 
3-8B). The constructs Flag-MDA5 1-350 and Flag-MDA5 1-449, which contain the 
CARDs and the HD motif I or the HD motif I/II, respectively, were able to interact with 
RABV P, whilst the constructs lacking the CARD domain did not pull down RABV P. 
This initially indicated that for the interaction with RABV P the MDA5 CARD domains 
are essential. However, a MDA5 construct only composed of aa 288-449, displaying 
the N-terminal part of the CARDs and HD motifs I/II, was also able to interact with 
RABV P. As the Flag-MDA5 HD construct did not associate with RABV P, the aa that 
seem to be decisive for interaction are 288-327, thus, the region of the CARD/HD 
junction.  
Furthermore, Co-IP experiments that analyzed the P/Lgp2 interaction showed that 
the RD of Lgp2 is dispensable for interaction whilst the HD is required (Fig. 3-8C). This 
finding also reveals parallels to the paramyxovirus V protein that not only interacts 
with MDA5 but also with Lgp2 via its HD (Parisien et al., 2009). The V proteins of 
distinct paramyxoviruses, such as MeV, mumps virus, Hendra virus, Nipah virus, and 
human parainfluenca virus type 2, target a 130-residue region in the MDA5 HD, 
which is highly homologous between MDA5 and Lgp2 (Parisien et al., 2009). Also the 
N-terminal part of the MDA5 HD, shown to be essential for MDA5/P interaction, 
shows a high homology to Lgp2. However, an indirect interaction of P to Lgp2 cannot 
be excluded, as Lgp2 itself might bind to MDA5. It also has to be mentioned that a 
direct MDA5/P interaction has not been proven so far. Thus, a further protein might 
be interjacent and the interaction indirect. 
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By the generation of RABV P deletion constructs, regions of P could be revealed that 
seem crucial for binding to MDA5 (Fig. 3-9, 3-10). Taken the results of diverse Co-IPs 
together, RABV P mutants that lack the PNTD or the aa 217-245 of the PCTD, exhibited a 
reduced ability to interact with Flag-MDA5 and Flag-MDA5 288-449. An N-terminal Ig-
tag on P also strongly attenuated the interaction, corroborating the importance of 
the RABV P N-terminus. It is possible that the two RABV P domains identified are 
brought into close proximity only in the tertiary structure and form an interface for 
MDA5 binding. As no complete 3D structure of P could be resolved so far, this 
possibility can only be speculated. 
As shown in preceding experiments, the RABV P mutants lacking aa 176-186 lost the 
ability to interfere with IRF3 activation. Therefore, it was of interest if this specific 
deletion interferes with MDA5/P interaction. In a Co-IP experiment, MDA5 was 
coexpressed with RABV P∆Ind1 and the interaction compared to RABV P wt. 
Furthermore, the effect of the MDA5 ligand poly(I:C) on the strength of interaction 
was analyzed. Neither did RABV P∆Ind1 show a decreased binding to MDA5, nor did 
poly(I:C) increase the interaction. Therefore, the aa 176-181 are not required for 
MDA5/P interaction. In addition, it can be concluded that the unstimulated and 
stimulated conformation of MDA5 interacts with RABV P to comparable levels, most 
probably by exposing the P interaction interface to similar degrees (Fig. 3-10).  
As already mentioned, an interaction of RIG-I with RABV P was only observed in cells 
infected with SeV DI-H4. This indicates that RIG-I undergoes conformational changes 
upon ligand binding, allowing for P binding only after activation. This presumption 
was corroborated by Co-IP experiments that revealed an interaction of RABV P with a 
constitutively active form of RIG-I, composed of the RIG-I CARDs and HD motif I (Fig. 
3-11B). 
As reported by Zou et al “The RIG-I/MDA5 viral surveillance system is conserved in 
vertebrates. The RIG-I like helicase family appears to have evolved from a common 
ancestor that originated from genes encoding different core functional domains” 
(Zou et al., 2009). It is rather likely that P targets a certain functional domain of the 
RLRs or aa adjacent to such a domain, which is/are conserved to a higher or lesser 
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extent, and whose exposure requires distinct conformational changes, determining 
the possibility of interaction.  
 
4.4 MDA5 ATPase activity is not a prerequisite for downstream 
signaling  
Structural and biochemical analyses of RIG-I suggest that the ligand-induced 
conformational switch, liberating the CARDs for signaling, depend on ATP-hydrolysis 
by the HD (Cui et al., 2008). However, it was also shown that the catalytic activity of 
the HD motifs is not categorically required for downstream signaling. Only specific HD 
motifs, that differ between MDA5 and RIG-I, correlate with signaling capacity 
(Bamming and Horvath, 2009). Binding of the paramyxovirus V protein to specific 
motifs of the MDA5 and Lgp2 HD inhibits ATP hydrolysis. The V/MDA5 interaction is 
claimed to inhibit MDA5-dependent IFN induction (Parisien et al., 2009).  
In contrast to V, P binding does not inhibit poly(I:C) induced ATPase activity of RIG-I 
or MDA5, as revealed by ATPase assays (Fig. 3-13). As P can inhibit IFN induction 
downstream of RLRs by blocking IRF3 S386 phosphorylation, an effect on IFN 
induction due to RLR binding was not detectable. Our working hypothesis is that P 
binding blocks the N-terminal RLR CARDs or prevents conformational changes 
required for association with downstream molecules like IPS-1. The finding that RLRs 
are targeted by P gene products of both paramyxoviruses and rhabdoviruses further 
emphasizes a general and crucial role of RLRs in the host defense against negative 
strand RNA virus infection and illustrates the functional similarities of P gene 
products among these viruses. 
Considering the results of the dual luciferase assay and the ATPase assay, where non-
stimulated full-length MDA5 has a basal activity to induce signaling but ATPase 
activity depends on poly(I:C) stimulation, it seems that ATP hydrolysis and 
downstream signaling are distinct events and that ATP hydrolysis is not a prerequisite 
for (basal) signaling, as proposed in a recent study (Bamming and Horvath, 2009). 
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4.5 RABV P interacts with an activation intermediate of IRF3, 
depending on S396/S398 phosphorylation 
In Co-IP experiments evidence was provided that RABV P indeed does not interact 
with IRF3 in non-stimulated cells; however, in cells where the RLR pathway was 
activated a strong interaction of RABV P with IRF3 was determined (Fig. 3-14A/B). 
Coevally, TBK1 and IKKi did not show binding to RABV P, neither in non-stimulated 
nor in stimulated cells. Therefore, the interaction seems to be direct or tightly 
interconnected by proteins downstream of TBK1/IKKi in the RLR signaling cascade, 
such as CypB. CypB knockdown resulted in inhibition of IRF3 phosphorylation, 
dimerization, DNA and coactivator binding, and IFN-induction, which would make it a 
hypothetical target for RABV P. However, the interaction must be upstream of 
nuclear translocation, as IRF3 is accumulated in the cytoplasm in the presence of P 
(Rieder et al., 2011).  
IRF3 is the key regulator of IFNβ expression and its activation by the kinases TBK1 or 
IKKi involves phosphorylation at specific C-terminal Ser and Thr residues (site1: 
S385/S386; site 2: S396, S398, S402, T404, S405; further residues: S339, S390). A 
prerequisite for IRF3 transcriptional activity is the phosphorylation of S385/S386. 
However, the order of phosphorylation events that lead to activation (i.e. S385/S386 
phosphorylation) are still highly discussed. Distinct models of an IRF3 
phosphorylation sequence have been suggested. On the one hand it is suggested that 
phosphorylation of site 2 Ser and Thr residues relieve an auto-inhibitory structure of 
IRF3 that allows for S385/S386 phosphorylation (Servant et al., 2003; Panne et al., 
2007). On the other hand, the initial site 2 phosphorylation and auto-inhibition are 
thought to be irrelevant. Rather the phosphorylation of site 1 only (Takahasi et al., 
2010) or an initial phosphorylation of site 1, followed by site 2 phosphorylation 
(Bergstroem et al., 2010) are proposed to be required for activation of IRF3. The 
interaction of RABV P with IRF3, depending on its activation, can be used as tool to 
elucidate the activation mechanism of IRF3. 
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Recent studies, based on structural data (Qin et al., 2003), biochemical analyses and 
molecular biological approaches (Servant et al., 2003; Panne et al., 2007; Clément et 
al., 2008) provide a strong evidence for the auto-inhibitory model of IRF3. In its 
inactive state, the N- and C-terminal auto-inhibitory segments of the IRF association 
domain (IAD), such as helices H1 and H5, respectively, interact with each other and 
together cover a hydrophobic surface on the H3 and H4 helices of the IAD, which is 
involved in IRF3 dimerization and binding to CBP. Hydrophobic residues on the H3 
and H4 helix include L322, P324, I326, V327, L329, I330 and C371, A374, L375, M378 
and A379, respectively. These residues are masked by the hydrophobic interactions 
with L192, L195 and L196 of the H1 helix, V391, L393 and I395 in the L6 loop, T408, 
L412, L415 and V416 of the H5 helix, and M419 and P421 in the C-terminal extension 
(the IRF3 aa sequence and a detailed assignment of specific domains can be found in 
the appendix). As the helices H1 and H5 form an interdigitating interaction, with the 
aa 192-196 of H1 inserting into a space provided by the β12-L6-β13 region and H5, a 
synergistic effect conferring auto-inhibition is suggested. In a study by Qin et al. it 
was shown that replacement of hydrophobic residues of H1 and H5 to arginine 
results in IRF3 dimerization without stimulation (Qin et al., 2003).  
It is claimed that phosphorylation of IRF3 site 2 Ser/Thr residues by virus-induced 
kinases triggers a conformational change possibly involving the disruption of the 
hydrophobic interactions of H1/H5 and H3/H4, allowing for site 1 S385/S386 
phosphorylation. It has to be mentioned that site 1 and 2 phospho-sites are located 
between H4 and H5, in the region of β12-L6-β13, where the H1 inserts in the auto-
inhibited state. Unmasking of the H3/H4 interface as result of charge repulsions 
exposes a hydrophobic surface on H3/H4 involved in protein-protein interaction, 
such as IRF3 dimerization and binding to proteins of the IRF3 enhanceosome, such as 
CBP (Fig. 4-3). We propose that after the first step of activation RABV P can interact 
with a (partially) open conformation of IRF3, thereby inhibiting S385/S386 
phosphorylation. 
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Figure 4-2: Structural model of IRF3 activation upon sequential phosphorylation. Structure of IRF3 C-terminal 
domain as illustrated in a recent publication (Qin et al., 2003). The left conformation shows the auto-inhibited 
state, where H1 and H5 helices interact with and shield the H3 and H4 interface. This model suggests an initial 
phosphorylation of site 2 residues S396, S398, S402, T404 and S405, by virus-induced kinases that lead to 
conformational changes, unshielding H3 and H4 helices, allowing for S385/S386 phosphorylation and further 
activation. Location of phosphosites (without S390 and S339) are circled in red. 
 
In all conducted Co-IPs, the coexpression of RABV P and IRF3 only resulted in 
interaction when the cells were previously stimulated with SeV DI-H4 or by 
coexpressing ∆RIG-I. Using phospho-specific antibodies it was revealed that binding 
of P increased in a time- and dose dependent manner, during a time course of 2 - 24 
h p.i. with SeV DI-H4 and after transfection of increasing levels of ∆RIG-I, respectively. 
It is obvious that strength/quantity of P/IRF3 interaction correlates with IRF3 
stimulation (Fig. 3-15, 3-17). In the time course of IRF3 activation after SeV DI-H4 
stimulation and in the absence of RABV P, it was obvious that site 2 residues S396 
and S398 (peak at 8-10 h p.i.) are phosphorylated previously to S386 (peak at 12 h 
p.i.). Interestingly, RABV P binding inhibited phosphorylation of S386, which is 
essential for transcription of IFNβ, at all time points after IRF3 stimulation, while 
phosphorylation at phosphosites S396 and S398 seem to be unaffected (Fig. 3-16, 3-
17). Therefore, these experiments not only show activation-dependent P/IRF3 
interaction but also support the initial phosphorylation of site 2 residues prior to 
S385/S386 phosphorylation.  
As it seems that P/IRF3 interaction depends on IRF3 activation and increases with 
S396 and S398 phosphorylation, it was of interest whether the phosphates at site 2 
residues (or at S386 and S339) are directly involved or a prerequisite for binding of 
RABV P. Site-directed mutagenesis was carried out to exchange respective Ser/Thr 
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phospho-sites to non-phosphorylatable Ala or to phosphomimetic Asp. Interestingly, 
after SeV DI-H4 infection, the IRF3 constructs containing a mutation of S396/S398 to 
A showed a strong decrease in P interaction compared to wt IRF3, while the other 
mutations (S402, T404, S405A) did not seem to affect interaction (Fig. 3-18, 3-19). 
Therefore, an essential role of S396/S398 phosphorylation with respect to IRF3 
activation, but also for RABV P binding was suggested.  
In a recent study it was reported that expression of IRF3 holding the minimal 
mutation of S396 to aspartic acid is sufficient to induce S385/S386 phosphorylation, 
activation of IRF3 and induction of type I IFN, RANTES, and ISG promoters (Servant et 
al., 2003). Here we also saw that the mutation of site 2 residues to aspartic acid (IRF3 
5D) had an intrinsic potential to phosphorylate S385/S386 residues in the absence of 
stimulation, probably by kinases other than TBK1, leading to a constitutively active 
IRF3 form (Fig. 3-19A). However, structural changes in IRF3 5D that would support an 
auto-inhibitory mechanism were not observed so far (Takahasi et al., 2010). 
Interestingly, IRF3 5D or IRF3 mutants where single site 2 residues were exchanged to 
Asp did not lead to an association with RABV P in unstimulated cells, however, upon 
stimulation an interaction was induced (Fig. 3-19). This further indicates that 
phosphomimetic forms, which lead to S385/S386 phosphorylation, are not sufficient 
for P binding. Further activation mechanisms that induce a characteristic 
conformation for perfect P binding must therefore exist. It is possible, that the 
described transcriptional activity by the IRF3 S396D or IRF3 5D mutants is reflecting a 
picture of leaky IRF3 proteins which only reveal their full functional capacities after 
further stimulation. Taken together, although it seems as if site 2 residues are 
phosphorylated prior to site 1 residues, the relevance of site 2 phosphorylation, and 
the complete events leading to IRF3 transcriptional activation after virus infection 
remain ambiguous.    
 
4.6 RABV P binds to the H3/H4 helix of IRF3 
The previous findings indicate that although S396/S398 phosphorylation facilitates P 
binding, conformational changes independent from phosphorylation at auto-
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inhibitory structures occur that allow for P interaction. In further Co-IP experiments, 
the domain(s) of IRF3 that play a role in RABV P interaction was/were elucidated. 
Various Flag-IRF3 constructs were generated and coexpressed with RABV P in 
absence or presence of stimulation by SeV DI-H4 infection.  
Strikingly, in case of the IRF3 constructs that lack the H1 helix an association with P 
could be detected in uninfected cells. This interaction was even increased upon 
deletion of the H2 helix. This supports an important inhibitory role of H1 (and maybe 
H2) not only for IRF3 activation but also for P binding. However, the interaction of P 
with all IRF3 constructs was strongly induced in cells infected with SeV DI-H4. IRF3 
constructs that lack the described auto-inhibitory structures, such as IRF3 300-427, 
which lacks H1/H2, and IRF3 200-384, which lacks H1 and H5, show a substantial 
increase in P pull-down. IRF3 300-427 associated strongest with P, although the 
expression level of this mutant was very low (Fig. 3-20). Surprisingly, the construct 
IRF3 200-427, which also lacks the H1 helix (aa 192-196) showed a weaker interaction 
for so far unidentified reasons. Full-length IRF3 and IRF3 185-427, which only lacks 
the DBD/PRR but still contains the H1 and H5, show a reduced interaction in infected 
and uninfected cells, which again implies a special inhibitory role of the IRF3 IAD H1. 
As the H2 helix is also dispensable for interaction, RABV P most probably binds at the 
H3/H4 interface depending on so far unknown modifications and intramolecular 
displacements. 
From these findings it appears that IRF3 H1 confers a quite strong inhibition that is 
only partially released upon activation of the cells with SeV DI-H4. In case the H1 is 
lacking, RABV P should have free excess to the IAD H3/H4, which might be further 
induced by the lack of H2. As the mutant IRF3 200-384 lacks the H5 helix, 
mechanisms beside the S390, and site 1 and 2 residue phosphorylations must be 
involved in conformational rearrangements favoring P binding. Furthermore, the 
contribution of the constitutively phosphorylated upstream S173/S175 was excluded.  
An indirect interaction of RABV P and IRF3 bridged by a specific protein, such as a 
chaperone, is pro forma not ruled out so far. The possibility that the interaction 
additionally requires a specific activation of RABV P is under investigation. 
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4.7 RABV P binding to H3/H4 shields adjacent S385/S386 from 
phosphorylation 
The RABV P∆Ind1, P∆Ind2 and P∆Ind1/2 lost their ability to interfere with IRF3 
activation. The most logical reason that appeared was that the mutants lost their 
ability to bind to IRF3. However, P∆Ind1, P∆Ind2 and P∆Ind1/2 were still able to 
interact with IRF3 in stimulated cells and with intensities comparable to wt RABV P. 
However, IRF3 S386 phosphorylation was not inhibited. Furthermore, when P∆Ind1 is 
overexpressed in stimulated cells, the S396 and S398 phosphorylation remained 
unchanged.  
These data indicate that P∆Ind1 specifically lost the ability to interfere with S386 
phosphorylation while binding to IRF3 like wt P. This data indicates that the internal 
deletions of RABV P∆Ind1, P∆Ind2 and P∆Ind1/2 lead to a changed confirmation that 
is inefficient in blocking S386 phosphorylation.  
                       
Figure 4-3: Model of IRF3 inhibition by RABV P and loss of inhibition by P∆Ind mutants. It is suggested that 
specific modifications in IRF3 after stimulation, that go along with phosphorylation of site 1 Thr and Ser residues, 
induce conformational changes in IRF3 that expose certain domains in the region of the H3/H4 region. To these 
regions RABV P can bind and inhibit S386 phosphorylation, required for full activation of IRF3. In the RABV P∆Ind 
mutants the conformation is probably also altered so that the P mutants can still bind, yet the binding does not 
inhibit the S386 phosphorylation anymore. 
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Taking all acquired results into consideration, a model of IRF3 activation and binding 
by RABV P and P non-inhibiting mutants is suggested. Upon stimulation of the RLR 
signaling cascade, sequential phosphorylation occurs that takes part in 
conformational rearrangements of IRF3. However, other, so far unknown alterations 
are required for inducing a fully active IRF3 form. RABV P targets a very specific 
activation stage of IRF3, probably due to exposure of an interaction interface in 
H3/H4 conferred by a defined conformation. It seems that the auto-inhibitory H1 
(and possibly H2) of the IRF3 IAD confers a strong blockage of the H3/H4 helix as 
deletion of H1 increases RABV P binding after activation. In a study by Qin et al., an 
IRF3 was generated where hydrophobic aa L192, L195, and L196 of H1 were mutated 
to Arg, leading to homo-dimerization of IRF3 without further stimulation (Qin et al., 
2003). In ongoing attempts, this IRF3 H1 mutant, but also mutants where L322, I326 
and I330 of the H3 helix and L375, M378 and A379 of the H4 helix were mutated to 
Arg, are analyzed with respect to P interaction. These mutations might generate an 
IRF3 that can be bound by RABV P without stimulation (H1 mutant) or which cannot 
be bound by P anymore (H3/H4 mutants) to give further details on IRF3 activation 
but also inhibition. 
It is assumed that via an interaction with the H3/H4 interface, the P protein shields 
S386 from phosphorylation whilst leaving S396 and S398 phosphorylations 
unaffected. Conformational restrictions of P∆Ind mutants, however, preclude 
shielding and allow for S386 phosphorylation, hence, IRF3 transcriptional activation.  
 
4.8 Conclusion and future perspectives 
As IFN induction is a major target of the RABV countermeasures to avoid an antiviral 
immune response, it is a potent target for therapeutic approaches. The findings of 
this thesis strongly point towards a central role of successful IRF3 activation in the 
defense against RABV and most likely this is also true for many other viruses. Not 
only RABV P but also the phosphoproteins of related BLVs seem to be a major factor 
in determining pathogenicity of a lyssavirus in a certain host. In concomitant and 
ongoing experiments the ability of particular BLV P proteins to inhibit IRF3 activation 
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in human cells is analyzed. The P protein of EBLV-1, which shows a high phylogenetic 
relation to RABV P, was able to strongly inhibit IRF3 activation, while P proteins of 
more distantly related BLVs did not exhibit this inhibitory potential. This adaptation 
might be decisive in the establishment of a novel human pathogen with altered 
virulence. Revealing the specific mechanisms of RABV to invade the host IFN system 
and the virus-host interactions leading to RABV pathogenicity, should help to find 
biological substances that counteract virus propagation or in designing novel 
attenuated viruses for immunization, gene therapy or oncolytic approaches. A 
conversion of the collected data to clinical application could be the development of 
IRF3-like small molecules that inhibit P binding to IRF3 (antiviral), or the development 
of P-like small molecules that inhibit IRF3 activation (anti-inflammatory). 
Furthermore, the generated recombinant virus SAD ∆Ind1, which was highly 
attenuated in mice because of a strong IFN induction, represents a potential 
candidate for novel vaccines. 
Future research has to be undertaken to unravel the full mechanistic background of 
the interference of IFN induction by RABV P. The functional relevance of the 
described P/RLR interaction would be of major interest, such as a possible blockage 
of RIG-I and MDA5 to bind to downstream molecules like IPS-1. Furthermore, a direct 
interaction has to be verified or the interjacent protein identified. As P potently 
inhibits IFN induction downstream of the RLRs (at IRF3), possible effects of the P/RLR 
interaction on IFN expression are hard to reveal. In this respect, a P mutant would be 
helpful that is not able anymore to bind IRF3 but can still interact with MDA5. 
Furthermore, the specific region of RABV P required for RLR interaction has to be 
elucidated more precisely. It would also be necessary to identify more defined 
regions in RIG-I and Lgp2 that confer P binding, and undertake sequence comparisons 
with the identified MDA5 interaction interface (for alignment of full RLR aa 
sequences see appendix).  
Further experiments also have to be directed at the site of IRF3 inhibition. As already 
discussed, mutants of IRF3 were generated where hydrophobic residues in the IAD 
H1, H3, and H4 helices were replaced by Arg (see discussion) to destroy auto-
inhibitory hydrophobic interactions or potential P binding sites and analyzed for P 
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interaction in ongoing attempts. It is also of interest whether IRF3 200-384 or IRF3 
300-427 form dimers in the absence of activation due to the lack of H1, if this 
potential interaction is increased by activation, and if RABV P has an influence on 
this. In case spontaneous dimerization is lost in the presence of P it might 
coincidence with the ability of P binding. Furthermore, IRF3 has been recently shown 
to interact with Bax via a BH3 domain in the H4 helix to induce apoptosis. To 
investigate whether P binds to residues in the H4 helix, it would be interesting if 
binding of P to IRF3 can outcompete Bax binding, or if presence of Bax inhibits P 
binding.  
To characterize the phosphorylatable sites in IRF3 in the absence or presence of 
RABV P, a phospho-specific mass spectrometry analysis is undertaken. Further 
collaborations might allow us to determine a structure of the RABV P/IRF3 complex. 
As IRF7, like IRF3, transcribes type I IFN genes in response to RABV infection, and also 
IRF3/IRF7 heterodimers are formed during innate immune signaling (H3/H4 helix), it 
is of interest if RABV P can also bind to IRF7 or prevent IRF3/IRF7 dimer formation. As 
already published (Rieder et al., 2011), RABV P can also inhibit IRF7 induced signaling 
yet to a lesser degree than IRF3 induced signaling. 
In a sequence comparison of human, dog, bat, and mouse IRF3 a high conservation 
can be seen. Especially the auto-inhibitory structures of the IAD are highly 
homologous among the species (for sequence comparison see appendix). This 
conservation further underlines a central role of IRF3 across distinct species. 
Comparing the ability of RABV P to interact with IRF3 from distinct species and 
further mutational analyses could unravel particularly essential residues for this 
association and might partially explain the large reservoir species of RABV. 
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5 Appendix 
Sequence alignments: 
           
Figure 5-1: Sequence alignment of human Lgp2, RIG-I and MDA5. RLR sequences were aligned with the 
ClustalW2 software and the conservation was illustrated by blue colors (dark blue: highly conserved). Lgp2 is 678 
aa long, RIG-I is 925 aa long and MDA5 is 1025 aa long. The numbers above the alignment do not correspond to 
the aa positions but are generated by the software.  The motifs I, Ia, II, III, IV, V, and VI are outlined by red boxes. 
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Figure 5-2: Sequence comparison of IRF3 from human, dog, bat, and mouse. IRF3 sequences were aligned with 
the ClustalW2 software and the conservation was illustrated by blue colors (dark blue: highly conserved). IRF3 is 
composed of an N-terminal DBD, a central IAD and N-terminal regulatory domain, as illustrated in a recent 
publication (Qin et al., 2003). The auto-inhibitory helices H1 and H5 helices are indicated in red writing. H2, H3 
and H4 helices are indicated in blue writing. The known phospho-sites involved in IRF3 activation are illustrated in 
red boxes. The residues of the IRF3 BH3 domain in the H4 helix that are required for Bax binding are marked by 
turquoise boxes.  
 
 
Buffers and Solutions: 
 
Mini Preparation: 
Flexi I: 
100 mM Tris-HCl pH 7.5 
10 mM EDTA 
200 μg/ml RNase 
Flexi II: 
200 mM NaOH 
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1 % (w/v) SDS 
Flexi III: 
3 M potassium acetate 
2 M acetic acid, pH 5.75 
 
Agarose gel electrophoresis: 
10 x TAE: 
2 M Tris-HCl, pH 7.8 
0.25 M Sodium acetate x 3 H2O 
0.25 M EDTA 
1 x TAE + EtBr: 
100 ml 10 x TAE 
150 μl Ethidium bromide solution 1% 
to 1 l H2O 
OG loading buffer: 
50 % (v/v) 10x TAE 
15 % (w/v) Ficoll 400 
0.125 % (w/v) Orange G 
10x TE: 
100 mM Tris-HCl, pH 7.5 
10 mM EDTA 
Blue juice: 
0.125 % (w/v) Bromphenol blue 
0.125 % (w/v) xylenecyanol 
0.125 % (w/v) Orange G 
15 % (w/v) Ficoll 400 
50 % (v/v) 10 x TAE 
1 kb marker: 
380 μl 1 x TE 
100 μl Blue juice 
20 μl 1 kb DNA ladder  
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PCR marker: 
167 μl Gel loading dye blue (6x) 
733 μl H2O 
100 μl PCR Marker  
 
SDS-PAGE: 
Jagow gel buffer: 
3 M Tris-HCl, pH 8.45 
0.3 % (w/v) SDS 
Jagow anode buffer: 
200 mM Tris-HCl, pH 8.9 
Jagow kathode buffer: 
100 mM Tris-HCl, pH 8.25 
100 mM Tricine 
0.1.1 % (w/v) SDS 
SDS sample buffer: 
62.5 mM Tris-HCl, pH 6.8 
2 % (w/v) SDS 
10 % (w/v) glycerol 
6 M Urea 
5 % (v/v) β-mercaptoethanol 
0.01 % (w/v) Bromphenol blue 
0.01 % (w/v) Phenol red 
10% APS 10 % (w/v) ammonium persulfate 
Stacking gel 4%: 
3.5 ml Jagow gel buffer 
1.4 ml acrylamide 29:1 Rotiphorese Gel 40 
18 l TEMED 
116 l APS 
9 ml H2O 
Separating gel 10%: 
12 ml Jagow gel buffer 
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9 ml acrylamide 29:1 Rotiphorese Gel 40 
2 ml glycerol 
17 l TEMED 
175 l APS 
12.9 ml H2O  
 
Coomassie staining: 
Staining solution: 
50 % (v/v) methanol 
10 % (v/v) acetic acid 
0.1.1 % (w/v) Brilliant blue 
Wash solution: 
50 % (v/v) methanol 
10 % (v/v) acetic acid 
 
Western blot: 
10 x Semi dry buffer: 
480 mM Tris-HCl, pH 8.6 
390 mM Glycine 
0.05 % (w/v) SDS 
1 x Semi dry buffer: 
100 ml 10x Semi dry buffer 
180 ml methanol 
to 1 l H2O 
1 x PBS: 
1.37 M NaCl 
27 mM KCl 
12 mM KH2PO4 
65 mM Na2HPO4 x 2H2O (pH 7.4) 
PBS-Tween: 
1 x PBS 
0.05 % (v/v) Tween-20 
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Northern blot: 
RNA agarose gel: 
2 g agarose (RNA grade) 
4 ml 50 x phosphate buffer 
26.7 ml formaldehyde, 37 % 
167.3 ml H2O ultra pure 
50 x Phosphate buffer: 
250 mM Na2HPO4 x 2H2O (pH 6.8-7.0) 
250 mM NaH2PO4 x H2O 
Glyoxal solution: 
8.8 M glyoxal 
Acridine orange solution: 
1 x Phosphate buffer 
33.3 M Acridine orange 
10 x SSC: 
1.5 M NaCl 
150 mM Na-citrate x 2H2O (pH 7.0) 
Zeta hybridizing buffer: 
250 mM Na2HPO4 x 2H2O (pH 7.2) 
250 mM NaH2PO4 x H2O 
1 mM EDTA 
7 % (w/v) SDS 
Zeta wash buffer 5 %: 
8 % (v/v) 50 x phosphate buffer 
1 mM EDTA 
5 % (w/v) SDS 
Zeta wash buffer 1 %: 
8 % (v/v) 50 x phosphate buffer 
1 mM EDTA 
1 % (w/v) SDS 
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Native Gel:  
2x Native sample buffer: 
125 mM Tris-Cl, pH 6,8 
30 % glycerol 
0.01 % (w/v) Bromphenol blue 
Lysis buffer: 
50 mM Tris-Cl, pH 8,0 
1% NP-40 
150 mM NaCl 
5 mM orthovanadate 
100 µg/ml leupeptin 
1mM PMSF 
Gel buffer: 
1,5 M Tris, pH 8,8 
Native gel 7,5%: 
3,5 ml acrylamide   
5 ml Tris (1,5 M)   
20 ml TEMED    
200 l 10% APS 
11,3 ml H2O d. 
Lower chamber buffer: 
25 mM Tris-Cl, pH 8,4 
192 mM glycine 
Upper chamber buffer: 
25 mM Tris-Cl, pH 8,4 
192 mM glycine 
1% DOC  
 
Co-IP: 
Standard Co-IP buffer: 
50 mM Tris-HCl pH 7.5 
150 mM NaCl 
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2 mM EDTA 
1 mM Na3VO4 
0.5 % (v/v) NP-40 
1 mM NaVO4 
1 x Complete Protease Inhibitor 
Sepharose A Co-IP Buffers: 
Buffer A: 
100 mM Tris pH 8.0 
Buffer B: 
10 mM Tris pH 7.4 
PBS 5mM EDTA: 
1 x PBS 
5mM EDTA 
 
Immunofluorescence: 
3 % PFA/PBS: 
1 x PBS 
3 % (w/v) paraformaldehyde 
PBS/0.5 % Triton X-100: 
1 x PBS 
0.5 % (v/v) Triton X-100 
PBS/2 %BSA/0.1 % Triton X-100: 
1 x PBS 
0.1 % (v/v) Triton X-100 
2 % BSA 
PBS/0.1 % Triton X-100: 
1 x PBS 
0.1 % (v/v) Triton X-100 
 
His-tag protein purification: 
5 x Buffer A: 
250 mM KH2PO4, pH 7.5 
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1000 mM NaCl 
75 mM Imidazol 
5 x Buffer B: 
250 mM KH2PO4, pH 7.5 
1000 mM NaCl 
1500 mM Imidazol 
1 x Buffer A or B: 
50ml 5 x Buffer A/B 
200ml H2O d. 
0.07 % (v/v) β-Mercaptoethanol 
10 x Dialysis buffer: 
500 mM Tris-HCl, pH 8.0 
1500 mM NaCl 
50 mM DTT 
1 x Dialysis Buffer: 
500 ml 10 x Dialysis buffer 
10 % (v/v) Glycerol 
to 5 l H2O d. 
 
In vitro ATPase assay: 
5 x ATPase buffer: 
100 mM Tris, pH 7.5 
100 mM NaCl 
5 mM MgCl2 
100 g/ml BSA 
1 mM DTT 
ATPase dilution buffer: 
 10 l 5 x ATPase buffer 
2,5 l ATP (2 mM) 
1 l RNaseIN 
5 l poly(I:C) (0.1 M) 
20 nM -32P-ATP  
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to 40 l H2O 
 
General solutions: 
70% Ethanol: 
700 ml ethanol p.a. 
to 1 l H2O d. 
80 % Acetone: 
800 ml acetone p.a. 
to 1 l H2O d. 
 
Primer sequences: 
Table 2. Primer sequences PCR primer 
Primer Sequencea,b Origin 
Fl-MDA5 1-350 XhoI 3’ 5’-TAT CTC GAG TTA CTT CTT GTC TAA GTG ATC-3’ human 
Fl-MDA5 1-449 XhoI 3’ 5’-TAT CTC GAG TTA GTT GGT GTG ATG ACA TTC-3’ human 
Fl-MDA5 287-449 
Acc65I 5' 
5'-ATA GGT ACC ATG GAC TAC AAA GAC GAT GAC GAT AAA 
GGA AGT GAT TCA GAT GAA-3’ 
human 
His6-MDA5 Acc65I 5’ 5’-ATA GGT ACC ATG CAT CAT CAT CAT CAT CAT TCG AAT GGG 
TAT TCC-3’ 
human 
Fl-RIG-I CD Acc65I 5’ 5’-ATA GGT ACC GCC ACC ATG GAC TAC AAA GAC GAT GAC GAT 
AAA ACC ACC GAG CAG CGA-3’ 
human 
RIG-I HD 3’ 5’-GCC TCT GGT TTG GAT CAT-3’ human 
RIG-I RD 5’ 5’-AGA GGA AGA GCA AGA GGT-3’ human 
RIG-I RD XhoI 3’ 5’-TAT CTC GAG TCA TTT GGA CAT TTC-3’ human 
Fl-MDA5 CD Acc65I 5´ 5’-ATA GGT ACC GCC ACC ATG GAC TAC AAA GAC GAT GAC GAT 
AAA TCG AAT GGG TAT TCC-3’ 
human 
MDA5 HD 3´ 5’-ACC ACG GGC CTG GAC CAT-3’ human 
MDA5 RD 5’ 5’-CGA GCC AGA GCT GAT GAG-3’ human 
MDA5 RD XhoI 3’ 5’-TAT CTC GAG CTA ATC CTC ATC ACT-3’ human 
Fl-Lgp2 HD Acc65I 5’ 5’-ATA GGT ACC GCC ACC ATG GAC TAC AAA GAC GAT GAC GAT 
AAA GAG CTT CGG TCC TAC-3’ 
human 
Lgp2 HD 3’ 5’-GCC CCT GGC CTG GAC CAT-3’ human 
Lgp2 RD 5’ 5’-CGT GCC TGG GCC GAT CAG-3’ human 
Lgp2 RD XhoI 3’ 5’-TAT CTC GAG TCA GTC CAG GGA GAG-3’ human 
RIG-I CD 3’ 5’-TGG AAT CGT TCC CTT TTT-3’ human 
MDA5 HD 5’ 5'-GAT GCT GGT GTT CAA TTG-3’ human 
MDA5 CD 3’ 5’-TTC TCC ATT TTC CAA GTT-3’ human 
RIG-I HD 5´ 5’-TCA CTA TCC ATC TTT ACT-3’ human 
Fl-RIG-I CD Acc65I 5’ 5’-ATA GGT ACC GCC ACC ATG GAC TAC AAA GAC GAT GAC GAT 
AAA ACC ACC GAG CAG CGA-3’ 
human 
RIG-I HD 3’ 5’-GCC TCT GGT TTG GAT CAT-3’ human 
RIG-I RD 5’ 5’-AGA GGA AGA GCA AGA GGT-3’ human 
RABV P Acc65I 5’ 5’-ATA GGT ACC AGC AAG ATC TTT GTC AAT-3’ human 
RABV P XhoI 3’ 5’-TAT CTC GAG TTA GCA AGA TGT ATA GCG-3’ human 
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RABV P AgeI 5’ 5’-ATA ACC GGT ATG AGC AAG ATC TTT GTC-3’ human 
IPS-1 Acc65I 5’ 5’-ATA GGT ACC GCC ACC ATG CCG TTT GCT GAA GAC-3’ human 
IPS-1 XhoI 3’ 5’-TAT CTC GAG CTA GTG CAG ACG CCG CCG GTA-3’ human 
Fl-TRADD Acc65I 5’  5’-ATA GGT ACC ATG GAC TAC AAA GAC GAT GAC GAT AAA 
GCA GCT GGG CAA AAT GGG CAC-3’ 
human 
TRADD BglII 3’ 5’-TAT AGA TCT C TA GGC CAG GCC GCC ATT-3’ human 
Fl-Sintbad EcoRI 5'  5’-ATA GAA TTC ATG GAC TAC AAA GAC GAT GAC GAT AAA 
GAG TCC ATG TTT-3’ 
mouse 
Sintbad NheI 3’  5’-TAT GCT AGC CTA GAT CTT GC T GTT CTC-3’ mouse 
Fl-Nap1 EcoRI 5’  5’-ATA GAA TTC ATG GAC TAC AAA GAC GAT GAC GAT AAA GAC 
ACG CTA GTA-3’ 
mouse 
Nap1 NheI 3’  5’-TAT GCT AGC TTA ACT TTT GTA AAG GCA-3’ mouse 
Fl-NEMO EcoRI 5’  5’-ATA GAA TTC ATG GAC TAC AAA GAC GAT GAC GAT AAA AAT 
AGG CAC CTC-3' 
human 
NEMO NheI 3’  5’-TAT GCT AGC CTA CTC AAT GCA CTC CAT-3’ human 
Rip1 Acc65I 5’ 5’-ATA GGT ACC ATG CAA CCA GAC ATG TCC-3’ human 
Rip1 XhoI 3’ 5’-TAT CTC GAG TTA GTT CTG GCT GAC GTA-3’ human 
Nap1 BamHI 5’ 5’-ATA GGA TCC ATG GAC ACG CTA GTA GAA-3’ mouse 
Fl-Nap1 BamHI 5’ 5’-ATA GGA TCC ATG GAC TAC AAA GAC GAT GAC GAT AAA 
GAC ACG CTA GTA GAA GAT-3’ 
mouse 
Nap1 HindIII 3’ 5’-TAT AAG CTT TTA ACT TTT GTA AAG GCA-3’ mouse 
TRADD BamHI 5’  5’-ATA GGA TCC ATG GCA GCT GGG CAA AAT-3’ human 
Fl-TRADD BamHI 5’ 5’-ATA GGA TCC ATG GAC TAC AAA GAC GAT GAC GAT AAA 
GCA GCT GGG CAA AAT GGG-3’ 
human 
TRADD HindIII 3’ 5’-TAT AAG CTT CTA GGC CAG GCC GCC ATT-3’ human 
Sintbad 5' 5’-ATG GAG TCC ATG TTT GAA-3’ mouse 
NEMO BamHI 5’ 5’-ATA GGA TCC ATG AAT AGG CAC CTC TGG-3’ human 
Fl-NEMO BamHI 5’ 5’-ATA GGA TCC ATG GAC TAC AAA GAC GAT GAC GAT AAA AAT 
AGG CAC CTC TGG AAG-3’ 
human 
NEMO HindIII 3’ 5’-TAT AAG CTT CTA CTC AAT GCA CTC CAT-3’ human 
TBK1 XhoI 3’ 5’-TAT CTC GAG CTAAAGACAGTCAACGTTGCG-3’ human 
Fl-IRF3 Acc65I 5’ 5’-ATA GGT ACC ATG GAC TAC AAA GAC GAT GAC GAT AAA 
GGA ACC CCA AAG CCA CGG ATC-3’ 
human 
IRF3 XhoI 3’ 5’-TAT CTC GAG TCA GCT CTC CCC AGG GCC CTG-3’ human 
RABV P 175 3’ 5’-AGC CGC CAT CCT GGC TTT-3’  
RABV P 187 5’ 5’-TCG GCT ACC AAT GAA GAG-3’  
Fl-RABV P HpaI 5’ 5’-ATA GTT AAC ATG GAC TAC AAA GAC GAT GAC GAT AAA AGC 
AAG ATC TTT GTC AAT CCT AGT GCT-3’ 
 
IRF3 150 Acc56I 5' 5'-ATA GGT ACC ATG GAC TAC AAA GAC GAT GAC GAT AAA 
GCC CCA CTC CCA GAT CCG GGA CCC-3’ human 
IRF3 185 Acc56I 5' 5'-ATA GGT ACC ATG GAC TAC AAA GAC GAT GAC GAT AAA CTG 
GGG CCC TCT GAG AAC CCA CTG-3’ human 
IRF3 200 Acc56I 5' 5'-ATA GGT ACC ATG GAC TAC AAA GAC GAT GAC GAT AAA 
CCG GGG GAA GAG TGG GAG TTC GAG-3’ human 
IRF3 300 Acc56I 5' 5'-ATA GGT ACC ATG GAC TAC AAA GAC GAT GAC GAT AAA CTC 
CCC AAC AGC GGG CAT GGG CCT-3’ human 
IRF3 384 XhoI 3 ' 5'-TAT CTC GAG TCA GGC ACC CCC TAC CCG GGC-3’ human 
 
a Underlined nucleotides: cleavage sites for restriction enzymes 
b Italic nucleotides: protein tags 
 
 
5  Appendix 
 
 
127 
Table 3. Primer sequences mutagenesis PCR primer 
Primer Sequence Origin 
IRF3 5ADDDD 5' 5’-AAT ACT GTG GAC CTG CAC ATT GCC AAC GAC CAC CCA CTC-3’ human 
IRF3 5ADDDD 3' 5’-GAG TGG GTG GTC GTT GGC AAT GTG CAG GTC CAC AGT ATT-3’ human 
IRF3 5DADDD 5' 5’-AAT ACT GTG GAC CTG CAC ATT GAC AAC GCC CAC CCA CTC-3’ human 
IRF3 5DADDD 3' 5’-GAG TGG GTG GGC GTT GTC AAT GTG CAG GTC CAC AGT ATT-3’ human 
IRF3 5AADDD 5' 5'-AAT ACT GTG GAC CTG CAC ATT GCC AAC GCC CAC CCA CTC GAC 
CTC GAC GAC-3’  
human 
IRF3 5AADDD 3' 5'-GTC GTC GAG GTC GAG TGG GTG GGC GTT GGC AAT GTG CAG 
GTC CAC AGT ATT-3’ 
human 
IRF3 5DDAAA 5' 5'-ATT GAC AAC GAC CAC CCA CTC GCC CTC GCC GCC GAC CAG 
TAC AAG GCC TAC-3’  
human 
IRF3 5DDAAA 3' 5'-GTA GGC CTT GTA CTG GTC GGC GGC GAG GGC GAG TGG GTG 
GTC GTT GTC AAT-3’ 
human 
IRF3 5ADAAA 5' 5'-ATT GCC AAC GAC CAC CCA CTC GCC CTC GCC GCC GAC CAG TAC 
AAG GCC TAC-3’  
human 
IRF3 5ADAAA 3' 5'-GTA GGC CTT GTA CTG GTC GGC GGC GAG GGC GAG TGG GTG 
GTC GTT GGC AAT-3’ 
human 
IRF3 398D 5'  5’-ACT GTG GAC CTG CAC ATT TCC AAC GAC CAC CCA CTC TCC CTC 
ACC TCC-3’ 
human 
IRF3 398D 3'  5’-GGA GGT GAG GGA GAG TGG GTG GTC GTT GGA AAT GTG CAG 
GTC CAC AGT-3’ 
human 
IRF3 398A 5'  5’-ACT GTG GAC CTG CAC ATT TCC AAC GCC CAC CCA CTC TCC CTC 
ACC TCC-3’ 
human 
IRF3 398A 3'  5’-GGA GGT GAG GGA GAG TGG GTG GGC GTT GGA AAT GTG CAG 
GTC CAC AGT-3’ 
human 
IRF3 S339A 5' 5'-ACG GAA GGA AGC GGA CGC GCA CCA CGC TAT GCC CTC TGG-3’ human 
IRF3 S339A 3' 5'-CCA GAG GGC ATA GCG TGG TGC GCG TCC GCT TCC TTC CGT-3’ human 
IRF3 S339D 5' 5'-ACG GAA GGA AGC GGA CGC GAC CCA CGC TAT GCC CTC TGG-3’ human 
IRF3 S339D 3' 5'-CCA GAG GGC ATA GCG TGG GTC GCG TCC GCT TCC TTC CGT-3’ human 
IRF3 wt (revert 
339S) 5' 
5'-ACG GAA GGA AGC GGA CGC TCA CCA CGC TAT GCC CTC TGG-3’ human 
IRF3 wt (revert 
339S) 3' 
5'-CCA GAG GGC ATA GCG TGG TGA GCG TCC GCT TCC TTC CGT-3’ human 
IRF3 T395I 5' 5'-ACT GTG GAC CTG CAC ATT TCC AAC AGC CAC-3’ human 
IRF3 T395I 3' 5'-GTG GCT GTT GGA AAT GTG CAG GTC CAC AGT-3’ human 
IRF3 revert 415/419 
5' 5'-CTG CAG GAC TTG GTG GAG GGC ATG GAT TTC CAG GGC-3’ human 
IRF3 revert 415/419 
3' 5'-GCC CTG GAA ATC CAT GCC CTC CAC CAA GTC CTG CAG-3’ human 
IRF3 396A 5' 5'-ACT GTG GAC CTG CAC ATT GCC AAC AGC CAC CCA CTC TCC CTC 
ACC TCC-3’ human 
IRF3 396A 3' 5'-GGA GGT GAG GGA GAG TGG GTG GCT GTT GGC AAT GTG CAG 
GTC CAC AGT-3’ human 
IRF3 T390A 5' 5'-GCC TCC TCC CTG GAG AAT GCT GTG GAC CTG CAC ATT TCC-3’ human 
IRF3 T390A 3' 5'-GGA AAT GTG CAG GTC CAC AGC ATT CTC CAG GGA GGA GGC--
3’ human 
IRF3 3A 5' 5'-CAC ATT TCC AAC AGC CAC CCA CTC GCC CTC GCC GCC GAC CAG 
TAC AAG GCC TAC CTG-3’ human 
IRF3 3A 3' 5'-CAG GTA GGC CTT GTA CTG GTC GGC GGC GAG GGC GAG TGG 
GTG GCT GTT GGA AAT GTG-3’ human 
IRF3 2A 5' 5'-GAG AAT ACT GTG GAC CTG CAC ATT GCC AAC GCC CAC CCA 
CTC TCC CTC ACC TCC-3’ human 
IRF3 2A 3' 5'-GGA GGT GAG GGA GAG TGG GTG GGC GTT GGC AAT GTG CAG human 
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GTC CAC AGT ATT CTC-3’ 
IRF3 revert 5' 5'-AAT ACT GTG GAC CTG CAC ATT TCC AAC AGC CAC CCA CTC TCC 
CTC-3’ human 
IRF3 revert 3' 5'-GAG GGA GAG TGG GTG GCT GTT GGA AAT GTG CAG GTC CAC 
AGT ATT-3’ human 
IRF3 192-95-96A 5' 5'-CCC TCT GAG AAC CCA GCG AAG CGG GCG GCG GTG CCG GGG 
GAA GAG TGG GAG-3’ human 
IRF3 192-95-96A 3' 5'-CTC CCA CTC TTC CCC CGG CAC CGC CGC CCG CTT CGC TGG GTT 
CTC AGA GGG-3’ human 
IRF3 192-95-96R 5’ 5'-CCC TCT GAG AAC CCA AGG AAG CGG AGG AGG GTG CCG GGG 
GAA GAG TGG GAG-3’ human 
IRF3 192-95-96R 3’ 5'-CTC CCA CTC TTC CCC CGG CAC CCT CCT CCG CTT CCT TGG GTT 
CTC AGA GGG-3’ human 
IRF3 322-26-30R 5’ 5'-GGC GTG TTT GAC AGG GGG CCC TTC AGG GTA GAT CTG AGG 
ACC TTC ACG GAA-3’ human 
IRF3 322-26-30R 3’ 5'-TTC CGT GAA GGT CCT CAG ATC TAC CCT GAA GGG CCC CCT GTC 
AAA CAC GCC-3’ human 
IRF3 375-78-79R 5’ 5'-ACG TGC CTC AGG GCC AGG GT A GAA AGG AGG CGG GTA GGG 
GGT GCC-3’ human 
IRF3 375-78-79R 3’ 5'-GGC ACC CCC TAC CCG CCT CCT TTC TAC CCT GGC CCT GAG GCA 
CGT-3’ human 
 
Table 4. Primer sequences qRT-PCR primer 
Primer Sequence Origin 
hIFN  5’ 5’-TCC AAA TTG CTC TCC TGT TG-3’ human 
hIFN  3’ 5’-GCA GTA TTC AAG CCT CCC AT-3’ human 
GAPDH 5’ 5'-TGG TAT CGT GGA AGG ACT CA-3' human 
GAPDH 3’ 5’-CCA GTA GAG GCA GGG ATG AT-3’ human 
 
Table 5. Primer sequences sequencing primer 
Primer Sequence 
pCAGGs 5’ 5’-GCT CCT GGG CAA CGT GCT GG-3’ 
pCAGGs 3’ 5’-GCT CAA GGG GCT TCA TGA TG-3’ 
pCMV 5’ 5’-CGC AAA TGG GCG GTA GGC GTG-3’ 
pBGH 3’ 5’-TAG AAG GCA CAG TCG AGG-3’ 
IRF3 middle 3' 5’-CAG AAT GTC TTC CTG GGT ATC-3’ 
IRF3 middle 5' 5’-TGG CTC TGG GCC CAG CGG CTG GGG-3’ 
Flag 5’ 5’-GAC TAC AAA GAC GAT GAC GAT AAA-3' 
TRADD 5’ 5’-ATG GCA GCT GGG CAA AAT-3’ 
TRADD 3’ 5’-CTA GGC CAG GCC GCC ATT-3’ 
NEMO middle 5' 5'-AGC AGG CCG AGG AGG CCC-3' 
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7 List of abbreviations 
A/a     adenine 
aa     amino acid 
A     ampere 
ABLV     Australian bat lyssavirus 
abs.     absolute 
ARAV     Aravan virus 
bp     base pair 
BLV     bat lyssavirus 
C/c     cytosine 
°C     degree Celsius 
cDNA     complementary DNA  
CARD     caspase activation and recruitment domains 
CypB      cyclophilin B 
Da     Dalton 
DC     dendritic cells 
ddH2O    double distillated water 
D-MEM     Dulbecco´s modified eagle medium 
DNA      deoxyribonucleic acid 
ds (DNA/RNA)    double strand (DNA/RNA) 
DUVV     Duvenhage virus 
E.coli      bacteria species Escherichia coli 
e.g.     for example (from latin: “exempli gratia”) 
EMCV     encephalomyocarditis virus 
EBLV-1 /2    European bat lyssavirus-1/2 
et al.      et alii 
EtBr     Ethidium bromide 
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FADD     Fas-associated protein with death domain 
g     gram 
G-MEM    Glasgow MEM BHK-21 1x 
Fl     Flag 
G/g     guanine 
GAS     gamma activated sequences 
GFP     green fluorescent protein 
h      hour 
HD     helicase domain  
Hsp90     heat shock protein 90 
HRP     horse radish peroxidase 
i.e.     that is (from latin: “id est”) 
IFN      interferon 
IFNAR     IFNα/β receptor 
IFNGR     IFNγ receptor 
IKK     IκB kinase  
IPS-1     IFNβ promoter stimulator 1 
IRAK     Interleukin-1 receptor associated kinase 
IRF     IFN regulating factor 
IRKV     Irkut virus 
ISG     IFN stimulated gene 
ISGF     IFN stimulated gene factor 
ISRE      IFN stimulated response element 
JAK     Janus kinase 
KHUV     Khujand virus 
l      liter 
LB      Luria Bertani 
LBV     Lagos bat virus 
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LDR     leader sequence 
Lgp2      laboratory of genetics and physiology 2 
M      molar 
mA      milliampere 
min     minute 
MAL     MyD88 adapter-like 
MDA     melanoma differentiation-associated protein 
MeV     measles virus 
MeLe RNA    MeV leader RNA  
mg      milligram 
min      minute 
MOKV     Mokola virus 
mRNA     messenger RNA 
MyD88    myeloid differentiation protein 88 
Nap-1     NAK-associated protein 1 
nc     non-coding 
NDV     Newcastle disease virus 
NF-κB     nuclear factor κB 
NK cells    natural killer cells 
NS3/NS4A    non-structural proteins 3/4A 
2’,5’-OAS    2’, 5’ oligo-adenylate synthetase  
o/n     over night 
ORF      open reading frame 
p / n / µ / m / k   pico / nano / micro / milli / kilo 
PBS      phosphate buffered saline 
PCR     polymerase chain reaction 
pH     potential hydrogenii 
Pin-1     peptidyl-propyl isomerase 
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PKR      RNA-activated protein kinase 
poly(I:C)    polyinosine-polycytidylic acid 
5’-pppRNA    5’-triphosphate RNA 
P/S     penicillin/streptomycin 
p.i.     post infection 
p.t.     post transfection 
RABV     rabies virus 
RD     regulatory domain 
RIG     retinoic acid inducible genes 
Rip1     receptor interacting protein 1 
RLR     RIG-like receptor 
RNA      ribonucleic acid 
RNase      ribonuclease 
RNF125    ring-finger protein 125 
rpm     rotations per minute 
RT     room temperature 
s      second 
SAD     Strain Alabama Dufferin 
SDS      sodium dodecylsulfate 
SeV     Sendai virus 
SHIBV     Shimoni bat virus 
SIKE     suppressor of IKKε 
ss (DNA/RNA)    single strand (DNA/RNA) 
STAT     signal transducer and activator of transcription 
SV     simian virus 
T/t     thymine 
TAE      tris acetat EDTA 
TANK     TRAF family member-associated NF-κB activator 
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TBK1     TANK-binding kinase 1 
TBKBP1    TBK1-binding protein 1 (also named Sintbad) 
TEMED     N,N,N‘,N‘-tetramethylendiamine 
Th-1     T helper cell subset 
TICAM     TIR -containing adapter molecule 1 
TIR     Toll-IL-1 receptor homology domain 
TIRAP     TIR domain-containing adapter protein 
TLR     Toll-like receptor 
TNF     tumor necrosis factor 
TRADD    TNF receptor associated death domain protein 
TRAF     TNF receptor associated factor 
TRAM     TRIF-related adaptor molecule 
TRIF     TIR - domain-containing adaptor-inducing IFN  
TYK2     tyrosine kinase 2 
U     units 
U/u     uracil 
UV      ultraviolet light 
V      volt 
v/v     volume/volume 
w/v     weight/volume 
wt     wild type 
WCBV     West Caucasian bat lyssavirus  
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